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Background: Peanut allergy (PA) is responsible for life-threatening allergic reactions. Household peanut 
consumption (HPC), used as an indirect measure of environmental peanut exposure (EPE), is associated 
with PA especially when compared against atopic controls. 
Aims: To determine the association between EPE, peanut sensitization (PS), PA and explore the modifying 
effect of an impaired skin barrier. To assess the route of PS using peanut specific immune responses in skin 
versus gut derived T-helper (Th) cells. 
Methods: Peanut antigen in dust was assessed using ELISA, Mass Spectrometry (MS) and basophil 
activation test (BAT). HPC was compared to peanut-dust levels and airborne peanut. The impact of EPE on 
PS was determined in three cohorts with genotypic and phenotypic skin barrier function measures. Recall 
responses to peanut in skin versus gut-homing memory Th-cells were assessed using gene expression 
profiles and intracellular cytokine staining.  
Results: HPC was the most important factor for peanut-dust in the infants’ environment. BAT confirmed 
biological activity of peanut in dust; MS confirmed whole sequences of major peanut allergens. Airborne 
peanut was only transiently above peanuts being shelled. Early EPE increased the risk of PS; this was 
augmented by atopy and markers of skin barrier impairment.  Th2 gene expression was not increased in skin 
versus gut-homing memory CD4+Th cells from peanut allergic children.  IL9 was the most accurate 
classifier for PA versus PS and atopic non-peanut allergic (NA) children.  
Conclusions: EPE is a risk factor for PS in atopic children, especially when skin barrier is impaired; this 
supports the concept of epicutaneous peanut sensitization. Peanut is unlikely to be sufficiently airborne to 
induce inhalational sensitization. Although, there was no differential expression of Th2 cytokines in skin 
versus gut-homing Th cells, longitudinal assessment as children progress from PS to PA may show Th2 
cytokines initiate in skin-homing Th cells then spread to gut-homing Th cells. IL9 may be a useful 
biomarker for peanut allergy. The role of IL9 in mast cell activation, trafficking and proliferation also 
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provides a compelling explanation for the immunobiology underlying epicutaneous sensitization and 
elicitation of allergic reactions. 
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PhD hypothesis, aims and structure 
The overriding hypothesis of this PhD is that early EPE, measured by peanut protein levels in household 
dust, is a risk factor for the development of PS and PA in children with an impaired skin barrier. The aims of 
this PhD were to describe characteristics of environmental peanut exposure, the association between this and 
PS and PA in children with an impaired skin barrier and finally in-vitro work to support the concept that PS 
occurs through the skin using recall responses to peanut from memory Th2 cells. This PhD thesis is a thesis 
incorporating publications, therefore the results section comprises accepted publications instead of 
conventional results chapters (where the results of this PhD have been published).  
 
The structure of this PhD thesis comprises an Introduction section separated into several chapters (Chapters 
1-5) to evaluate the literature surrounding the hypothesis of this PhD. The Methods section (Chapter 6) 
summarizes the methods incorporated into the publications and describes in full the methods for the work 
that has not yet been published. The Results sections (Chapter 7) contains articles accepted for publication 
(Publication 1-5 described in the section on peer reviewed publications arising from this PhD); where the 
work has not yet been published, these results are described in the conventional way.  This is followed by a 
Discussion section (Chapter 8), References (Chapter 9) and Appendices (Chapter 10) which comprise 
further details required for background, optimisation and justification of methods and statistics employed as 
well as standard operating procedures for certain methods, participant questionnaires and information sheets 
used. 
In keeping with the aims of this PhD there are three themes to this thesis as described below: 
Characterization of environmental peanut exposure (EPE): 
a. Validation of environmental sampling methods and peanut protein quantification 
b. Household peanut consumption and its relationship with peanut levels in dust  
c. Household characteristic and participant factors related to peanut levels in household dust 
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d. Persistence of peanut protein on human hands and saliva after peanut consumption 
e. Persistence of peanut protein in household bed and furnishings 
f. Analysis of airborne peanut 
g. Basophil activation test to confirm biological activity of peanut in dust 
h. Mass spectrometry to determine major peanut protein allergens in dust 
 
2) Influence of EPE on PS and PA in children with an impaired skin barrier 
a. Comparison of cohort studies employed (MAAS, CoFAR and BAMSE)  
b. Review of potential confounding factors for influence of EPE on PS and PA 
c. Overview of FLG genotyping in three cohort studies 
d. Statistical powering and analysis for influence of EPE on PS and PA in children with an 
impaired skin barrier 
e. Evaluation of threshold level of EPE for PS and PA 
 
3) In-vitro evaluation of the route of PA using memory Th cell responses to peanut in skin versus gut-
homing Th subsets  
a. PBMC isolation, culture, staining and sorting into peanut specific memory Th cell in skin 
versus gut-homing Th subsets in children with PA and NA children  
b. Gene expression of sorted cells following RNA extraction, cDNA synthesis, amplification, 
biotin labelling and fragmentation for Affymetrix gene microarray  
c. Analysis of gene microarray results using Partek Suite ANOVA analysis and Random Forest 
automated classification approach  
d. Confirmation of gene microarray findings by reverse transcriptase quantitative polymerase 
chain reaction (RT-qPCR) in PBMCs from children with PA, PS and NA children  
e.  Confirmation of gene microarray findings on a protein level by intracellular cytokine 
staining in PBMCs of children with PA versus PS 
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Glossary of terms and abbreviations 
AAAAI American Academy of Allergy, Asthma, and Immunology 
Allergy Immune response to a usually innocuous protein in individuals sensitized to that 
protein which results in an adverse reaction 
Allele One member of a pair or series of alternative genes occupying the same position on 
matching chromosomes. 
Allergen  Substance capable of inducing an allergic immune response 
α4β7+ / β7+  Alpha-4, beta-7 Integrin surface gut-homing marker on T cells 
Angioedema  Swelling due to influx of fluid subcutaneously or in the submucosa 
Anaphylaxis Severe form of an allergic reaction which may cause respiratory or cardiovascular 
compromise 
Antibody An immunoglobulin protein produced by B-cells that binds specifically to an antigen 
APC   Antigen presenting cell 
Ara h 1 Arachis hypogaea 1 is a major peanut allergen, which belongs to the vicilin family of 
seed storage proteins  
Ara h 2 Arachis hypogaea 2 is a major peanut allergen, which belongs to the 
conglutin family of seed storage proteins 
Basophil Lymphocyte usually circulating in the blood, which has granules containing 
inflammatory mediators such as histamine 
BAMSE ‘Barn’ (children) Allergy Milieu (environment) Stockholm Epidemiology study 
recruited 4089 unselected newborn children from 1994-1996 
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mMCP-1  Mouse mast cell protease is indicative of mucosal mast cell degranulation and 
increases in mice undergoing systemic anaphylaxis  
β-lactoglobulin Beta-lactoglobulin: A major cow’s milk allergen 
Biorad Experion chip  Automated quantitation of protein using gel electrophoresis 
Biorad Protein assay A dye-binding protein quantitation assay; a differential colour change of a dye occurs 
in response to various concentrations of soluble protein 
Bla g 1   Blattella germanica Allergen 1: A major cockroach allergen 
bp base pair is a pair of complementary nitrogenous molecules that are the building 
blocks of the DNA double helix.   
Brefeldin A  Redistributes intracellularly produced proteins from the cis/medial Golgi complex to 
the endoplasmic reticulum 
Bronchoalveolar lavage Bronchoscope washes lungs with fluid in order to take samples for 
microscopy, culture or histology 
BSACI British Society of Allergy and Clinical Immunology 
CD Cluster of differentiation molecules are cell surface markers useful for the 
identification and characterization of white blood cells 
CD4 CD4 is a glycoprotein present on the surface of various immune cells such as T helper 
cells, and antigen presenting cells such as dendritic cells and macrophages. T cells 
that express CD4 are called T helper cells.  
CD8 CD8 is a transmembrane glycoprotein present on the surface of circulating T cells and 
serves as a co-receptor for the T cell receptor. T cells that express CD8 are called 
cytotoxic T cells.  
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CD14 CD14 is a glycoprotein expressed in the cell membrane of monocytes and 
macrophages. It is an important component of the innate immune system as it is a co-
receptor for the detection of bacterial lipopolysaccharide protein 
CD63 CD63 is a cell surface marker which is expressed after cross-linking of the high 
affinity IgE receptor on basophils and mast cells 
CD203c CD203c is a transmembrane glycoprotein in basophils and mast cells 
CLA  Cutaneous Lymphocyte Antigen is an adhesion molecule that binds to E-selectin in 
skin capillaries, ensuring the preferential homing of CLA+ T cells to the skin 
CoFAR study Part of the NIH-sponsored Consortium of Food Allergy Research;  512 children aged 
3-15 months with a history of eczema and milk or egg allergy, but without known PA 
were recruited from 2006 
COT Committee on Toxicity of Chemicals in Food, Consumer Products and the 
Environment  
CRD Component resolved diagnostics: component allergen analysis of major allergenic 
proteins 
CT Cholera toxin is a common adjuvant used to sensitize mice to an allergen 
Ct Cycle threshold is the number of cycles required for the fluorescent signal to cross the 
threshold in polymerase chain reactions 
CV Coefficient of variation is used to define variability:  It is the standard deviation of a 
group of values divided by their mean 
Da Dalton: standard unit used to indicate the atomic mass  
DACT1 Dapper antagonist of β catenin homolog 1: Inhibits dishevelled activation of JNK (c-
Jun N-terminal kinase) and β catenin signalling pathways 
DBPCFC   Double-blind placebo-controlled food challenge 
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Deionised  Water free from ions (molecule with net positive or negative charge) 
 
Densitometry Assay which uses optical density to measure substances  
Der p 1 Dermatophagoides pteronyssinus Type 1: A major HDM allergen 
Der p 2 Dermatophagoides pteronyssinus Type 2: A major HDM allergen 
DNA Deoxyribonucleic acid is a molecule made of repeating units called nucleotides that 
encode the genetic instructions for the functioning of cells and organisms 
DNase Deoxyribonuclease is an enzyme that degrades DNA by catalysing the 
cleavage of phosphodiester linkages in the DNA backbone 
EAT Enquiring About Tolerance study is a large population based randomised controlled 
study assessing whether early introduction of solids with concomitant breastfeeding 
protects against food allergy at 3 years of age 
EAACI  European Academy of Allergy and Immunology  
ELISA Enzyme linked immunosorbent assay: antibody based assay used in the detection of 
proteins  
Eppendorf  Generalised trademark of laboratory tubes which may be centrifuged 
Epicutaneous  On the skin 
EDC Epidermal differentiation complex: a cluster of genes involved in the terminal 
differentiation of keratinocytes.  
Eosinophilia Increase in the number of eosinophils; a lymphocyte which predominates in allergy, 
parasitaemia and some forms of leukaemia 
EPE   Environmental peanut exposure 
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EPIT    Epicutaneous immunotherapy  
Epitope  Part of a protein recognised by the immune system 
FACS   Flow-cytometry 
FAM 6-carboxyfluorescein reporter fluorescent marker in Taqman PCR probes 
FcεRI  High-affinity receptor for the Fc region of Immunoglobulin E which is found on mast 
cells and basophils 
Fel d 1   Felis domesticus allergen 1: A major cat allergen 
Fluff   Unsieved larger particles in dust such as hair and cloth fibres. 
FFQ   Food frequency questionnaire 
Filaggrin A protein which forms a dense protein lipid matrix in the skin. It is important for 
maintaining the skin barrier and mutations of the gene that codes for profilaggrin (the 
precursor of filaggrin) are associated with eczema. 
FLG  Gene that codes for the protein profilaggrin (the precursor of filaggrin) within the 
epidermal differentiation complex 
FTMS   Fourier transform mass spectrometry  
g  gravitational force which refers to the acceleration applied to the centrifuge  
GALT   Gut-associated-lymphoid tissue 
Glycan   A polysaccharide or oligosaccharide 
GNG8 Guanine nucleotide-binding protein (G protein): Modulator /transducer in various 
transmembrane signalling systems 
Haplotype    Groups of closely linked alleles that tend to be inherited together 
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HDM HDM – small arachnids that feed off shed human skin cells and are usually found in 
soft furnishing and bedding of homes 
HLA Human leucocyte antigen is part of the human Major Histocompatibility Complex 
(MHC) which helps the body differentiate between self and non-self.  
HUWE1  HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase 
Horse-radish peroxidase Enzyme which is used to amplify signals in many immunoassays 
HPLC  High performance liquid chromatography: Separation of components in a mixture by 
passing a pressurized liquid and a sample mixture through a column packed with a 
solid adsorbent material. Each component in the sample mixture interacts differently 
with the adsorbent material thus leading to differential flow and elution off the 
column 
HSPA5  Heat shock 70kDa protein 5 encodes a protein that is localized in the lumen of the 
endoplasmic reticulum and is involved in the folding and assembly of proteins  
IgG Immunoglobulin G: One of the five major classes of immunoglobulin and part of the 
adaptive immune system  
IgE Immunoglobulin E: One of the five major classes of immunoglobulin responsible for 
allergy and in protecting against parasites 
IIS Infant Immune Study: Birth cohort of 400 children from Tucson, Arizona, US in 
whom 50% are high-risk for atopy as their mothers have allergic rhinitis 
IL Interleukin:  Cytokines (signalling molecules) which are produced predominantly by 
activated CD4+ Th cells, but also B cells, mast cells, macrophages and endothelial 
cells  
IL   Gene encoding interleukin (e.g. IL9 is the gene encoding IL9) 
Immunoblotting Western blotting for detection of proteins 
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Incidence Number of new cases of a disease that occur over a particular time period in a defined 
population 
IOM Inhalable occupational medicine: type of sampling head used for the Casella Tuff 
Personal Air Monitor 
ISAAC  International Study of Asthma and Allergies in Childhood 
iTregs Inducible T regulatory cells are cells that acquire a regulatory function after coming 
out of the thymus.  These include: T regulatory 1 cells, which secrete IL-10; T helper 
3 cells, which secrete TGF-β, and Foxp3+ Treg cells. 
JACI   Journal of Allergy and Clinical Immunology 
kDa kilo Dalton: the molecular mass of 1000 Dalton which is the standard unit used to 
indicate the atomic mass 
L   Litres 
LC   Liquid chromatography 
LEAP Learning Early About Peanut Study is a high-risk randomised controlled study 
assessing whether early introduction of peanuts in the diet protects against peanut 
allergy at 5 years of age 
LLQ   Lower limit of quantitation 
LN Lymph node 
LR Logistic regression: statistical analysis to determine associations between exposure 
and outcome variables 
LTA   Lymphotoxin A 
MAAS Manchester Asthma and Allergy Study: Birth cohort study of 1184 children from the 
UK from 1995-1997  
Mast cells  Cells which reside in tissues and are characterized by granules which contain 
inflammatory mediators such as histamine    
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MS Mass spectrometry: analytical tool involving the ionisation of molecules and their 
subsequent separation and detection based on their mass (m)- to-charge (z) ratios 
(m/z). 
Matrix effect Substances inside a sample other than the substance one is measuring which may 
interfere with the analysis  
MAF Minor allele frequency is the frequency of the least common allele in a population 
Methacholine Parasympathomimetic drug that induces increased secretions and smooth muscle 
activity in the lung; it is used as a test for asthma 
μl or mcl  Microlitre (1000th of a millilitre) 
μg or mcg  Microgram (1000th of a milligram) 
μm   Micrometres (1000th of a millimetre) 
MGB Minor Groove Binder: Taqman MGB probes contains a non-fluorescent quencher 
(NFQ) to absorb energy (light) emitted from the reporter dye during real-time 
quantitative polymerase chain reactions 
MHC Major Histocompatibility Complex allows differentiation of self versus non-self and 
is called the Human Leucocyte Antigen (HLA) in humans.  
MMCP-1 Mouse mast cell protease 1 is a member of the chymase family of serine proteases and 
is a cardinal feature of IgE mediated anaphylaxis in mice 
Monensin                    Prevents protein secretion by blocking transport within the Golgi stack; the Golgi 
stack modifies proteins delivered from the endoplasmic reticulum then packages and 
sends them to different parts of the cells 
Monoclonal antibody  Antibodies produced by the same parent cell (cloned) which are directed 
against one epitope  
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m/z m stands for mass and z stands for number of charged ions; this provides a mass to 
charge ratio for ionized peptides which can be used to identify proteins of interest  
N Normality means the number of equivalent weights of a solute per litre of a solution 
NA   Non-peanut allergic 
n/a   Not applicable 
NDFIP2  Nedd4 family interacting protein 2: Promotes NF-κB signalling 
ng   Nanogram (1000
th
 of a μg)  
NICE   National Institute for Health and Care Excellence   
NMF  natural moisturizing factor is a collection of water soluble molecules in the cornified 
layer formed predominantly from breakdown products of filaggrin 
NPV   Negative predictive value 
OD Optical density is the absorbance of light at a particular wavelength; in this case 
through the ELISA well sample  
OFC   Oral food challenge 
OVA   Ovalbumin: A major hen’s egg allergen 
P   P-value 
PA   Peanut allergy 
PBMC  Peripheral blood mononuclear cells 
PBS   Phosphate Buffered Saline (without calcium or magnesium) 
PCA Principal Component Analysis shows the variation in all the genes expressed in a 
gene microarray analysis in one 3-dimensional image 
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ppm   Parts per million. 1 ppm = 1mg/litre or 1μg/ml or 1ng/μl  
Polyclonal antibodies  Mix of different antibodies produced by different B-cells which are directed 
towards different epitopes of a protein 
PPV   Positive predictive value  
Prevalence Total number of cases of a disease at a given time-point in a defined population 
PS   Peanut sensitization 
Random Forest Automatic classification approach 
RAST Radio-allergosorbent test is a radioimmunoassay to test for specific IgE 
RF   Random Forest is a supervised classification algorithm 
ROC Receiver Operating Characteristic curve is a graphical representation of the predictive 
accuracy of a model or diagnostic tool, combining sensitivity and 1-specificity to 
determine the area under the curve at all possible cut-offs 
ROX ROX is a dye within the PCR Mastermix which is used to normalise the experiment  
RNA Ribonucleic acid: a family of biological molecules essential for coding and expression 
of genes 
RNase Ribonuclease is an enzyme which catalyses the degradation of RNA and is 
ubiquitously present in the environment and is secreted by human skin cells 
RP-HPLC-ESI-MS     Reverse phase high performance liquid chromatography electrospray ionisation mass 
spectrometry 
RPMI   Roswell Park Memorial Institute medium 
RQ Relative quantitation in real-time quantitative polymerase chain reaction relates the 
PCR signal for a target gene against another sample such as a negative control or 
comparator group  
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rs Spearman Rank: non-parametric correlation coefficient for non-normally distributed 
data 
RT-qPCR  Real time quantitative polymerase chain reaction 
SCIT    Subcutaneous immunotherapy  
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis is used to separate out 
proteins according to their molecular size and weight. SDS denatures proteins into 
polypeptides 
Sensitization  Immune system produces IgE antibodies against a usually innocuous antigen such as a 
pollen or food 
Sensitivity Number of true positive results divided by the combination of true positive and false 
negative results 
siRNA Small interfering RNAs are 20-25 nucleotide double stranded RNA molecules that 
interfere with the expression of a specific gene 
SPT Skin prick test: Allergy tests where purified standardized allergen is applied to the 
skin and pierced with a lancet; wheal and flare are measured at 15 minutes 
SNP Single nucleotide polymorphisms occur when a single base differs between members 
of paired chromosomes in an individual  
SOP Standard operating procedure: a consistent set of instructions for research work 
Specificity Number of true negative results divided by the combination of true negative and false 
positive results 
Spectrophotometry Assay which measures the colour of a solution by determining the amount of light 
absorbed in the ultraviolet, infrared, or visible spectrum 
SPRRs  Small proline-rich proteins assist in the formation of the cornified envelope of the 
epidermis 
STAT6  Signal transducer and activator of transcription 6 
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Stratum corneum Outermost layer of the skin (epidermis) 
ST6GALNAC1  ST6 (alpha-N-acetyl-neuraminyl-2, 3-beta-galactosyl-1, 3)-N-acetylgalactosaminide 
alpha-2, 6-sialyltransferase 1 
TCR   T cell receptor 
TGF-β Transforming growth factor beta family of cytokines are peptides which regulate 
cellular differentiation, proliferation, adhesion and migration 
Tgif1    TGFβ-induced factor homeobox 1 
Th T-helper (Th) cells are a sub-group of lymphocytes which express CD4 on their cell 
surface and help B-cells to produce antibodies. 
Th1 T-helper cell Type 1: Produce cytokines which are important in defence against 
pathogens such as IFN-γ and IL-2 
Th2 T-helper cell Type 2: Produce cytokines such as IL4, IL5 and have an important role 
in allergy and defence against parasites  
TLR Toll-like receptor: Class of proteins which reside on APCs in order to recognise 
microbial pathogen associated molecular patterns (PAMPs) and activate the innate 
immune system 
TMB Tetramethylbenzene; a substrate broken down by enzyme horse-radish peroxidase 
which gives rise to colour change measured by spectrophotometer 
Tris Tris (hydroxymethyl) aminomethane is a primary amine (one of three hydrogen atoms 
of ammonia is replaced by a hydrocarbon group). It is commonly used as a buffer 
Trypsin  A serine protease produced by the pancreas which hydrolyses (breaks down) proteins 
Tween   Common detergent used in biochemistry 
UK   United Kingdom 
Urticaria Itchy red rash resulting from degranulation of mast cell inflammatory mediators such 
as histamine; also called ‘nettle rash’ or ‘hives’ 
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US United States of America 
VIC Reporter fluorescent marker in Taqman PCR probes. Proprietary marker thus no 
further details available through Applied Biosystems 
w/v weight /volume; to prepare solid in liquid solvent;  1% w/v is 1gram  per 100 ml, 
100% is 100grams in 100 ml  
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Chapter 1 Introduction  
1.1 Statement of the problem 
Food allergy is an increasingly important public health concern. 
(1)
 In prospective studies challenge proven 
food allergy has been shown to be between 5% and 6% (depending on whether defined by double blind 
placebo controlled food challenges or open challenge and a good clinical history respectively) in the United 
Kingdom (UK) 
(2)
 and 8% 
(3)
 in the United States of America (US) in the first three years of life. PA is 
characterised by severe reactions 
(4;5)
 and significantly impairs quality of life for both the child and their 
family. 
(6-8)
 Although there are exciting research developments in the prevention (www.leapstudy.co.uk) and 
treatment of established PA,
(9-11)
 at present dietary avoidance and appropriate rescue treatment of allergic 
reactions secondary to accidental exposure remains the mainstay of management; thus prevention is key.  
 
In this PhD an epidemiological approach was employed to determine a novel, previously unexplored, route 
of PS via EPE and the role of the skin barrier in mediating this effect. Subsequently genetic biomarkers of 
PA versus tolerance were evaluated in recall responses of skin versus gut-homing memory T helper (Th) 
cells in peanut allergic, peanut sensitized and non-peanut allergic (NA) children using gene and protein 
expression analyses.  To highlight the clinical relevance of this PhD the introduction first provides an 
overview of PA followed by a review of known genetic and environmental risk factors for PS and PA. The 
evidence surrounding potential routes of sensitization to peanut, in particular epicutaneous sensitization is 
described as well as the role of environmental allergen exposure in the development of other allergic 
diseases. Validation of the method to quantify peanut protein in dust and surface wipes was carried as part of 
my MSc thus I will discuss data from my MSc as part of the introduction to this PhD.  
 
1.2 Increasing prevalence of PA 
Sequential cohort studies have demonstrated an increase in the prevalence of PA from 0.5% (1989) to 1% 
(1996) in the UK 
(12)




 Subsequently the Isle of Wight study assessed three cohorts of children (aged 3-4 years old) either born 
in 1989 (Cohort A), from 1994-1996 (Cohort B) or from 2001-2002 (Cohort C). They showed an initial 
increase in the prevalence of PA from 0.5% (Cohort A) to 1.4% (Cohort B) then levelling off at 1.2% 
(Cohort C). 
(15)
However, two UK studies published after 2002 found a rate of PA of 1.8% 
(16)
  and 1.85% 
(17)
 
in school aged children either confirmed by oral food challenge (OFC) or allergy testing above the 95% 
positive predictive value (PPV) for peanut with peanut skin prick test (SPT) ≥8mm or peanut specific IgE 
(sIgE) ≥15kU/L.(18) The Australian HealthNuts Study also confirmed a prevalence of 1.9% PA using 
diagnostic OFCs; however, infants were recruited to this study from baby clinics, thus may have had eczema 




The rise in PA prevalence coincides with a general increase in allergic disease. Using objective markers of 
allergic disease, hospital admission rates for anaphylaxis and food allergy are increasing. In the UK, out of a 
total of 49,300 admissions for systemic allergic reactions between 1990-2001, which were obtained from 
hospital discharge codes based on the international classification of diseases (ICD),  anaphylaxis rates rose 
from 6 to 41 per million population and food allergy rates rose from 5 to 28 per million population. 
(20)
 No 
detail as to the responsible food allergen was provided. A similar study in Australia using data from ICD 
discharge codes found an increase in hospital admissions for food induced anaphylaxis of 350% between 
1994-2005.
(21)
  In children between 0-4 years old the increase was due mainly to peanut induced 
anaphylaxis. Thus one could argue that because PA has become more prevalent and is characterised by more 
severe allergic reactions that the rise in admissions for anaphylaxis is due, to a certain extent, to the rise in 
PA prevalence. 
 
1.3 Severity of peanut and tree nut allergic reactions 
PA is characterised by severe reactions. 
(4;5)
 In registries of food related anaphylactic deaths, there is often 
no differentiation between peanuts and tree nuts, therefore the following section will include reference to 
both peanuts and tree nuts. Peanuts and tree nuts are the commonest cause of food related anaphylactic 
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deaths in the UK and USA in children and adults;  
(4;22-24)
 this may be due to the increased prevalence of PA, 
(14;16;19)
 the increased allergenicity that may occur through peanut processing (predominantly roasting) 
(25)
 





Several studies have confirmed that peanut and tree nuts are the most common cause of food related 
anaphylactic reactions treated in hospital emergency departments. 
(21;27;28)
 At the Royal Children’s Hospital 
in Australia, a review of all emergency department attendances between 1998-2003 (coding for 
‘anaphylactic shock caused by adverse food reaction’), found that peanut and tree nuts (predominantly 
cashew nut) combined accounted for 37/104 (36%) of food-related anaphylaxis. 
(29)
 Confirmatory findings 
were obtained from Australia’s National Hospital Morbidity Database, where they found that 23% of food 
related anaphylactic admissions were due to peanut, and 39% were due to peanut and tree nuts combined.
(21)
  
In the US a database from the Health Maintenance Organization in Washington identified cases of 
anaphylaxis from 229,422 children using IDC codes between 1991 and 1997. 
(28)
 Peanut was the most 
common cause of anaphylaxis, with 10 peanut attributable cases out of 67 confirmed cases of anaphylaxis. A 
further 7 cases were due to tree nuts and 5 due to unspecified nuts, thus the total percentage contribution for 
anaphylaxis from peanut and tree nuts was up to a maximum of 22/67 (33%). 
 
In the US PA is the leading cause of food allergy related fatalities, followed by tree nuts. Bock et al. (2001) 
reported on the cases of deaths as a result of food allergies from a registry kept by members of the American 
Academy of Allergy, Asthma & Immunology (AAAAI) and the Food Allergy and Anaphylaxis Network 
(FAAN). Over 6 years (1994 to 1999), there were 32 registered food allergy related deaths between ages 2 to 
33 years. 
(4)
 In 10 cases there was only a probable identification of the likely food culprit. Peanut was 
responsible for 20/32 (62.5%) fatalities and peanut and tree nuts combined were responsible for 30/32 (94%) 
fatalities. Over a subsequent 6 years (2001-2006) Bock et al.(2007) reviewed a further 31 food allergy 
related deaths aged 5 to 50 years of which 17/31 (55%) were due to peanut and 25/31 (81%) were due to 
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peanuts or tree nuts.
(22)
 In the second series peanut and tree nuts were accounting for fewer fatalities; with 
cow’s milk being responsible for 4 fatalities and shrimp for 2 fatalities. As this was a voluntary register 
rather than data capturing all fatalities due to anaphylaxis, this decrease in nut-related fatalities may be due 
to increased awareness of the potential for other food allergens to cause allergic reactions. 
 
In the UK food allergy related fatalities were sought from the Office of National Statistics which keeps a 
record of all UK death certificates; since 1993 these have been coded to allow searches for anaphylaxis as a 
cause of death. Over seven years (1992 to1998) there were 37 food allergy related fatalities due to peanut 
and 25/37 (68%) were due to peanut and/or tree nuts combined. 
(24)
 Age was not specified for each case but 
they specified that no nut allergic fatalities occurred before 13 years of age. Over the next 7 years (1999-
2006), 48 fatalities ranging from 5 months to 85 years were related to food anaphylaxis, of which 9/48 
(19%) reacted to peanuts and 18/48 (37.5%) reacted to peanuts and/or tree nuts combined. 
(23)
 Death 
occurred typically from respiratory arrest.
(23)
 The rate of fatalities from food allergy related anaphylaxis has 
not increased (6-7 per year) in the UK even though the rate of hospital admissions for anaphylaxis has.
(20)
 
This may indicate better management of food allergic reactions when these reactions do occur.  
 
In a recent article in press by Turner et al. 2015,
(30)
 fatalities from the same Office of National Statistics 
were reviewed between 1992-2012, thus comprised the data obtained above and extended this by another 7 
years. Of the 124 of fatalities highly likely to be secondary to a food allergen during this period, 95 (77%) 
were attributed to a known food allergen. Peanut was responsible for the fatality in 19/85 (22%) adults and 
6/39 (16%) children. Peanut and /or tree nuts were responsible in 30/85 (35%) adults and 11/39 (28%) 
children; this calculation included unspecified nuts. 
 
In Australia, over 9 years (1997-2005) there were 112 anaphylaxis fatalities based on death certificates 
entered into a National Mortality Database. Further details were sparse and a large proportion of 
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anaphylactic deaths were unspecified. However of the 7 food induced anaphylaxis fatalities (aged 5-35 
years), peanut was the offending food in 3 of the 5 cases where data were available.
(21)
 
The percentage of fatalities attributed to peanut or tree nuts was lower in the UK and Australia than the US, 
however, peanut and tree nuts were still the main culprit foods for food allergy related fatalities in all three 
countries. There are limitations in the available data that may account for this discrepancy. Firstly in the UK 
and Australia there was uncertainty regarding the food responsible for the fatality; for example, in the UK 18 
unspecified food allergy related fatalities may have also been due to peanut or tree nuts bring the total up to 
a maximum of 36/48 (75%) cases. Conversely the US data is likely to have been subject to selection bias 
towards peanut and tree nut reported deaths as these cases came from a voluntary registry. 
(4;22)
 There are a 
reported 100 food related anaphylaxis deaths in the US each year; 
(31)
  this would equate to approximately 
600 fatalities over 6 years, which is much higher than the registered approximately 30 fatalities reported by 
Bock et al.(2001, 2007) over each 6 year period. 
(4;22)
 To date no study has evaluated the culprit food in all 
US food related anaphylactic deaths; however, if this were performed it is likely that there would be a 
similar rate of peanut anaphylaxis related deaths to that reported in the UK and Australia, as they are 
similarly westernized countries where roasted peanuts are commonly consumed. 
 
Two recent publications from US national public databases assessed the rate of food anaphylaxis fatalities. 
Ma et al. (2014) reviewed data from 3 public US databases from admissions, emergency and death reports; 
between 1999-2009, each year the fatalities due to food anaphylaxis ranged from 4-7%.
(32)
 Jerschow et al. 
(2014) assessed records from the National Centre for Health Statistics’ Multiple Cause of Death  between 
1999-2010.
(33)
 The authors showed a similar rate of food related anaphylactic related deaths (6.7%) to the 
publication by Ma et al. (2014) of 164 (6.7% of all anaphylactic deaths, making it the least common cause of 
anaphylactic deaths). Both publications were limited by the use of ICD-10 which prevented the 
identification of the culprit food; however, Ma et al (2014) did show that peanut related anaphylaxis 
resulting in emergency attendances and admission had increased from n=256 (4%) to n=512 (7 %).  A 
summary figure of the studies described above is depicted in Figure 1. 
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In the UK, over half of deaths related to peanut anaphylaxis occurred in individuals whose previous peanut 
allergic reactions had been mild. 
(23)
 Thus a previous mild allergic reaction cannot reassure the patient that 
they are less likely to have a severe reaction in the future. Risk factors for fatal peanut allergic reactions 
include asthma (even well-controlled), location of exposure remote to the home environment and non-timely 
delivery of adrenaline (although mortality was not invariably prevented by early adrenaline alone).
(22-24)
   
 
1.4 Impact on the quality of life in children and families with PA 
Given the potential for severe allergic reactions it is not surprising that PA leads to heightened anxiety and 
reduced quality of life in the individual and family of the individual who has PA. When PA was compared 
with other chronic health conditions such as diabetes mellitus 
(7)
 and chronic rheumatoid arthritis,
(6)
 children 
and families with PA fared worse. In particular they suffered from increased anxiety 
(7)
 and disruption in 
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Avoiding peanut in the diet not only entails avoidance of peanut as an ingredient in food but patients may 
also be advised to  avoid known cross-reactive legumes and seeds. This may compromise nutrition. 
(34)
 Pre-
packed foods frequently have an advisory warning referring to possible nut contamination; these advisory 
labels are increasingly more prevalent and frequently contribute to anxiety in food allergic individuals. 
(35;36)
 
The Anaphylaxis Campaign found that 56% (71/127) of foods randomly selected from a shopping basket 
which would not normally contain nuts as an ingredient indicated a risk of nut contamination. 
(37)
 In a more 
detailed evaluation they found that the peanut or tree nut allergic individual was unable to match a substitute 
for 18% of the items and in 9% of cases had to make do with a product of poorer quality. Additionally, nut 
allergic individuals took almost 40% longer to shop and paid on average 11% more than individuals without 
nut allergies.  
 
 
1.5 Natural history of PA 
PA usually persists into adulthood, and was previously thought to never be outgrown. However, several 
studies have now shown this is not the case; studies have shown that between 18-59% of children outgrow 
their PA (references in ascending order of PA resolution). 
(38-45)
 Although all of these studies confirmed 
resolution of PA by OFC, only two of these studies confirmed PA at baseline with a diagnostic OFC.  
(39;41)
 
Most other studies based their definition of PA at baseline on a history of clinical reaction or positive SPT or 
sIgE with no history of ingestion; thus it is likely that some of these children were peanut sensitized rather 
than allergic at baseline which would have falsely elevated the rate of PA resolution described. Chances of 
outgrowing PA were highest if the child had a milder initial allergic reaction and low SPT/sIgE tests on first 
presentation, 
(38;40;42)
 and if they had fewer additional allergies (implying less complex atopic disease). 
(46)
 
Unfortunately PA which has been confirmed as resolved on  diagnostic OFC can reoccur  in up to 8% of 
cases; 
(44)





1.6 Immunological process of food allergic sensitization  
Many children have their first documented allergic reaction to peanut on first known oral exposure which 
implies a high frequency of prior occult sensitization. 
(47;48)
 In three observational studies 72-100% of 
children reacted to peanut on first known exposure.
(5;47;49)
  To develop PA one must first be exposed to 
peanut protein or a cross-reactive protein in order for the immune system to be primed to produce the IgE 
specific for peanut which binds to the surface of mast cells. This process of ‘sensitization’ is often followed 
by clinical allergy. The process of sensitization starts with the interaction between an antigen presenting cell 
(APC), which has engulfed antigen/allergen and a naïve CD4+ T helper lymphocyte. T lymphocytes (or T 
cells as they will be called in this PhD) are the conductors of the immune system. T helper (Th) lymphocytes 
assist other lymphocytes in their immunological process such as activating and maturing B cells to produce 
antigen specific antibodies and activating cytotoxic CD8+T cells and macrophages. They are defined as T 
helper cells by the presence of the CD4 glycoprotein on their cell surface. An ever expanding array of T cell 
subsets is being discovered such as Th1, Th2, Th17 and Th9 cells; these T cell subsets may work together or 




‘Naïve CD4+ Th cells leave the thymus after the process of thymic education through positive and negative 
selection has been completed in order for these cells to effectively identify pathogens without harming their 
host. This occurs via interaction of thymocytes through their T cell receptor with peptide-MHS complexes 
that are expressed by thymic epithelial cells and dendritic cells in the cortex of the thymus, thus also confers 
antigen specificity of the naïve Th cell.
(51)
 They are considered to be immunologically naïve until they 
encounter MHC-peptide complexes for which their T cell receptors have a high affinity.
(52)
 Professional 
APCs such as dendritic cells, Langerhans cells and macrophages express both Major Histocompatibility 
Complex (MHC) Class I and II on their cell surface (see Section 1.7.1) and are able to activate or prime 
naïve T cells. Naïve T cells are dependent on co-stimulatory molecules for activation and require higher 
concentrations of antigen than memory T cells; however, investigators have not found differences in antigen 




During the process of sensitization, antigens (food allergens) are engulfed and processed by APCs which 
then migrate to the regional LN. Within the cortical region of the regional LN the APC presents the antigen 
in a recognizable form (as a peptide on a MHC Class II receptor) to naïve CD4+ Th cells via a T cell 
receptor (TCR) specific for that peptide. Once the naïve CD4+ Th cell recognizes a peptide: MHC ligand, 
signaling through the TCR induces a conformational change in the cell adhesion molecules (e.g. lymphocyte 
function associated antigen -1 [LFA-1] on the T cell develops a greater affinity for ICAM-1 or ICAM-2 on 
the APC) which stabilizes the association between the two cells. During this time the naïve CD4+ Th cell 
differentiates into effector CD4+ Th2 cells and proliferates. This process is regulated by other concomitant 
signals (co-stimulatory molecules e.g. Β7 on the APC binding to CD28 on the T cell which promotes the 
survival and expansion of T cells) and cytokines (e.g. IL-21; IL-12;  IL4; IL4 + TGF-β; IL6 + TGF-β (+/- 
IL21 / IL23); IL6 + TNF-α or TGF-β) which direct Th cell differentiation into various Th subsets (e.g. 
follicular Th; Th1; Th2; Th9; Th17; Th22 or T regulatory in order of previously stated cytokines).
(54)
 The 
cytokines responsible for Th cell differentiation and the function of different effector cytokines produced by 











Figure 2: Differentiation of naïve T cell into Th subsets following antigen presentation by dendritic cell 
(DC) to naïve T cell.  




Th2 differentiation induced by IL4 operates through the transcription factor STAT6 (signal transducer and 
activator of transcription 6). 
(55)
 Effector CD4+ Th2 cells secrete IL4 and IL13 which promotes B 
lymphocyte immunoglobulin class-switching from IgM, IgG or IgA to IgE, and initiates B cell 
differentiation from naïve B cells to memory B cells and IgE-secreting plasma cells. 
(56;57)
 These plasma 
cells, which may be long-lived, 
(58)
 continue to produce and secrete sIgE antibodies directed against a 
specific peptide of the offending food protein. SIgE antibodies subsequently bind to the high-affinity 
receptor for the Fc region of IgE (FcεRI) on the surface of mast cells in target organs such as the skin, 
gastrointestinal and respiratory tract, and basophils in the blood circulation. 
(59)
 Upon subsequent re-
exposure, sIgE on the surface of mast cells and basophils binds the specific peptide resulting in IgE cross-





 This results in the allergic manifestations of immediate hypersensitivity reactions in 
different target organs including the skin (hives, angioedema), gastrointestinal tract (vomiting and diarrhea), 
respiratory tract (stridor, wheeze and ensuing difficulty breathing) and cardiovascular system (pallor, low 
blood pressure, collapse). This process is displayed below for allergic sensitization to HDM allergen 
Dermatophagoides pteronyssinus Type 1 (Der p 1) as an example (Figure 3). Der p 1 has cysteine protease 
activity that breaks down the tight junctions by breaking down transmembrane protein occludin.
(60)
 Peanut 
proteins are not known to have protease activity; however, this has not been actively studied.  
 
Figure 3: Mechanism of allergic sensitization using HDM allergen (Der p 1) as an example. 
Copyright from Janeway's Immunobiology, 8th Edition by Murphy et al. (2012)  







1.7 Genetic risk factors for PA 
There is a significant genetic influence on the development of PA as shown by the 64% concordance rate for 
PA in monozygotic twins. 
(62)
 In a UK study which assessed 622 adults and children and their families with 
suspected PA, grandparents reported PA in 0.1% (3/2409), aunts and uncles in 0.6% (7/1213), parents in 
1.6% (19/1218), and siblings in 6.9% (42/610). 
(63)
  On further evaluation by SPT and diagnostic OFC the 
researchers found a 7% prevalence of PA in siblings of peanut allergic individuals. 
(63)
 Identifying genes 
which predispose to the development of PA would facilitate the provision of personalized medicine. 
 
1.7.1 Major Histocompatibility Complex (MHC) 
Given that APCs present processed antigen to naïve CD4+ Th cells via the MHC Class II ligand (see Section 
1.6) one could anticipate that variations in the genes that code for the MHC would be important predictors of 
allergic disease. MHC allows differentiation of self versus non-self and is called the Human Leucocyte 
Antigen (HLA) in humans. HLA Class 1 molecules regulate inflammatory responses and apoptosis 
(programmed cell death) and HLA Class II molecules, present on APCs, activate T cells and have been 
shown to control T cell recognition of peanut antigens.
(64)
 Variation in the genes coding for HLA Class II 
DRB1*11, 
(65)
  DRB1*08, DRB1*08/12 tyr16 and DQB1*04 
(66)
 have been associated with PA versus atopic 
controls. However, more recently, two studies compared HLA Class II genes in children with PA versus 
their siblings without PA.
(67;68)
 The studies were designed to focus on variations in HLA Class II genes due 
to an association with PA rather than due to differences in the HLA Class II genes of non-related 
individuals. 
(67;68)
 Although DRB1*0803 was higher in both sets of siblings compared with unrelated 
controls, there was no difference between peanut allergic and peanut tolerant siblings. 
(68)
 Thus, at present, 
there is conflicting evidence as to whether variations in HLA Class II genes are responsible for the 





1.7.2 Genetic polymorphisms 
1.7.2.1 Background 
Genetic risk factors can be determined by assessing variations at a specific deoxyribonucleic acid (DNA) 
sequence that is known to code for a gene. Coding DNA sequences (genes) are transcribed into ribonucleic 
acid (RNA) and then translated into proteins. Variations in the sequence of DNA are called polymorphisms 
if the less common allele (an alternative form of a given gene) occurs in more than 1% of the individuals in 
any population. 
(69)
 Variations in DNA sequence may consist of a substitution of one of the bases (such as 
arginine (A), thiamine (T), cytosine (C) and guanine (G) which are the building blocks of nucleotides and 
thus DNA), deletions or insertions of one or more bases. Over 90% of DNA polymorphisms are single 
nucleotide polymorphisms (SNPs) which occur when a single base differs between members of paired 
chromosomes in an individual. The frequency of SNPs are approximately one every thousand base pairs. 
(69)
 
A SNP may occur within a gene resulting in altered gene expression and thus protein formation. This is 
referred to as a mutation. However, the majority of SNPs are silent (do not lead to altered gene expression 
and proteins) and the functional significance of these is not yet understood. The 1000 Genome Project 
Consortium has provided a haplotype (groups of closely linked alleles that tend to be inherited together) map 




1.7.2.2 Genetic polymorphisms of the innate immune system 
Two SNPs in the glycoprotein CD14, which is expressed on APCs and acts as a receptor for 
lipopolysaccharide (bacterial cell wall) and other pathogen associated molecular patterns (PAMPS), are 
associated with PA. 
(71)
 Homozygous (both alleles) polymorphisms for CD14 (TT) are 4 times more 
common in food allergic individuals than non-atopic controls. 
(72)
 CD14 has also been shown to modulate 
the effect that exposure to bacterial products (such as in farming environments) 
(73)





of Th2 responses. In a similar manner, variations in genes that code for other APC receptors (Toll-like 
receptors) that recognise PAMPS modify the association between day care attendance and atopic wheeze at 
follow-up between the ages of 1 to 11 years. 
(74)
 CD14 has a key role in the innate immune system and 




1.7.2.3 Genetic polymorphisms of transcription factors 
Variation in APC receptors may alter the way allergens are processed and presented to T cells, but additional 
mutations within genes that code for downstream signal transduction within the T cell may also influence 
whether atopy or tolerance ensues. In a study by Amoli et al. (2002), SNPs in the gene encoding for the Th2 
transcription factor STAT6 were approximately three times more frequent in 71 peanut or tree nut allergic 
individuals versus 184 blood donors controls. 
(76)
 However, there was no difference in the rate of STAT6 
mutations between the same 71 nut allergic individuals and 45 atopic individuals without nut allergy which 
suggest that the STAT6 SNPs increased the risk of atopy rather than nut allergy per se. 
(76)
 Given the role of 
STAT6 in Th2 differentiation under the influence of IL4 (see Section 1.6) variations in the gene that codes 
for STAT6 may inhibit or promote Th2 differentiation to allergens in general rather than peanut or tree nut 
allergens. Polymorphism in interleukins such as IL10 
(77)
 and IL13 
(78)
 have also been associated with food 
allergy but not PA specifically. Variations within genes important for skin barrier function will be discussed 
inSection 4.2. 
 
1.7.3 Microarray analysis for hypothesis generation  
The previously described gene analysis method described is hypothesis driven: i.e. researchers already need 
to have a hypothesis as to which genes might affect atopic disease or modify an environmental exposure. 





may be important biomarkers of allergic disease or tolerance.  The use of gene microarrays, evaluates all 
genes expressed in affected versus non- affected individuals which allows the discovery of novel genes and 
the generation of hypotheses on the basis of these findings.  
 
Holt’s research group identified novel Th2-associated genes in ‘recall’ responses to HDM (HDM) using 
gene microarray analysis in HDM allergic vs. non-atopic controls.
(79)
 CD8+ and CD4+ T cells were isolated 
from HDM-stimulated peripheral blood mononuclear cells (PBMCs) by positive selection using Dynabeads. 
RNA was extracted from CD4+ and CD8+ T cells and screened for allergen-induced gene activation using 
Affymetrix microarray technology. Genes identified were then validated using independent panels of 
subjects by real time quantitative polymerase chain reaction (RT-qPCR). Kinetic analysis revealed an early 
12-24hr wave of atopy-associated genes involved in signalling (such as DACT1, NDFIP2 and GNG8 see 
Glossary for further description) followed by a later 24-48hr wave of genes encoding the Th2 effector 
cytokines (such as IL5, IL13 and IL9). This group subsequently performed a network analysis on the genes 
activated in the CD4+Th cells. They used pair-wise gene-gene co-expression in response to HDM 
stimulation and activation to determine modules of interconnected genes which were defined as ‘atopy 
associated modules’.49 They found that blocking ‘hubs’ of connectivity within an ‘atopy associated module’ 
collapsed the whole module thus providing possible target genes for therapy.  
 
Gene expression microarrays have been used to elucidate the mechanisms underlying peanut oral 
immunotherapy,
(80)
 and for the prediction of efficacy for venom immunotherapy. 
(81)
 Of interest in peanut 
allergic children undergoing oral immunotherapy, T-cell microarrays showed down-regulation of apoptosis 
related genes (such as BCL2L11 and GADD45A in p53-dependent apoptosis and TNFSf8 in the TNFs/NF-
κB/IAP anti-apoptosis). This suggests a novel role for apoptosis in inducing oral tolerance and may not have 





Chapter 2 Routes of peanut sensitization 
To devise effective PA prevention strategies it is important that the route of PS is understood. In the next 
section I will discuss the literature pertaining to various routes of peanut exposure and the public health 
recommendations that have arisen from this. 
 
2.1 In utero peanut allergen exposure 
The data surrounding maternal peanut consumption and PS in the unborn child are conflicting. From a 
mechanistic point of view, IgE in cord blood was thought to be produced by the foetus as foetal cells are 
capable of producing IgE from the second trimester; 
(82)
 furthermore total IgE 
(83-85)
 and allergen sIgE  (to 
HDM) 
(86)
 in cord blood have been previously used to predict atopy in the child. The ALSPAC (Avon 
Longitudinal Study of Parents and Children) study is a large birth cohort consisting of over 14,000 pregnant 
mothers recruited from 1991-1992. Children of mothers recruited to the ALSPAC study that went on to 
develop PA (confirmed by double blind placebo controlled OFCs) had their cord blood assessed 
retrospectively. There was no detectable peanut-sIgE (using a cut-off of 0.35kU/L) in the cord blood of 




Cord blood may not actually be reflective of foetal IgE production but of maternal IgE production.
(87)
 In the 
Copenhagen Studies on Asthma in Children (COPSAC) cohort Bonnelykke et al. (2008, 2010) demonstrated 
that total and sIgE levels in cord blood were frequently the result of maternofoetal IgE transfer. 
(87;88)
 
Maternofoetal IgE transfer was assessed by comparing levels of total IgE or sIgE in cord blood, maternal 
blood and in the infant 6 months after birth. Additionally the authors correlated cord blood IgE levels with 
cord blood IgA as this is used as a measure of maternal blood contamination of cord blood (IgA is not 





blood was maternal in origin in 46% of positive (defined as total IgE >0.5kU/L) cord blood samples. 
(87)
  
SIgE to inhalant and food (cow’s milk and egg) allergens was present in 14% of cord blood samples but the 
corresponding sIgE was not found at 6 months of age in the infant, 
(88)
 which suggests that sIgE in cord 
blood was either maternally derived or not of clinical significance. Cord blood IgA was highly correlated 
with total and sIgE levels thus both total and sIgE in cord blood may reflect maternal atopy instead of the 
infant’s atopic status. 
 
2.2 Peanut allergen exposure via breast milk 
Cow’s milk (β-lactoglobulin) and egg (OVA) proteins have been measured in breast milk.  (89;90) A study by 
Vadas et al. (2001) 
(91)
 used the Neogen ‘Veratox’ peanut polyclonal sandwich ELISA to quantify peanut 
protein in the breast milk of 23 lactating women.  Within one to three hours of eating 50g of dry roasted 
peanuts, proteins with molecular weights corresponding to the major peanut allergens Ara h 1 (66 kDa) and 
Ara h 2 (17 kDa) were detected in breast milk using SDS-Densitometry (gel electrophoresis used to separate 
out proteins according to their molecular size).  On the basis of this the authors postulated that Ara h 1 and 
Ara h 2 were excreted in their whole form in breast milk. However, Vadas et al. (2001) did not confirm their 
findings with a Western blot using antibodies directed against Ara h 1 and 2, thus could not confirm whether 
these proteins were Ara h 1 and 2 or different proteins with similar molecular weights.   More recently 
Bernard et al. (2014) measured the major peanut allergen Ara h 6 in breast milk using anti-Ara h 6 
monoclonal antibodies.
(92)
 Ara h 6 in maternal breast milk was detectable within 10 minutes of maternal 
peanut consumption and reached peak levels of 550pg/ml around 30 minutes following ingestion followed 
by a reduction over time but was still present at 26 hours post ingestion.  Ara h 6 in breast milk was able to 
bind IgE from peanut allergic patients using a competitive Enzyme AllergoSorbent Test (EAST); this assay 
showed inhibition of labelled Ara h 2 and 6 binding to immobilized IgE from peanut allergic patient serum 





albumins Ara h 2 and Ara h 6 are the main peanut allergens found in breast milk. This may be because these 
2S albumins are less susceptible to gastric and protease digestion than other peanut allergens, such as Ara h 
1 which is less resistant to digestion.
(93)
 The authors also found native non-processed Ara h 6 in breast milk 
suggesting that this allergen undergoes very little processing in the gastrointestinal tract. Bernard et al. 
(2014) subsequently showed that IgE in breast milk was able to cause mast cell degranulation in vitro thus 
would be potentially capable of inducing allergic reactions in peanut allergic infants. Finally, Ara h 6 
immune complexes with IgG and IgA were also found in breast milk and were secreted independently of 
free Ara h 6 a little later, within 40 minutes, and reaching peak concentration at 220 minutes. There is 
therefore now evidence that major peanut allergens in breast milk are present in their whole form following 
maternal peanut consumption and could therefore pose a risk for PS in the breastfeeding child. 
 
 
2.3 Maternal peanut consumption during pregnancy and lactation  
2.3.1 Animal studies 
In animal studies maternal gastrointestinal exposure to peanut and/or hens’ egg during pregnancy and / or 
lactation, protected the offspring from developing peanut and/or egg allergy respectively. 
(94;95)
 Female mice 
were sensitized orally to peanut using cholera toxin (CT) adjuvant then were mated with naïve male mice.
(95)
 
When these peanut sensitized female mice were fed low dose peanut feeds with adjuvant during pregnancy 
and lactation (beneath the threshold to trigger an allergic reaction), 28% of their offspring developed 
anaphylaxis on subsequent intragastric exposure to peanut. However, if maternal mice did not receive low 
dose peanut feeds during pregnancy and lactation all of their offspring developed severe anaphylactic 
reactions on subsequent intragastric exposure to peanut. Anaphylaxis in the offspring mice was confirmed 
by a rise in plasma histamine and mouse mast cell protease 1 (mMCP-1) which are markers for anaphylaxis 
in mice.
(96)





pregnancy and breastfeeding, peanut specific IgG1, (a mouse specific allergic antibody) was detectable 
before their peanut challenge; this must therefore have been maternally derived via the placenta as these 
mice had not had any other form of peanut exposure. In the offspring whose mothers had received low dose 
oral administration during pregnancy and breastfeeding, those protected against peanut anaphylaxis had 





More recently, peanut antigen present in human breast milk was shown to prevent PS when fed to mouse 
pups prior to weaning.
(92)
 Peanut protein in human breast milk following maternal peanut consumption was 
shown to be biologically active by demonstrating binding of free Ara h 6 to peanut sIgE and subsequent 
mast cell degranulation. Pre-weaned mice were fed human breast milk containing no peanut or only free Ara 
h 6 (earlier time points following maternal peanut consumption) or containing both free Ara h 6 and IgG- 
and IgA-Ara h 6 immune complexes (later time points following maternal peanut consumption). Mice were 
then sensitized to peanut using repeated intragastric gavages of peanut and CT and subsequently underwent 
a peanut OFC. Following administration of peanut-free breast milk there was no reduction in mouse Th1 
(IgG2a) and Th2 (IgG1) responses to peanut, but these were significantly reduced following administration 
of human breast milk containing free Ara h 6 and with breast milk containing free Ara h 6 plus Ara h 6 in 
IgG and IgA immune complexes. There was also a trend towards a reduction in mMCP-1 in mice fed human 
breast milk with free Ara h 6 and free Ara h 6 plus Ara h 6 immune complexes, but this did not reach 
statistical significance when compared with mice fed breast milk without Ara h 6 or controls (not treated 
with breast milk) and there was no decrease in peanut sIgE. There was surprisingly no significant additional 
benefit of IgA- and IgG-Ara h 6 complexes (although this was associated with lower mMCP-1 levels than 
mice administered free Ara h 6 in breast milk); this may suggest that the presence of peanut allergen with 





tolerance, rather than any tolerogenic effects of antigen bound to IgA or IgG. In support of the tolerogenic 
effects of breast milk alone, this group showed higher regulatory (IL10) and Th1 (IFNγ) cytokine secretion 
from peanut cultured spleen cells in mice fed human breast milk whereas peanut cultured spleen cells in 
controls secreted Th2 (IL5) and Th17 (IL17) related cytokines.
(92)
 On the basis of these findings there does 
seem to be some animal data in support of exposure to peanut through breast milk preventing PS; however 
results for peanut exposure in utero are less clear. 
 
 
2.3.2 Human studies 
2.3.2.1 Evidence for an association between maternal peanut consumption and PS/PA in the child 
A number of observational studies have assessed the impact of maternal peanut consumption during 
pregnancy and breastfeeding; however, these studies have shown conflicting associations. There are three 
studies I will present in this section which provide evidence for maternal peanut consumption during 
pregnancy (and in some cases lactation) being a risk for PS in the offspring.  
 
1) In a small study from South Africa with 25 peanut sensitized individuals (defined as peanut sIgE 
>0.35kU/L) and 18 control subjects, there was a trend towards PS (OR 3.97 95% CI: 0.73-24 
P=0.063) if mothers ate peanut more than once a week during pregnancy.
(97)
 There was no 
significant association between maternal peanut consumption during breastfeeding and PS in their 
children.  
 
2) The CoFAR study (a prospective US cohort of 512 infants with egg or cow’s milk allergy or 
moderate to severe eczema with cow’s milk or egg sensitization) assessed the association between 





≥5KUA/L) in their children. Peanut consumption during pregnancy was defined as ‘avoided’,’ <2 
times weekly’, ‘>2 times weekly’, ‘daily’ or ‘not known’. A dose response relationship between 
maternal peanut consumption during pregnancy and a serological diagnosis of likely PA was 
reported. Furthermore, in a subgroup analysis of 71 infants who were never breastfed, peanut 
consumption >2 times weekly during pregnancy increased the risk of peanut IgE ≥5kU/L 5-fold (OR 
4.99, 95% CI, 1.69-14.74; P=0.004). 
(98)
 There was no significant association between maternal 
peanut consumption during breastfeeding and likely PA in children recruited to the CoFAR study. 
 
3) A Canadian study by DeRoches et al. (2010) included 202 children less than 18 months old who had 
been referred to an allergy clinic for a presumed peanut allergic reaction in the last month. 
(99)
 
Controls were children under 18 months of age without a history of food allergy being seen in other 
paediatric clinics (n=201).  Maternal peanut consumption was assessed by a non-validated dietary 
food frequency questionnaire (FFQ) where respondents were asked to specify the frequency with 
which they had eaten peanut containing foods during pregnancy and lactation (at least daily, 5-6 
times weekly, 2-4 times per week, once a week or 1-3 times a month or never). In the case of peanut 
butter they were also asked to report the average portion size, however, they were not asked this 
information for other peanut containing foods thus the amount of peanut protein consumed could not 
be quantified. Peanut consumption during pregnancy was found to be higher in peanut allergic cases 
(196/202=97%) than controls (176/199=88%) with an adjusted OR of 4.22 (1.57-11.30). Peanut 
consumption during breastfeeding was also higher in the peanut allergic cases (154/162=95%) than 
controls (124/157=79%) with an adjusted OR of 2.28 (1.31-3.97). Multivariate logistic regression 







DeRoches et al. (2010) therefore concluded that the route of PS was likely to be via maternal peanut 
consumption in utero or via lactation. However, the questionnaires were administered after PA was 
confirmed in clinic. This could have resulted in recall bias of maternal peanut consumption during 
pregnancy and lactation because, at the time, this was considered a risk factor for PA and was 
recommended against in atopic families;
(100)
 thus mothers could have overestimated the amount of 
peanut they consumed during pregnancy and lactation once they knew that their child had PA. The 
authors also acknowledged that using non-atopic children as controls was a limiting factor in the 
study design as these children would have had a lower rate of PA regardless of the level of maternal 
peanut consumption during pregnancy or lactation.  
 
Despite these limitations there is some observational data described in these three studies which points 
towards an association between maternal peanut consumption, particularly during pregnancy and later PA in 
the their offspring. In the next section I present evidence to the contrary and in particular will focus on a 
study, similar in many ways to the DesRoches et al. (2010) study which showed different results once they 
included household peanut consumption (HPC) in their analysis.  
 
2.3.2.2 Evidence against maternal peanut consumption during pregnancy / lactation and PS / PA 
Three large cohort studies (BAMSE study n=4089, 
(101)
 ALSPAC study n= 13,971, 
(49)
 and the Isle of Wight 
study n=1456) 
(102;103)
 did not find an association between maternal peanut consumption during pregnancy or 
lactation and PS or PA in their children.  
 
Fox et al. (2009),
(104)
 recruited peanut allergic children under 24 months (n=133) and high-risk egg allergic 
controls (n=150) who had been referred to a paediatric allergy clinic, predominantly due to eczema. 
Children without atopy were recruited from general paediatric clinics (n=150). A validated peanut FFQ was 





year of life (average peanut protein consumption in grams/week). Dietary questionnaires were performed 
before the diagnosis of peanut was ascertained therefore reducing the risk of recall bias. Although maternal 
peanut consumption during pregnancy and lactation was higher in peanut allergic cases than high-risk 
controls on univariate LR analysis, once HPC in the first year of the child’s life was entered into the model 
maternal peanut consumption during pregnancy and lactation was no longer significantly associated with 
PA. Maternal peanut consumption during pregnancy and lactation and HPC were measured using the same 
dietary questionnaire and was quantified in g/week. Thus peanut consumption could be assessed using 
continuous rather than categorical variables (thus had a similar power to determine effects).  
 
To separate out the different routes of peanut exposure involved, the authors evaluated families where there 
was disparity between maternal peanut consumption during pregnancy and lactation and HPC in the first 
year of life. In families where the only peanut consumption was due to HPC (because mothers excluded 
peanut during pregnancy and lactation) the relationship between peanut consumption (household but not 
maternal) and the likelihood of PA persisted. In families where the only peanut consumption was by the 
mother during pregnancy or lactation but with no other household members eating peanut then the 
association between peanut consumption (maternal) and likelihood of PA was lost. 
(105)
 There was a positive 
albeit weak correlation between maternal peanut consumption during pregnancy (Spearman Rank 
correlation coefficient rs=0.45) and lactation (rs=0.51) and HPC during the first year of the child’s life.  
These results, taken together suggest that the apparent association between maternal peanut consumption 
during pregnancy and lactation and PA was attributable to the link between maternal peanut consumption 
and HPC and that HPC was the predominant risk factor. The impact of HPC on PA will be discussed in 






2.3.3 RCTs assessing impact of maternal dietary avoidance during pregnancy / lactation 
The literature described above provides conflicting observational data on whether maternal peanut 
consumption during pregnancy and/or lactation is a risk factor for the development of PA. To assess a causal 
relationship a randomised controlled trial (RCT) where maternal diet during pregnancy and lactation was 
controlled would be required. There are several RCTs which have attempted to reduce prenatal and postnatal 
exposure to allergenic foods by manipulating the maternal diet in a bid to prevent the development of 
eczema, food and respiratory allergies in the child.  The RCTs performed did not, however, limit dietary 
restriction to just peanut but included a range of allergenic foods; they also did not focus on peanut allergic 
outcomes but on atopic sensitization and disease in general.  
 
The Cochrane Collaboration reviewed the evidence available up until 2012 from RCTs comparing maternal 
dietary antigen avoidance during pregnancy and lactation (in women with atopic family histories) but 
excluding trials with additional interventions such as manipulation of the infant’s diet. (106) Maternal dietary 
restriction of allergenic foods during pregnancy was not associated with a reduction in eczema in five RCTs, 
involving a total of 952 participants. 
(107-111)
 Maternal dietary restriction during lactation was not associated 
with a reduction in eczema or SPT sensitization to cows’ milk, egg or peanut in two RCTs involving a total 
of 523 participants.
(109;111)
 Furthermore, the authors found that mothers who underwent dietary restrictions 
gained less weight during pregnancy and there was an increased risk of preterm birth and reduced birth 
weight in the infant. 
(107;111)
 The authors therefore advised that there was insufficient data to recommend 
maternal dietary restriction during pregnancy and lactation and this may in fact incur risks for the mother 
and child due to nutritional insufficiencies.  
 
There are two publications from prospective RCTs from the US (Zeiger et al. 1989)
(112)
 and the Isle of 
Wight (Hide et al. 1992/1996, Arshad et al. 2007)
(113-115)





maternal and infant dietary restrictions on atopic disease which were not included in the Cochrane review 
cited in the paragraph above (as these studies included manipulation of the child as well as the maternal 
diet). In the study by Zeiger et al. (1989) high-risk children were recruited on the basis of at least one family 
member having atopic disease and evidence of sensitization by sIgE or SPT analysis.  The intervention arm 
dietary measures included maternal avoidance of all dairy, egg, peanut and concentrated forms of soya (e.g. 
tofu) plus limited wheat intake in the last trimester of pregnancy and during lactation. If formula fed, the 
infants were given Nutramigen (an extensively hydrolysed casein formula) until 12 months of age.  Parents 
were asked to avoid giving their infants dairy, egg, soya, peanut and wheat until 12 months of age, when 
cow’s milk could be introduced followed by soya, wheat, and then egg at 24 months and peanut at 36 
months. Compliance with this dietary regimen was ascertained by maternal self-reporting and daily diaries.  
 
At 12 months follow-up there was a reduction in cumulative ‘atopy’ defined as prevalence of food 
associated eczema, urticaria and /or gastrointestinal disease (5.1% in the intervention arm versus 16.4% in 
the control arm, P=0.007). At 24 month follow-up the intervention group showed a reduction in food SPT 
sensitization at16.5% (16/97) versus 29.8% (50/168); P= 0.019, predominantly due to fewer positive cow’s 
milk SPTs (1% versus 12.4%; P= 0.001) but also due to lower egg SPT (12.4% versus 17.3%). At 24 
months peanut SPT was slightly higher in the intervention arm at 5/97 (5.1%) versus the control arm at 
7/168 (4.2%). There was no difference detected in inhalant SPTs at 24 months. 
(112)
 At 7 years of age there 





Although the study by Zeiger et al. (1989) seemed to show an early protective effect of dietary 
manipulation, the reduction in cumulative ‘atopy’ at 12 months is likely to have been due to lack of dietary 
exposure to the foods, as infants in the intervention arm were not supposed to be having any allergenic 





which may have decreased environmental exposure to these foods (this information was not available in the 
study). The reduction in egg SPT sensitization could be explained by the fact that infants were only advised 
to start egg introduction at 24 months; however, the reduction in milk SPT at 24 months cannot be explained 
in the same way as parents were advised to introduce dairy into the infant’s diet at 12 months, thus lack of 
cow’s milk sensitization was not just due to delayed exposure.  
 
There were certain limitations to the study by Zeiger et al. (1989).  The patient population were recruited 
from the Kaiser Permanente Health plan, a private healthcare system that may have resulted in selection bias 
due to the skewed socioeconomic status of the population recruited. In the first year there was a 38% rate of 
drop out in the intervention arm of the study, predominantly due to inability to comply with the dietary 
intervention. These participants were excluded from the study and therefore the results obtained were based 
only on a per protocol analysis rather than an intention to treat analysis, which would have included 
outcomes from all children whose mothers’ were assigned to the intervention arm, even if their mothers had 
not complied with the dietary interventions. This study was additionally limited by a 43% loss to follow-up 
in both the intervention and control arm of the study bringing down the number of children assessed at age 7 
years to only 59 children in the intervention arm and 106 children in the control arm. The study is likely to 
suffer from several sources of bias: selection bias from the population recruited, bias due to the high drop-
out rate due to failure to comply with the study intervention (who were subsequently excluded from the 
study rather than included in an intention to treat analysis) and bias due to loss to follow-up. 
 
The Isle of Wight RCT (Arshad et al. 2007, n=120) reported a protective effect of combined maternal and 
infant dietary restriction in high-risk infants in conjunction with HDM reduction measures which persisted 
up to 8 years follow-up for eczema (OR 0.23 95% CI: 0.08-0.64; P<0.01), positive SPT to at least one 





(OR 0.42; 95% CI 0.19-0.92; P=0.03).
(114)
 High-risk infants were defined by allergic disease (asthma, 
eczema, or allergic rhinitis) in two immediate family members and high [>0.5kU/L] cord blood IgE levels. 
The intervention consisted of strict elimination of common allergenic foods (dairy, egg, fish, wheat, 
unhydrolysed soya and nuts) until 9 months of age,with breastfeeding mothers followed the same regimen 
(except wheat exclusion). Formula fed infants received a soya based hydrolysate (Aptimal HA, Milupa, 
UK).  Cow’s milk was introduced at 10 months, followed by egg at 11 months then other foods were 
introduced. Maternal compliance with the dietary intervention was assessed by random testing of breast milk 
for cow’s milk proteins; however, this information was not presented in the manuscript and very little data 
on dietary compliance assessment was provided. Additionally this study also excluded infants and mothers 
who found the dietary restrictions too difficult to manage, rather than including these children in an intention 
to treat analysis. Nevertheless, this cohort study benefited from no drop-outs as all 120 children were 
followed up at 1, 2, 4 and 8 years.   
 
HDM reduction measures (including infant anti-allergy mattress covers and acaricide sprays) successfully 
reduced HDM levels in the home as quantified by ELISA analysis of dust samples from the infants’ 
bedroom carpet, living room and upholstered bedroom. The addition of anti-allergy mattress covers in this 
study to the intervention may have contributed to why this study was effective in reducing atopy; food 
allergens may have been reduced in the infant bed thus leading to lower levels of environmental food 
allergen exposure.  
 
Following publication of the Cochrane review a large prospective cohort study (Growing Up Today Study 2) 
found that peanut and tree nut allergy was less common in the children of mothers who consumed more 
peanut or tree nuts respectively around the time of birth of the child.
(117)
 In non-atopic mothers the reduction 





mothers increased their peri-pregnancy peanut and tree nut consumption from less than once a month to at 
least 5 times a month. There were certain limitations to this study, however, as the authors used a non-
validated FFQ and peanut and tree nut allergy was not confirmed by OFC, but by review of medical notes 
and allergy tests by two paediatricians (one of whom was an allergist). Although the authors stated that they 
assessed peri-pregnancy maternal peanut consumption, in 76% of cases this was actually after birth and up 
to the child’s first birthday. The authors did not adjust for maternal peanut consumption during breastfeeding 
nor did they adjust for the child eating peanut, which would be more common in a peanut eating family and 
could therefore have led to oral tolerance induction.  
 
Overall, the literature in humans does not support maternal dietary restriction of allergenic foods (including 
nuts) during pregnancy and breastfeeding to reduce PS / PA or other atopic conditions. The only studies 
which did suggest a positive association between maternal peanut consumption during pregnancy and 
lactation and PS/PA (or benefit from dietary restrictions) were in high-risk children, thus future research to 
evaluate this further would be more appropriate in high-risk children. Although not directly related to peanut 
consumption and exposure, duration of breastfeeding is also frequently discussed as a potential modifier for 
allergic disease therefore I will discuss this briefly in the next section. 
  
2.3.4 Duration of breastfeeding and PS / PA 
The association between duration of breastfeeding and food sensitization/ allergy is fraught with the 
confounding effect of reverse causality i.e. that mothers breastfeed longer because their child is atopic or 
because there is a risk of atopy in the family. This was demonstrated in the ALSPAC study where on 
univariate analysis, duration of breastfeeding was associated with PA with a 2.6-fold risk if the infant was 





included maternal history of atopy and eczema, duration of breastfeeding was no longer associated with PA. 
Of note, the ALSPAC cohort obtained data on duration of maternal breastfeeding prospectively. 
(49)
 This 
may, in part, explain the reason why studies that have evaluated the role of breastfeeding on the risk of food 
allergy have ranged from reducing the risk of food allergy, 
(118)
 to neutral effects 
(119)
 to increasing the risk of 
atopic disease.
(120)
 Nonetheless, this is an important covariate to consider when evaluating risk factors for 
allergic disease.  
2.4 HPC during the child’s first year of life. 
Three studies to date have assessed whether ‘household’ exposure to peanut during the first year of life is a 
risk factor for the development of PS and PA. In the high-risk CoFAR study there was no association 
between household exposure to peanut and PS or likely PA.
(98)
 However, the CoFAR study used a crude 
measure of household exposure to peanut defined as: ‘Were/are there peanuts or peanut products in the 
house while breastfeeding?’. Although Sicherer et al. (2010) tried to ensure that this question would capture 
household exposure to peanut during infancy by qualifying the questions with ‘while breastfeeding’ this 
question did not assess whether the peanut products were eaten and thus handled or whether the peanut 
products had just stayed in the cupboard. 
 
A second study by DesRoches et al. (2010) (methodology discussed in Section 2.3.2.1) assessed potential 
environmental exposure to peanut by quantifying the presence of peanut containing foods in the child’s 
home and day-care centre. 
(99)
 Their study population included children < 18 months either referred for a 
presumed peanut allergic reaction in the last month (n=212) or non-atopic controls in other general 
paediatric clinics (n=201).  Peanut–containing products in the home environment or day-care were classified 
into peanut butter, peanuts in chocolate, peanuts in cookies or whole peanuts; thus household consumption 





sauce, Chinese, Thai and Indonesian food) were not included. They found less peanut butter, peanuts in 
chocolate and peanuts in cookies in the homes of the peanut allergic cases versus non-atopic controls, but no 
significant difference in the presence of peanut containing foods in day-care (with the exception of whole 
peanuts which were present more in day-care centres with peanut allergic children). 
 
A limitation of this study is that PA was already suspected in the month leading up to their assessment, thus 
it is highly likely that the parents of peanut allergic children would have removed many peanut products 
from the home in the weeks leading up to their clinic assessment. This would also explain why there was no 
difference between numbers of peanut containing foods in day-care between peanut allergic cases versus 
controls as they are unlikely to have removed all peanut-containing foods from the day-care, particularly 
before the child had a formal diagnosis of PA. Other limitations in this study, as in the CoFAR study, were 
that the measurement of household exposure to peanut was the presence of peanut-containing foods in the 
home rather than actual HPC; thus peanut butter could have been in the home but the frequency of use and, 
therefore, potential transfer into the environment or onto the child’s skin is not known. Furthermore, 
comparing peanut allergic cases against non-atopic controls may have also influenced the presence of peanut 
containing foods in the home: non-atopic families might be more likely to have peanut in their home as they 
are not concerned about the potential of peanut allergic reactions in any of their family members. 
 
The third study by Fox et al. (2009) 
(104)
 addressed several of the shortcomings in the previous two studies: 
1) Comparing peanut allergic cases (n=133) against both atopic egg allergic controls (n=160) and non-
atopic controls from general paediatric clinics (n=150). This allowed the study to tease out factors and 






2) Asking parents to complete the dietary questionnaire before their child was diagnosed with PA. If 
parents already knew their child was peanut allergic they were excluded from participation to prevent recall 
bias in the dietary questionnaires. After completing the questionnaire, they were assessed for PA by SPT 
(>8mm) or sIgE >15 kU/L, on the basis of previously validated 95% PPV, 
(18)
 or a double blind placebo 
controlled OFC. One must, however, consider that just being in an allergy clinic might invoke a higher index 
of concern about the possible role of household or personal nut consumption on the child’s allergic status. 
 
3) Quantifying  HPC (by combining peanut consumption of all household members in the child’s first 
year of life), rather than just stating the presence of peanut-containing foods in the home (as in the 
DesRoches et al.(2010) and Sicherer et al. 2010 studies described) is likely to have been a better 
representation of the amount of peanut containing food being eaten / handled thus more likely to lead to 
EPE. 
4) The study by Fox et al.(2009) assessing HPC using a validated semi-quantitative peanut FFQ with a 
large range of savoury and confectionery/bakery peanut containing foods. Validation of this FFQ for 
maternal recall over 2 years 
(121)
 and against a 7-day food diary over 6 months for the mother and infant 
(122)
 
made this dietary questionnaire suitable for this study design.  
 
5) The FFQ quantified the amount of peanut protein in each of the peanut containing foods and thus 
obtained an average level of peanut protein consumption (g/week) by combining the different types of 
peanut containing foods into one continuous variable.  Using a continuous variable will usually have more 
power to show an association than a categorical variable.  
In the study by Fox et al. (2009) HPC was ten times higher in peanut allergic children (18.8 gram/week) 
than high-risk egg allergic children without PA (1.9 grams/week) (P<0.0001) and three times higher than 





‘covered’ peanut containing foods such as chocolates were more likely to be associated with PA. The 
authors postulated that peanut butter, being stickier, was more amenable to transfer by hands; this could 
potentially be transferred onto the infant’s skin directly or onto their bedding or play-area.  A limitation of 
this study is that the authors did not directly measure peanut protein levels in the environment (such as in 
dust or surface wipe samples). Fox et al. (2009) also quantified peanut protein consumption by the child in 
their first year of life, and found that the dose response between increasing HPC and PA was abrogated in 
children who had eaten peanut within the first year of life. The counteracting influences of early oral peanut 
consumption versus exposure to peanut via other routes (such as through the environment via the 
epicutaneous route) is a central theme to this PhD. In the next Section I will discuss the evidence 
surrounding the impact of oral peanut consumption on the development of PA vs. tolerance in both animal 
and human studies.  
2.5 Animal studies of oral peanut and/or ovalbumin exposure 
The majority of food allergy research in mice is performed using ovalbumin (OVA) rather than peanut 
allergen. I have therefore included certain important animal studies which have assessed OVA sensitization 
and allergy where it is relevant to the argument being constructed. Yamashita et al. (2012) showed that OVA 
sensitization (using IP injection with alum) and subsequent anaphylaxis could be prevented in BALB/c mice 
through oral pre-treatment with 1mg OVA every day for 5 days; 
(123)
 this supports the concept of oral 
tolerance induction. In another study researchers were able to achieve oral tolerance or allergy to OVA or 
peanut depending on the dose employed.
(124)
 BALB/c mice were fed a single intragastric feed of peanut or 
OVA, ranging from 0.02mg to 100mg (0.001-5 mg/gram bodyweight) versus phosphate buffered saline 
(PBS). One week later mice were immunized at the base of the tail with 100 µg peanut or OVA with 
complete Freund’s adjuvant (heat killed and dried Mycobacterium tuberculosis). To assess the 





weeks and the swelling was recorded ( Figure 4). Mice were sacrificed a week later and proliferation of 
peanut specific T cells in the spleen and peripheral lymph nodes (LNs) from the tail base immunisation site 
was quantified by tritiated (H
3
) thymidine uptake by T cells cultured in peanut protein for 90 hours.  
There was a bell-shaped curve for clinical allergic reactivity dependent on the dose of intragastric OVA or 
peanut protein administered prior to sensitization ( Figure 4). At low doses up to 0.02 mg of OVA or up to 
0.2 mg for peanut protein there were increased allergen specific T cell proliferative responses, Th2 cytokine 
production and footpad swelling on challenge compared to PBS fed mice. Thus low-dose oral peanut 
consumption increased allergic responses in these mice. However, in mice fed ≥ 2 mg OVA (≥ 0.4 mg/gram 
bodyweight) or 100 mg peanut protein (5 mg/gram bodyweight) there was minimal footpad swelling 
following hind foot pad injection and significantly reduced T cell proliferation and cytokine responses vs. 
controls, demonstrating a protective effect of high-dose oral exposure against allergic reactions.  
 Figure 4: Clinical reactivity to hind foot pad challenge in peanut sensitized mice dependent on dose of 








































2.6 Human studies on oral peanut exposure 
Similar themes emerging in animal data with regard to oral tolerance induction have been investigated in 
humans, such as the timing of peanut introduction into the diet and peanut protein dosage required to prevent 
PA as described below. 
 
2.6.1 Age of introduction of peanut into diet and PS / PA 
A small case control study (n=43) by Frank et al. (1999) found that children who were sensitized to peanut 
had introduced peanut into their diet at an earlier age (12.5 vs. 17.3 months). However, participants did not 
undergo diagnostic OFCs to establish PA or tolerance. 
(97)
 PS was also anecdotally linked to earlier peanut 
consumption in an observational study of 62 consecutive peanut allergic children by Ewan et al. (1996) 
although age of introduction of peanuts was not described in this study. 
(125)
 In the study by DesRoches et al. 
(2010) (see Section 2.3.2.1 for description of study design) age of introduction of peanut into the child’s diet 
was similar between peanut allergic cases and non-allergic controls (11-12 months).  Conversely, a large 
cross-sectional study by Du Toit et al. (2008) demonstrated that early high-dose peanut consumption during 
infancy was associated with a lower rate of PA. 
(17)
 In this study, over 5000 Jewish primary school aged 
children from Israel and North London (UK) were assessed for PA by initial questionnaire for reported PA. 
Diagnostic OFC or allergy tests above the 95% PPV (peanut SPT ≥ 8mm or peanut sIgE ≥15kU/L) were 
used to confirm or refute this self-reported diagnosis. Peanut consumption during infancy was assessed by a 
validated peanut FFQ. 
(121;122)
 PA prevalence was 10 times higher in the UK (1.85%) than Israel (0.17%) 
(P< 0.001). Median peanut protein consumption during infancy (in grams/week) in UK Jewish children was 
0 grams versus 7.1 grams in Israeli Jewish infants (P<0 .001) and Israeli Jewish children ate peanut on 
average 8 times a week during infancy. The authors concluded that high and frequent peanut consumption 







There were certain limitations to the study by Du Toit et al.(2008); the authors adjusted for relevant 
covariates such as atopy (asthma, eczema or allergic rhinitis), other food allergies, age and sex and selected 
children of similar genetic background. However, the authors did not assess maternal peanut consumption 
during pregnancy or lactation, which may have influenced the development of peanut sensitization and 
allergy in these children. The authors postulated that the differences observed in PA rates in the UK versus 
Israel were likely to be due to specific weaning practices (high versus low peanut consumption during 
infancy). There were, however, also lower rates of other food allergies in Israel such as sesame, tree-nut 
allergy and egg allergy (P<0.05). The authors argued that this might be due to earlier and more frequent 
sesame seed consumption in Israel (this was not quantified in the publication) and due to cross-tolerance 
induction by peanut for sesame and tree nut allergy given the homology between amino acid sequences of 
these allergens. The higher rate of egg allergy was not explained and as such the possibility that other factors 
were also driving the reduction in PA in Israel cannot be excluded (such as for example Vitamin D), thus the 
need for an RCT to confirm these findings.  
 
The Learning Early About Peanut (LEAP) Study (www.leapstudy.co.uk), is an RCT which has evaluated 
whether early peanut consumption leads to a reduction in PA in high-risk children (of which some were 
already sensitized to peanut at baseline). In the LEAP study 640 infants at high-risk of developing PA (due 
to egg allergy or moderate–severe eczema) were randomised to either high-dose (2 grams peanut protein), 
frequent (3 times a week) peanut consumption from infancy until 5 years of age or peanut avoidance. 
(9)
 PA 
was assessed by OFC at 5 years of age to determine whether early high dose, frequent oral peanut 
consumption led to a reduction in PA in high-risk children. The LEAP study structure is displayed in 
displayed in Figure 5.
(126)
 There was a 98.4% retention rate. The outcomes were divided into children with 
negative peanut skin prick tests (SPT) (n=530) at baseline as a model for primary prevention of peanut 





prevention. In the intention to treat analysis, early regular peanut consumption reduced the rate of peanut 
allergy from 35.3% to 10.6% (a 70% risk reduction) in SPT positive children and reduced the rate of peanut 
allergy from 13.7% to 1.9% in the SPT negative group. In the per protocol analysis children with positive 
SPT reduced their peanut allergy from 34.0% to 0.0% (see Figure 6). These findings provide a strong basis 
for the role of early high-dose peanut consumption leading to a reduction in PA; however, the authors did 
not comment on whether children who ate a lower dose of peanut protein were protected against PA. Thus it 
may not be possible to set a cut-off for the minimum amount of peanut consumption required to prevent PA 
and it is still possible that children eating very low doses of peanut might increase their risk of PA.  
Figure 5: LEAP study design 
Reproduced with permission from Du Toit et al. (2015),
(126)






Figure 6: Results from the LEAP study 
Reproduced with permission from Du Toit et al. (2015),
(126)
 Copyright Massachusetts Medical Society. 
 
2.6.2 Dose of peanut oral exposure 
Given that low-dose oral peanut consumption increased allergic responses to peanut in animal studies, one 
could hypothesise that parents could inadvertently sensitize their infants to peanut by feeding them low 
quantities of peanut protein in foods, or Arachis (peanut) oils in milk formulae 
(127)
 and vitamin supplements 
(e.g. Abidec). Previous literature raised concerns about the implications of low dose exposure to Arachis Oil 
in infant vitamin supplements. De Montis et al. (1993) found a higher rate of PS in children administered 
vitamin D which contained Arachis oil in the first two years of life (daily administration - PS rate: 9/28= 





peanut oil in the first two years of life (PS rate: 2/40=5%). 
(128)
 However, the study was limited by a small 
sample size and lacked adjustment for other confounding factors (such as eczema or parental atopy).  
Subsequently, a Swedish group refuted this finding through retrospective analysis of their large 
observational cohort study (BAMSE) in which 98% of children received vitamin A and D in the first year of 
life. 
(129)
 They found no difference in PS rates (defined by sIgE ≥ 0.35kU/L) at 4 years of age in children 
who took oil based vitamin supplements (containing Arachis Oil) (n=2288) versus those who took water 
based vitamin supplements (without Arachis Oil) (n=159). 
(129)
 These results were adjusted for parental 
atopy, maternal age, maternal smoking, fish consumption and breastfeeding. In fact, children who had 
received oil based vitamin D supplements (containing Arachis Oil) had a lower risk of asthma, food 
hypersensitivity and sensitization to egg white, birch pollen, cat and horse allergen.  
 
Current data thus indicates that it is unlikely that Arachis oil in medication is a risk factor for developing PS 
or PA. However, peanut oils are refined in vitamin supplements and other medication thus are unlikely to 
contain any peanut protein. This has been demonstrated by the lack of SPT reactivity 
(101)
 and lack of clinical 
reactivity in peanut allergic patients 
(130)
 to refined peanut oil. To date, no study in humans has assessed the 
impact of low dose peanut consumption during infancy and the development of PA; thus, as yet, there is no 
clear evidence as to the role of low dose peanut oral exposure in infancy and PS or PA.   
 
2.7 Public health recommendations 
In 1998 the Department of Health Working Group for the Committee on Toxicity (COT) of Chemicals in 
Food, Consumer products and the Environment issued a report recommending that mothers whose unborn 
children had a first degree relative with atopic disease ‘may wish’ to avoid peanut during pregnancy and 





products in the first 3 years of life as this ‘may increase the risk of sensitization and should be avoided’ 
(p.29). 
(131)
Since the introduction and dissemination of these recommendations in 1998 the prevalence of PA 
has not significantly reduced, 
(15)
 and may have increased (between 2001-2005 prevalence of PA diagnosed 
in primary care doubled in England according to QRESEARCH national health database). 
(132)
Although this 
suggests that peanut avoidance in pregnancy, breastfeeding and early life is not effective at reducing PA, 
there are several explanations as to why this may not have been effective.  Data suggests that the COT 1998 
advice was only implemented correctly by a low percentage of the atopic population and mainly by families 
without an atopic history. 
(16)
 There are also other factors such as a rise in the incidence of eczema from 
when this recommendation was introduced (QRESEARCH UK national database showed a 42% increase in 
eczema diagnosis between 2001-2005)
(133)
 which may have negated any protective effect this dietary 
recommendation may have had.  
 
The 2007 House of Lords Science and Technology Committee report on Allergy highlighted that these 
recommendations may have resulted in an increase in the incidence of PA and thus recommended that ‘this 
advice should be withdrawn immediately’ (key recommendation 6.57). (1) A systematic review of studies 
published in this field was thus funded by the Food Standards Agency and performed by Thompson et al. 
(2008) ten years after the 1998 COT recommendations; 
(134)
they found no evidence that maternal 
consumption of peanuts during pregnancy or breastfeeding increased the risk of PS or PA in the child. The 
findings from that review, in addition to the Cochrane review performed in 2006 
(135)
 (updated in 2012 see 
Section 2.3.2.2), led to a revision of the recommendations from The Working Group for the Committee on 
Toxicity of Chemicals in Food, Consumer products and the Environment in 2009.  
 
The 2009 COT recommendations no longer advocate the avoidance of peanut during pregnancy, lactation or 





 ‘(i) In common with the advice given for all children, infants with a parent or sibling with an atopic disease 
should be breast-fed exclusively for around 6 months; 
 (ii) Infants and children who are allergic to peanuts or peanut products, should not consume them or foods 
that contain them; 
(iii) Those who are allergic to peanut should seek advice from medical professionals about avoidance 
strategies.’ (p. 25-26) (100) 
 
For both the 1998 COT recommendations and 2009 COT recommendations, there was very little advice 
provided to medical professionals on how to advise their patients. This may have been in part the reason 
why the original 1998 COT recommendations were incorrectly implemented and may also lead to 
unforeseen complications in implementing the 2009 COT recommendations.  
 
The 1998 COT report did state that sensitization to peanut might occur through the skin, ‘particularly 
abraded or damaged skin’ (p.11) through the application of peanut oil containing creams. However, they 
then stated that ‘given such creams contain refined oil, dermal sensitization is unlikely’ (p.11).(131) 
Consideration was also given as to whether inhalational or cutaneous exposure (via hand to hand 
transmission) led to sensitization, but no further scope or recommendations were made on the basis of this. 
Epicutaneous exposure was addressed in the Committee on Toxicity statement on the review of the 1998 
COT recommendations on peanut avoidance.  
(100)
 They stated that although mouse data supported the role 
of epicutaneous sensitization, there were not enough human data, as yet, to make Public Health 
recommendations. They highlighted that further studies were needed in humans: ‘to determine whether and 
to what extent the skin and respiratory tract are important routes of sensitization to peanut and other food 








In the next theory section I will review the literature on the role of epicutaneous exposure in the 
development of PS and PA. However, first I will discuss eczema and its relationship with food allergy as the 
consistent association between early onset, severe eczema and PA is one of the arguments used to support 






Chapter 3 Epicutaneous sensitization  
3.1 Eczema – nomenclature and prevalence 
Eczema is a chronic skin condition characterised by an itchy scaly rash. Atopic eczema is associated with 
the production of IgE against common food and aeroallergens. 
(136)
 The prevalence of eczema is increasing. 
In a longitudinal cohort study on the Isle of Wight, UK the population questionnaire based ‘current’ eczema 
rate was 11.9% (145/1214) at 4 years of age in 1993 and 14.3% (194/1358) at 10 years of age in 1999. The 
rate of ‘eczema ever’ at 10 years of age was 563/1373 (41%). (137) The ISAAC study (International Study of 
Asthma and Allergies in Childhood), assessed questionnaire based allergic conditions in over 100 different 
countries and found an increase in ‘current’ eczema over a 12 month period from 13% (1994-1995) to 16% 
(2002-2003) in 6-7 year old UK children. Evaluation of GP records in England from 2001 to 2005 
(QRESEARCH database) found that the diagnosis of eczema had increased by 42%, predominantly in 
children,  
(133)
 although this may be secondary to increased recognition of eczema in primary care. 
 
3.2 Eczema pathogenesis 
The pathogenesis of eczema was originally thought to be a consequence of an immunological abnormality 
leading to an inflammatory dermatosis (the inside–outside pathogenesis hypothesis). (138) Acute eczematous 
skin lesions are characterised by spongiosis (epidermal intracellular oedema) and cellular infiltrates 
(particularly CD4+ activated Th cells). This inflammatory process was thus thought to lead to an impaired 
skin barrier. More recently, research groups have argued that the permeability barrier abnormality in eczema 
is not merely a secondary consequence of disease activity but rather the driver of disease activity (the 
outside-inside pathogenesis hypothesis). 
(139)
 The outside-inside pathogenesis hypothesis gained 





genes responsible for the integrity of the skin barrier (see Section 4.2) which were shown to be important 
risk factors for the development of eczema. In additional support of the outside-inside pathogenesis 
hypothesis, eczema severity is associated with skin barrier permeability; uninvolved skin in patients with 
known eczema still displays barrier function abnormalities and treatments which improve skin barrier 
function by targeting lipid abnormalities (which lead to barrier abnormality) have anti-inflammatory effects. 
(140)
 It is thus feasible that, in the presence of an already impaired skin barrier, irritants, pathogens and 
allergens (such as peanut) might penetrate the skin leading to an inflammatory milieu which predisposes to 
allergic sensitization and subsequent allergy.  
 
3.3 IgE mediated food sensitization in children with a history of infantile eczema  
Eczema is often cited as the first step in the allergic march.
(141;142)
 One of the seminal papers evaluating the 
link between eczema and IgE mediated food sensitization was the Melbourne Atopy Cohort (MAC) 
study.
(143)
 In the MAC study, 620 children were recruited after birth based on a first degree relative with 
eczema, asthma, allergic rhinitis or IgE mediated food allergy. The study coordinators selected an additional 
group of 70 infants referred consecutively to their Paediatric Allergy Clinic with severe eczema 
unresponsive to emollients and topical steroids.  Eczema was defined according to the criteria of Hanifen 
and Rajka which had been modified by a UK working party; 
(144)
 this included a history of eczema, or visible 
flexural dermatitis, a history of dry skin and/or pruritis, onset under 2 years and a personal history of asthma. 
‘IgE mediated food sensitization’ in the MAC study was defined as a SPT twice the size of the histamine 
control to cow’s milk, egg or peanut. This usually meant an SPT wheal size of at least 6mm, which for 
children under 2 years of age would be highly predictive of food allergy (in one case series all OFCs were 
positive in children <2 years of age with SPT wheal diameters of 6mm for cow’s milk, 5mm for egg, and 
4mm for peanut).
(145)





At one year of age children in the MAC study with mild eczema had an approximately 3-fold increased risk 
of ‘IgE food sensitization’ (44/121 = 36%) compared with infants without eczema (44/394 = 11%).  
Children with severe eczema had an approximately 6-fold increased risk of ‘IgE food sensitization’ (19/29 = 
65%) compared with infants without eczema (44/394 = 11%). Thus, this study not only showed that eczema 
was a risk factor for food sensitization (and likely allergy given the SPT ≥ 6mm definition of sensitization), 
but also that severity of eczema conferred an additional risk for the development of food sensitization.   
 
 
The same group then assessed the association between eczema and food allergy using screening data from 
the EPAAC (Early Prevention of Asthma in the Atopic Child) study. 
(146)
 The EPAAC study was a 
multicentre international study with 2218 children (mean age 17 months) that had active eczema and a 
positive family history of atopy and/or asthma. The EPAAC study was designed to assess whether regular 
use of second-generation long-acting antihistamines might prevent the development of asthma in atopic 
children.  At the screening visit eczema was assessed using a Scoring Atopic Dermatitis (SCORAD) index. 
IgE mediated food allergy was assessed using PPV for ImmunoCAP previously established by diagnostic 
OFCs for cow’s milk (90% PPV under 1 year ≥2.5kU/L),(147) egg (94% PPV under 2 years  ≥0.35kU/L) (148) 
and/or peanut  (95% PPV aged 3.8 years  ≥14kU/L). (149) Using these predictive cut-offs, the rate of IgE 
mediated food allergy was associated with early onset (Figure 7) and more severe eczema (in early onset 






Figure 7: Onset of eczema and IgE mediated food allergy in the EPAAC study. 




Figure 8: Eczema severity and IgE mediated food allergy (defined by 90-95% PPV) in the EPAAC study. 






















































3.4 IgE mediated food allergy in children with a history of infantile eczema 
In the general population, the rate of confirmed food allergy in children ranges between 5-8%;
(2;3)
 however 
this is much higher in children with atopic eczema. The European Academy of Allergy and Immunology 
(EAACI) published a position paper on eczematous reactions to food in atopic eczema.
(150)
 The prevalence 
of food allergy in children with eczema ranged from 33-81% in 8 studies (Table 1). 
(151-158) 
 I performed a 
random effects statistical analysis on the rate of clinically confirmed IgE mediated food allergy in children 
with eczema in the studies published in this review, including the prevalence of food allergy and sample size 
of each study. The pooled rate of food allergy in children with eczema (ranging from mild to severe) was 
50% (95% CI: 37-62%) (Figure 9, p83). This calculation was obtained using random effects by 
incorporating the sample size and percentage of children with IgE mediated food allergy. The EAACI 
position paper incorrectly stated that in the study by Niggemann et al. (1999) the rate of IgE mediated food 
allergy in children with eczema was 51%; this is because they used the number of positive challenges 51% 




Eczema within the first 6 months of life was specifically shown to be a risk factor for PA (confirmed by 
diagnostic OFC) in the ALSPAC study, a longitudinal birth cohort study (see Section 2.1).
(49)
 There was an 
association between PA and a rash over joints and skin creases in the first 6 months of life (OR 2.6; 95% CI: 
1.4-5.0), and an oozing, crusted rash in the first 6 months of life (OR 5.2; 95% CI: 2.7-10.2). Additionally, 
there was a dose-response for PA with increasing severity of eczema within the first 6 months of life (the 
most severe eczema category had an OR 43.5, 95% CI: 5.79-327.13). Questionnaires to determine rashes 






Table 1: Challenge proven IgE mediated food allergy in children with eczema  
Study
(150)





Method of IgE mediated 
food allergy assessment 
Foods responsible (in 
order of frequency) 




Severe 56% Prospective analysis of 
DBPCFC 
Egg, peanut, milk 
Burks et al.  





33% Prospective analysis of 
DBPCFC 
Egg, peanut, cow’s 









63% Prospective analysis of 
DBPCFC 
Egg, peanut , cow’s 
milk 






37% OFC, ImmunoCAP >95% 
PPV, reaction + 
sensitization 
Egg, cow’s milk, 
wheat, peanut, barley 




Mild-severe 39% Prospective analysis of 
DBPCFC 
Egg, cow’s milk, 
wheat, soya (peanut not 
tested) 






81% Retrospective analysis of 
DBPCFC 
Egg, milk, peanut and 
soy 






34% OFC, ImmunoCAP >95% 
PPV, reaction + 
sensitization 
Eggs, peanut, milk, 
wheat, fish, soy, tree 
nuts. 






45% Retrospective analysis of 
DBPCFC 
Cow’s milk, egg, wheat 
and soy 







Figure 9: Confirmed food allergy in children with eczema using random effects 
 
 
On the basis of this and other studies there are now several guidelines which encourage clinical assessment 
of food allergy in young children with severe eczema. For example, the 2007 National Institute of Clinical 
Excellence (NICE) guidelines for the management of atopic eczema in children recommends that: 
‘Healthcare professionals should consider a diagnosis of food allergy … in infants and young children with 
moderate or severe atopic eczema that has not been controlled by optimum management (p. 7).’(159) 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 93.8%, p = 0.000)




Burks et al 1998
Eigenmann et al 2000
Sampson 1992
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Niggemann et al 1999





























3.5 Epicutaneous exposure to Arachis (peanut) oil  
Among peanut allergic children with eczema in the ALSPAC study (see Section 2.1), 90% had been topically 
exposed to creams containing Arachis (peanut) oil in the first 6 months of life.
(49)
 The authors argued that 
exposure to peanut through the skin may have led to PS and subsequent PA in these children. The ALSPAC 
study also assessed maternal use of Arachis oil-containing nipple creams whilst breastfeeding, which would 
imply oral exposure as well as cutaneous exposure and found no difference in maternal Arachis oil-containing 
nipple cream application comparing children who went on to develop PA versus those who did not develop PA. 
Questionnaires on creams used for the infant or nipple creams were obtained retrospectively; however they 
were obtained prior to the diagnosis of peanut allergy. Parents were asked to list the creams used and the 
researchers subsequently evaluated whether the creams contained Arachis oil. Thus although the retrospective 
nature of this information may have resulted in errors due to lack of recall, as parents are highly unlikely to 
have been aware of the Arachis oil content of these creams thus this is unlikely to have led to recall bias. 
 
In 2003 the Committee on the Safety of Medicine from the Medicines and Healthcare products Regulatory 
Agency (MHRA) reviewed the potential issue of Arachis oil in topical medicinal products and concluded that, 
because pharmaceutical grade oil is refined during the manufacturing process and only very small amount of 
peanut protein remain in refined peanut oil, there was ‘insufficient evidence to conclude that peanut oil leads to 
sensitization to peanut protein’ (p. 5). (160) Hourihane et al. (1997) performed DBPCFC with refined peanut oil 
on 60 individuals with known PA, and none reacted.
(130)
 However, a previous study showed that refined peanut 
oils used in food trademarks Ready, Imperial, Beffroi, Lesieur, Amphora and Homa contained 100-200 ng 
protein per gram of oil (by Protein Reagent Assay); using Western blot analysis the authors demonstrated the 








Most eczema creams no longer contain Arachis oil, although Dermovate NN Cream (Chemidex Pharma), a 
‘very potent’ topical steroid which includes antibiotics and antifungal medication contains Arachis Oil but has 
been discontinued in the UK. However, creams used for nappy rash, such as Zinc and Castor Oil Ointment 
(L.C.M Ltd, UK) and Siopel barrier cream (DermaUK, UK), and cream used for broken skin (Naseptin, 
Alliance Pharmaceuticals, UK) still contain Arachis oil. 
(162;163)
 Roaccutane, a cream currently used to treat 
moderate to severe acne also contains Arachis oil. There is a case report (in abstract form only) of a 3 year old 
child with peanut allergy and eczema who developed eczematous flare following application of a topical steroid 
(Flucinolone Acetonide 0.01%) which contained Arachis oil.
(164)
 The abstract stated that peanut protein was 
measured in this cream but did not specify the quantity in the abstract. Personal communication with one of the 
authors (Dr Soheila Maleki, US Department of Agriculture / Agricultural Research Service, February 2015) 
informed me that they measured between 10-20ng/ml peanut protein in this cream. Other historical uses of 
Arachis oil are in the intramuscular adrenaline preparations that were used for status asthmatic (no longer in 
use) and rectal paraldehyde for use in status epilepticus which used to be made up in Arachis oil but now is pre-
prepared in olive oil instead of Arachis oil. 
 
3.6 Animal models of epicutaneous allergen exposure 
In order to prove a causal relationship between epicutaneous allergen exposure and the induction of various 
allergic sequelae, several mouse models have been employed to date. In the sections below I will describe the 
mouse models that have been employed to prove the causal link between epicutaneous allergen application and 
the induction of eczema, allergen specific sensitization and anaphylaxis, allergic airway responses and 






3.6.1 Animal models of epicutaneous allergen application leading to eczema 
In several murine models, epicutaneous exposure has been shown to lead to local eczema at the site of antigen 
application. The eczema at the site of allergen application was characterised by spongiosis, infiltration by CD4+ 
T cells, eosinophils, mast cells and local expression of mRNA for the cytokines IL4, IL5 and IL13. 
(165;166)
 This 
mimics the immunohistological analysis of affected acute eczematous lesions in humans where there is a 
significant increase in the number of cells expressing IL4, IL5 and IL13 mRNA and protein, suggesting 
preferential accumulation of Th2 cells. In mouse models, local eczema eruptions following epicutaneous 
exposure resolved with treatment with topical steroids. 
(166)
 Figure 10 depicts the eczematous reaction of murine 
skin which was shaved with an electric razor and then had a patch applied with Aspergillus fumigatus (a mould 
allergen which is commonly used to induce inhalant sensitization) versus skin which was shaved but had only 
phosphate buffered saline (PBS) applied as a patch to the skin as a negative control.
 (167)
  This experiment 
demonstrated that it was the application of Aspergillus fumigatus rather than just the skin shaving or patch 
application that led to eczema.  
 
 
Spergel et al. (1999) showed that eczema following epicutaneous allergen application was Th2 dependent using 
mice genetically modified to be deficient in IL4 and IL5. 
(168)
 In their study murine skin was shaved with an 
electric razor and a patch of OVA was applied. OVA-patched skin from IL5 and IL4 deficient mice had no or 
significantly reduced eosinophils, reduced epidermal thickening and no thickening of the dermis in contrast 
with control mice. These results suggest the presence of a Th2 pathway for eczema induced by epicutaneous 







Figure 10: Skin of BALB/c mouse following epicutaneous exposure to Aspergillus fumigatus vs. PBS.  





3.6.2 Epicutaneous sensitization and allergen specific systemic reactions in mice 
In murine models, epicutaneous sensitization to food allergens has been shown to lead to systemic reactions, 
including fatal anaphylaxis, on subsequent oral exposure. This is relevant as oral exposure to an allergen (to 
which the individual is allergic) is the usual means by which humans have more severe allergic reactions. In an 
experimental model Hsieh et al. (2003) shaved the skin on the back of BALB/c and C57BL/6 mice and applied 
a 100 µg OVA impregnated patch for a week on three consecutive occasions. 
(169)
 Seven days following the last 
patch application, these mice developed high OVA-sIgE and IgG1 (capable of inducing mouse mast cell 
degradation and anaphylaxis). Following epicutaneous sensitization, mice were challenged with OVA (50mg) 
via an intragastric feed and anaphylaxis was confirmed by symptomatology, raised histamine levels in their 
serum and histological changes in the gut and lungs. Mice developed anaphylaxis at either Grade 3 (wheezing, 
laboured respiration, and cyanosis around the mouth and tail) or Grade 4 (slight or no activity after prodding, or 
tremor and convulsion) in 7 out of 8 (88%) cases. This allergic reaction was Th2 dependent, as when BALB/c 
mice were injected intraperitoneally with anti-IL4 antibodies, epicutaneous application of OVA failed to 





evaluated different aspects of epicutaneous sensitization, such as the need for an impaired skin barrier to 
achieve sensitization, the form of peanut protein more likely to induce epicutaneous sensitization and the 
comparison of epicutaneous sensitization with other forms of sensitization. 
 
 
3.6.3 Epicutaneous sensitization dependent on type of epidermal allergen application 
Animal models have shown that epicutaneous exposure to 100 µg of peanut protein or OVA induces a potent 
allergic Th2-type response, associated with IL4 secretion by T cells from draining LNs and high levels of 
peanut or OVA sIgE respectively. 
(165;170-173)
 In these studies mice only developed epicutaneous sensitization if 
the skin was abraded before application of peanut. This was achieved by removing the stratum corneum (or 
cornified layer) from the ear with 6-8 repetitions of adhesive tape or the back by shaving in order to mimic the 
desquamation of skin in eczema and other dermatoses with an impaired skin barrier. Strid et al. (2004) stated 
that if the cornified layer was not disrupted, there was no antibody response following antigen application. 
(170)
   
Strid et al. (2004) also showed that when 100μg of peanut protein or OVA was injected subcutaneously (into the 
dermal layer) rather than epicutaneously (onto the cornified layer) this gave rise to a predominantly Th1 non-
allergic response. 
(170)
   
 
 
Conversely, a recent study by Tordesillas et al. (2014) showed that repeated applications of defatted crude 
peanut extract from roasted peanuts onto intact skin  of C3H/HeJ and BALB/c mice induced PS to the major 
peanut allergens Ara h 1 and Ara h 2 and anaphylaxis upon IP peanut rechallenge.
(174)
 Mice underwent hair 
removal using a depilatory cream or direct application of peanut onto the ear without skin stripping and the 
cornified layer was confirmed to be intact on histology. These authors postulated that peanut protein was able to 





itself had adjuvant properties. In support of this, Tordesillas et al. (2014) showed that peanut antigen led to 
bystander sensitization for the milk allergen α-lactalbumin. Having previously shown that application of milk 
allergen α-lactalbumin onto intact skin did not lead to sensitization or allergy on rechallenge, the authors then 
showed that concomitant application of peanut protein in addition to milk allergen α-lactalbumin onto intact 
skin led to anaphylaxis on subsequent oral exposure to milk allergen α-lactalbumin.  
 
 
3.6.3.1 Epicutaneous sensitization is dependent on the form of peanut applied to the skin 
Recently, Moghaddam et al. (2014) showed differential effects of topical application of dry roasted peanut 
antigen versus raw peanut antigen onto eczema-like skin lesions.
(175)
 On subsequent oral gavage with roasted  
peanut, there was significantly higher peanut sIgE, Th2 cytokines from mesenteric LNs and eosinophilic 
infiltration of the lamina propria in mice that had received epicutaneous sensitization with dry roasted peanut 
than raw peanut. The authors postulated that dry roasting conferred greater immunogenicity to peanut antigen 
due to oxidation-driven generation of advances glycation end (AGE) products, however little information was 
provided on how this might come about. Nevertheless, differences in peanut preparation may also be important 
for epicutaneous sensitization. Dry roasted peanut have also been shown in in vitro work to bind higher levels 
of IgE and enhance some of the functional properties of the allergen (such as increasing the trypsin inhibitor 




3.6.3.2 Epicutaneous versus systemic (IP) sensitization and subsequent anaphylaxis on oral challenge  
Bartnikas et al. (2013) explored the mechanisms behind epicutaneous sensitization leading to subsequent 
anaphylaxis on oral challenge.
(177)
 Epicutaneous OVA and/or peanut application onto tape stripped skin of 
BALB/c mice led to intestinal mast cell expansion, increased serum IL4 and food-induced anaphylaxis. 





the respective allergen with an associated reduced core body temperature and raised MMCP-1 compared with 
mice sensitized with PBS. Where sensitization was achieved via intraperitoneal (IP) injection, anaphylaxis was 
achieved only after multiple oral challenges; thus epicutaneous sensitization seemed to prime the gut in a more 
effective manner for subsequent allergic reactions than systemic sensitization (IP).  Researchers were unable to 
elicit anaphylaxis to an oral challenge with OVA after sensitising via the oral route with 5mg OVA plus 
adjuvant (CT), although they did find a rise in OVA sIgE levels. Mast cells numbers in the jejunum increased 
after OVA epicutaneous sensitization (2.4 fold) but not after OVA oral sensitization, which may explain the 
resistance to anaphylaxis in the orally sensitized mice. When researchers performed epicutaneous sensitization 
in mice bred to be deficient in IgE, there was no intestinal expansion of mast cells, no rise in serum IL4 and no 
features of anaphylaxis on intragastric challenge, which suggested that the effects arising from epicutaneous 
sensitization are IgE dependent.   
 
3.6.4 Epicutaneous sensitization and allergic airway responses 
There are murine studies which suggest that epicutaneous sensitization may also lead to allergic responses in the 
airway. 
(165;169;171;173)
 In a study by Spergel et al. (1998) 100μg of OVA was applied to the shaved skin of 
BALB/c mice, which resulted in localized eczema at the site of application. 
(165)
 Subsequent aerosolized OVA 
induced eosinophilia in the bronchoalveolar lavage fluid and airway hyper-responsiveness to methacholine 
which was 10 times greater than in PBS sensitized mice. In another study, epicutaneous sensitization followed 
by a single nasal challenge to Aspergillus fumigatus induced clinical nasal symptoms (sneezing and itching), 
airway hyper-responsiveness and sneezing to methacholine, systemic raised IL4 and Aspergillus fumigates 
specific IgG1 and nasal mucosal eosinophilia. 
(167)
 Mice deficient in STAT6 (a Th2 transcription factor: see 
Section 1.6) who underwent the same procedure were completely protected from nasal mucosal eosinophilia, 
clinical symptoms and nasal/ airway hyper-responsiveness. This also implies a Th2 dependent mechanism for 





Unfortunately, no lung-homing markers for Th cells have as yet been identified, thus the mechanism of 
sensitization via the respiratory tract cannot be assessed by isolating these Th cells to assess recall responses to 
peanut.  
 
3.6.5 Epicutaneous sensitization and eosinophilic eosophagitis  
Epicutaneous exposure onto abraded skin in mice does not only lead to eczema, respiratory and systemic 
allergic responses but also primes the mouse for developing eosinophilic eosophagitis 
(178)
 via a Th2 dependent 
method. BALB/c mice were shaved and allergen (100 µg of OVA or 100 µg of Aspergillus fumigatus mould) 
was repeatedly applied using a patch onto abraded skin. Eosinophilic inflammation of the oesophagus was only 
achieved if epicutaneous sensitization with OVA or Aspergillus preceded an airway challenge with OVA or 
Aspergillus respectively. 
(178)
 Using mice deficient in IL4, 5, 13 or STAT6 (a Th2 transcription factor) Akei et 
al. (2005) found that IL5 was the most important Th2 mediator for eosinophilic eosophagitis but that IL4, IL13 
and STAT6 also contributed towards its pathogenesis. IL13 has also been shown to directly decrease FLG 
expression in the eosophagus of humans with eosinophilic eosophagitis. Eosophageal expression of FLG 
mRNA is downregulated in humans with eosinophilic eosophagitis, and normalizes after successful eosinophilic 
eosophagitis treatment. 
(179)
 However, FLG mutation 2282del4 is also overrepresented in patients with 
eosinophilic eosophagitis, thus may have a role in its aetiology. FLG is expressed in the oral mucosa (mRNA 
and protein), 
(180)
 and may be expressed in the upper esophageal mucosa (mRNA but not protein) 
(181)
 and 
stomach (mRNA only) 
(182)
 but is not present in the small intestine.
(182)
 (see Table 15, p264). 
 
3.6.6 Epicutaneous exposure prevents oral tolerance acquisition 
BALB/c mice underwent epicutaneous sensitization to peanut which induced peanut specific T cell proliferation 
from LNs and spleen, and serum peanut sIgE, IgG1 and IL4. 
(183)





protein 20 days after epicutaneous sensitization (which has been previously been shown to induce oral tolerance 
in Section 2.5), this led to even higher levels of peanut sIgE/IgG1 and IL4 from draining LNs, peanut specific T 
cell proliferative responses and hind foot pad swelling (following peanut injection) than PBS fed control mice. 
Additionally, epicutaneous peanut exposure disrupted previously established oral tolerance to peanut, and led to 
peanut specific T cell proliferation, IL4 and IL10 (a Th2 cytokine in mice)
(184)
 production and hind foot-pad 
swelling (following peanut injection) greater than control mice. Thus epicutaneous peanut exposure onto 
abraded skin was both able to prevent oral tolerance induction and partially switch off pre-established peanut 
oral tolerance. This may explain why some children develop certain food allergies after many years of tolerating 
these foods in their diet, and why some children are resistant to oral tolerance induction. Epicutaneous exposure 
to peanut in a child with a disrupted inflamed skin barrier could lead to immunological changes via facilitated 
antigen presentation (see section 3.10) and lead to a Th2 predominant response to peanut; this could both 
initiate a de novo allergy (usually in a child no longer regularly consuming peanut) or prevent the acquisition of 
tolerance during both the normal weaning process in infancy and in oral peanut immunotherapy trials. 
 
3.6.7 Summary of animal evidence and limitations of extrapolation to humans 
There is a significant body of animal evidence that indicates that epicutaneous exposure onto abraded skin 
primes the mouse for allergen specific systemic, airway and gastrointestinal allergic responses via a Th2 
dependent mechanism. More recently allergen specific systemic reactions were replicated after epicutaneous 
sensitization to peanut on intact skin, as peanut was found to have adjuvant properties that obviated the need for 
skin abrasion or concomitant adjuvants.
(174)
 However, it is important to highlight the differences between mouse 
models and allergic processes in humans. Wild mice do not naturally exhibit food or aeroallergen sensitization 
and related allergies, 
(185)
 whereas these are reasonably common in humans and very common in humans who 





to mimic humans with a genetic predisposition for atopy. BALB/c mice are bred to be good IgE responders, 
(186)
 
and C3H/HeJ mice have a point mutation in Toll-like receptors and defect in their innate immune system and 
LPS-induced cytokine production;
(187)
 thus this influences how these mice respond to specific antigens. 
Allergen specific IgG1 is bound to the cell surface of mast cells in mice and may leads to degranulation when 
cross-linked by specific allergens, 
(188)
 whereas IgG1 does not lead to mast cell degranulation in humans.  IL10 
is considered to be a Th2 cytokine in mice, whereas in humans Th1, Th2 and Treg cells secrete IL10, but IL10 
is considered to be a predominantly tolerogenic cytokine. 
(189)
 Having highlighted only some of the differences 
between mice and humans in allergic models of disease, it is evident that, although they provide good in vivo 
mechanistic models of disease, the responses obtained must be taken in context and, where ethically possible, 




3.7 Epicutaneous immunotherapy 
Given the body of literature supporting the concept of epicutaneous sensitization, it is important to briefly 
consider the recent studies which suggest that is it also possible to desensitize through the skin. Although this 
might seem contradictory, on further review this body of work provides further understanding as to how antigen 
may present to immune cells via the skin. In mouse studies there is compelling data that topical application of 
pollen, HDM, OVA and peanut may desensitize mice. 
(191-193)
 Specifically, peanut epicutaneous immunotherapy 
(EPIT) was shown to be as effective in desensitising mice as subcutaneous immunotherapy (SCIT) in reducing 
the IgG1/IgG2 ratio, methacholine airway hyperresponsiveness and IL4, IL5, IL13, eotaxin and eosinophils in 
the bronchoalveolar lavage of mice. 
(193)
 In the Arachild pilot study (a multicentre double blind placebo 
controlled clinical trial), ‘Viaskin’ patches containing peanut protein (100 µg) versus placebo were applied onto 
the skin of children with proven peanut allergy.
(194)
 After 18 months 67% of children aged 5-11 years of age 





(equivalent of  approximately 5 peanuts). A reduction in peanut sIgE and an increase in IgG4 correlated with 
the response rate of individuals. 
 
In order to better understand the mechanism by which topical application of antigen was supporting a 
tolerogenic response this research group showed that EPIT only works when the allergen patch is applied onto 
healthy intact skin. 
(195)
 Application of peanut onto intact skin led to reduced IgE and a rise in IgG2a (a marker 
of tolerance induction in mice). Using the same concentration of allergen, timing of application and patch 
methodology that induced desensitization, stripping the skin of the mouse before applying the patch reinforced 
allergen sIgE and did not modify IgG2a. In further mechanistic work they showed that, in skin which had been 
abraded, there was free passage of allergens through the skin into the bloodstream and lymphatics. 
(195)
 Free 
passage of allergens through the skin did not occur following EPIT onto intact skin; the powdered form of the 
allergen was solubilized by perspiration and disseminated into the cornified layer. When allergen (OVA) was 
placed onto intact skin of BALB/c mice, processed allergen was transported to LNs by migratory Langerhans 
cells in the epidermis rather than reaching the LNs through the blood stream.
(196)
 Additionally they showed that 
dendritic cell maturation differed in stripped versus intact mouse skin; following skin stripping and application 
of OVA, migrating dendritic cells were skewed towards higher production of IL5 and lower IFNγ. OVA 
application onto intact skin in mice led to dendritic cells expressing mixed IL5 and IFNγ responses from 




These findings therefore conflict with the study by Tordesillas et al. (2014)
(174)
 where application of peanut 
protein using patches onto intact skin led to PS and clinical PA in mice. Tordesillas et al. (2014) argued that the 
adjuvant properties of peanut antigen were due to peanut inducing an innate immune response from 





Th2 cytokine production.  Another potential adjuvant property of peanut antigen could be to have proteolytic 
activity on tight junctions as does Der p 1 (see Section 1.6); however, none of the known peanut allergens have 
been shown to have proteolytic activity (personal communication, Dr Soheila Maleki, US Dept of Agriculture, 
New Orleans, March 2015). Peanut lectins (also known as peanut agglutinins) are proteins that bind specifically 
to carbohydrates and were previously used as an adjuvant in mechanistic assays (personal communication 
Professor Jonathan Hourihane Feb 2015). However, in the literature when mice were fed peanut agglutinins this 
led to oral tolerance rather than allergy.
(198;199)
 On the other hand, there are peanut glycans (oligosaccharides) 
that do enhance the Th2 immunogenicity of peanut.
(200;201)
 Helminths are rich in glycosylated proteins that are 
recognised by pathogen recognition receptors on dendritic cells leading to Th2 skewing; the glycan of the Ara h 
1 glycoprotein binds to the C-type lectin receptor on dendritic cells called dendritic cell (DC)-specific 
intercellular adhesion molecule-grabbing nonintegrin (SIGN). Binding of Ara h 1 glycan to DC-SIGN facilitates 
antigen uptake, activation and increased capacity for Th2 skewing in the dendritic cell. 
(200;202)
 Thus Ara h 1 
may have intrinsic adjuvant properties, other than protease activity that could facilitate epicutaneous 
sensitization.  
 
3.8  Mechanisms underlying epicutaneous sensitization versus oral tolerance induction. 
Previous in-vitro work has used homing markers on CD4+ Th cells for the skin (Cutaneous Lymphocyte 
Antigen: CLA+) and gut-associated-lymphoid tissue (integrin α4β7+) as markers for the route of initial route of 
sensitization. 
(203-205)
  CLA is an adhesion molecule that binds to E-selectin in skin capillaries, ensuring the 
preferential homing of CLA+ T cells in the skin. Integrin α4β7+ binds to mucosal addressin cell adhesion 
molecule-1 (MAdCAM-1) expressed in venules of the mesenteric LNs in the gastrointestinal lamina propria and 
Peyer’s patches. In patients with contact allergy secondary to epicutaneous sensitization to nickel, the nickel 
specific Th cell proliferation responses were largely confined to CLA-expressing Th cells. 
(204)





participant volunteers were orally or parenterally immunized with keyhole limpet haemocyanin (KLH), a 
respiratory protein isolated from a mollusc that is known to be highly immunogenic in humans. Following 
sensitization, immunomagnetic selection was used to deplete circulating Th cell with α4β7+ homing markers. In 
participants that had been orally immunised, depletion of α4β7+ Th cells reduced KLH proliferative responses 
by a mean of 71%, whereas in parenterally immunised participants, this made no different to proliferative 
responses to KLH. 
(205)
 This demonstrated that sensitization to KLH had occurred predominantly through α4β7+ 
Th cells in humans orally immunised with KLH.  
 
In recent research assessing Th cell memory response to peanut in children with PA there was differential 
peanut specific Th cell proliferation in peanut allergic (n=10) versus peanut tolerant (n=10) children.
(203)
 Peanut 
specific Th cell proliferative responses were higher in CLA+ Th cells in peanut allergic children than peanut 
tolerant children. There was mixed CLA/ α4β7 Th cell proliferation in peanut tolerant children (Figure 11). The 
specificity of Th cell responses was confirmed by also culturing cells from peanut allergic and non-allergic 
donors with OVA which showed no differential CLA/β7 stimulation index. Cytokine responses from CLA+ 
peanut-specific Th cells in peanut allergic children showed a trend towards Th2-polarisation (IL13 and IL4 
secretion), whereas cytokine responses from α4β7+ peanut-specific Th cells in peanut tolerant children showed 









Figure 11: Ratio of Stimulation Indices for CLA/β7 Th memory cells in peanut and OVA.  




To assess cytokine responses in the peanut allergic versus non allergic children the authors used the Th1/Th2 
cytokine ratio (e.g. IFNγ/IL4) to correct for responses from unstimulated cells. Cytokine responses from CLA+ 
peanut-specific Th cells in peanut allergic children showed a trend towards Th2-polarisation (IL13 and IL4 
secretion). Cytokine responses from α4β7+ peanut-specific Th cells in peanut tolerant children showed a trend 
towards Th1-polarisation (IFNγ and TGFβ). These findings therefore support the hypothesis that peanut 






3.9 Mechanism of epicutaneous sensitization  
3.9.1 Langerhans cells  
Human skin is exposed to millions of different antigens. The Langerhans cell (LC) is the predominant antigen 
presenting cell (APC) in the skin and has an important role in initiating Th2 immune responses to antigens. 
(185)
 
T cells grown with cultured Langerhans cells from mouse ears secrete IL4 and stimulate IgE production by B 
cells consistent with a Th2 bias. 
(206)
 Researchers have demonstrated, through the use of LC depleted mice, that 
LCs are a prerequisite for the polarization of CD4+ Th cells required for the development of atopic eczema. 
(207)
 
In mouse models LCs are activated by tape stripping leading to skin barrier impairment; in one study tape 
stripping alone was sufficient to drive LC migration from the epidermis to skin draining lymph node (LN), and 
LC precursors from the bone marrow to the epidermis. 
(208)
 Another study showed that LC morphology in mice 
began to mature within 2 hours of tape stripping; the LC dendrites pulled in and the cell body widened until, by 
24 hours, the LC were completely oval.
(170)
 The LCs also increased cell surface expression of MHC Class II 
(see Section1.7.1) consistent with the process of maturation of dendritic cells.
(209)
 Although tape stripping alone 
did not promote LC emigration to LNs in this study, two hours after application of antigen (peanut or OVA) the 
majority of LC had migrated away from the epidermis to skin draining LNs. 
(170)
 T cells from skin draining LNs 
produced large amounts of IL4 after epicutaneous immunization but very little IFNγ and IL10. (170) IL4 has been 




LC express three receptors likely to be involved in the pathogenesis of eczema and allergic sensitization through 
the skin: the high affinity receptor for IgE (FCεRI), the low affinity receptor for IgE (FCεRII/CD23) and the 
thymic stromal lymphopoietin (TSLP)-receptor. 
(211)
 The FCεRI on LCs differs from those on effector cells like 





uptake and presentation to T cells increases up to 1000 fold 
(212)
 via a mechanism now understood as facilitated 
antigen presentation. 
(213)
 This is very important in the context of allergen exposure through the skin as, through 
facilitated antigen presentation, even tiny amounts of allergen on the surface of the epidermis could lead to 
activation of allergen specific T cells, especially in children with an impaired skin barrier. In the next sections I 
will discuss other important mediators of epicutaneous sensitization and their interplay with LC and Th cells. 
 
3.9.2 Thymic Stromal Lymphopoietin  
One of the main cytokines responsible for epicutaneous sensitization through an impaired skin barrier is thymic 
stromal lymphopoietin (TSLP). TSLP is increased in the cornified layer of patients with atopic eczema 
compared with patients with healthy skin and also positively correlates with eczema severity (using 
SCORAD).
(214)
 TSLP is highly expressed by the keratinocytes of children with eczema
(215)
 and by the epithelial 
cells of asthmatics.
(216)
 TSLP deficient mice are protected from developing allergic skin and airway 
inflammation following antigen exposure,
(217-219)
 which highlights the importance of this cytokine in allergic 
sensitization.  Pro-inflammatory cytokines TNF-α and IL1-α, secreted in response to skin stripping, (220) induce 
TSLP secretion from human keratinocytes. 
(221)
 TSLP levels also increase following topical application of OVA 
onto tape stripped skin. 
(177)
 TSLP expression correlates with LC maturation, upregulation of the TSLP receptor 
on LCs, migration of LC cells to skin draining LNs where they promote the differentiation of naïve Th cells to 
Th2 cells and Th2 proliferation.  
(215;218;222)
  TSLP has also been showed to induce Th2 skewed APCs to the 
mesenteric LNs following tape stripping, thus providing evidence of a skin to gut migration. 
(223)
 These findings 
therefore link TSLP to the early stages of epicutaneous sensitization: by increased secretion by skin disruption 






3.9.3 TSLP and IL9 in allergic skin and lung inflammation 
As well as TSLP’s effects on Th2 differentiation, proliferation and cytokine secretion, TSLP is also linked to 
the newly discovered Th9 cell (see Section 1.6) and its signature cytokine Interleukin 9 (IL9). TSLP promotes 
Th9 differentiation and function in human naïve T cells and mice by inducing greater STAT5 binding to IRF4 
and GATA3 promotors which are required for Th9 cell development.
(224)
 TSLP also increases IL9 expression 
and IL9 production in Th9 cell cultures through a Th9 TSLP receptor.
(224)
 There are greater numbers of TSLP 
receptors on Th9 cells than Th2 cells, suggesting that TSLP may be even more important for the activation of 




TSLP and IL9 are both found in inflamed eczematous skin. Although, no murine model to date examined the 
interdependency between these two cytokines for epicutaneous sensitization, Th9 cells are required for TSLP-
induced allergic inflammation in the lungs.  Intranasal challenge with either OVA alone or OVA plus TSLP was 
performed after adoptively transferring OVA-specific Th9 cells to mice. 
(224)
  The addition of TSLP to the OVA 
intranasal challenge enhanced airway inflammation, IL9 and Th9 cell-mediated eosinophilia in the 
bronchoalveolar lavage and mucous production.
(224)
 Neutralizing IL9 antibodies in this model decreased 
eosinophil counts, IL9 and Th2 cytokines in the bronchoalveolar lavage. In contrast using IL13 blocking 
antibodies reduced airway inflammation and Th2 cytokines but had little effects on IL9 gene and protein levels 
in the lung. In mice bred to have overexpression of TSLP in their lungs, IL9 was induced and contributed to 
airway inflammation. In the OVA and TSLP co-administration model, allergic airway inflammation was 
reduced in SfpiI
ck-/-
mice that had a T cell PU.1 deletion (Th9 lineage specific transcription factor in mice); this 
demonstrated the requirement for Th9 cells in mice for TSLP-induced allergic inflammation in the lungs. 
(224)
 





Figure 12: Interleukin-9 is required for allergic airway inflammation mediated by the cytokine TSLP 




3.9.4 IL9 and mast cells in epicutaneous sensitization and clinical reactivity 




 of patients with atopic eczema versus patient without atopic eczema; 
it is even further raised in the serum of children with severe atopic eczema.
(227)
 In mouse models of 
epicutaneous sensitization, IL9 is induced by tape stripping, 
(228)
 potentially via TSLP as described in Section 
3.9.3 and Figure 12. One of the main functions of IL9 is to promote mast cell differentiation and proliferation in 
response to an antigen (see Section 1.6 for function of mast cells in allergic reaction).  In the presence of antigen 
specific IgE and antigen, IL9 also activates mast cells and promotes the secretion of pro-allergic cytokines IL13, 
IL4, IL5, IL9 and IL10 (a Th2 cytokine in mice) from mast cells in-vitro. 
(229;230)
 To date there is no study which 





antigen exposure; however, there is evidence that IL9 is necessary for mast cells to migrate from the kidney 
tissue to draining LNs.
(231)
 In this mouse model, infiltration of mast cells in the LNs was abrogated when an 
anti–IL9 monoclonal antibody was administered. IL9 could similarly play a role for epicutaneous sensitization 
through mast cell activation, trafficking to draining LNs and induction of pro-allergic cytokines. Once primed 
antigen specific Th2 cells interact with B cells to promote IgG class-switching to IgE in the presence of IL4; 
this IgE production is also potentiated by IL9. 
(232;233)
 In addition, the effects of IL9 on mast cell proliferation 
and migration may have an important role in clinical reactivity. The literature supporting the role of mast cells 
in Ps and PA is described below. 
 
3.9.4.1 Role of mast cell activation and trafficking in epicutaneous sensitization 
It is known that mast cells rapidly migrate to the lung mucosa and degranulate after antigen exposure in human 
asthmatics.
(234)
 In a mouse model of epicutaneous sensitization by Wang et al. (2014), 
(235)
 topical application of 
dinitrofluorobenzene (DNFB) led to mast cell activation and degranulation in the skin. Following epicutaneous 
antigen application mast cell migrated from the skin to skin-draining LNs; 
(235)
 this was demonstrated using two 
experimental findings: (1) there was a 50% reduction in mast cell density in the skin and 5-fold expansion of 
mast cells in the skin-draining LNs and (2) fluorescent labelled mast cells injected into the left or right footpads 
were found in the popliteal LNs of the respective leg following epicutaneously antigen exposure (not in 
controls). Following migration to LNs, mast cells recruit Th cells to the LN by producing large amounts of the 
chemokine CCR4 also known as macrophage inflammatory protein (MIP)-1β. In the study by Wang et al. 
(2014), the primary source of MIP-1β was from mast cells and increases in MIP-1β occurred in parallel with an 
expansion of T cells in the LNs and was inhibited by 50% with the use of anti-MIP-1β antibodies.(235) Activated 
mast cells are an important source of pro-allergic cytokines,
(236)
 thus could lead to subsequent Th2 skewing of 





Mast cells have furthermore been shown to induce LC migration from the skin to skin-draining LNs. Jawdat et 
al. (2004) showed an increase in mature LC in mouse skin draining LNs following intradermal injection of anti-
trinitrophenyl (TNP) IgE followed by intravenous challenged with TNP-conjugated to bovine serum 
albumin.
(237)
 Mast cells were necessary for LC migration in this model as mice deficient in mast cells had no 
migration of LC to the skin-draining LNs. The mechanism by which mast cells induce LC migration is 
dependent on local mast cell degranulation and histamine release as treatment with anti-histamine abrogated the 
migration of LCs. Histamine alone however was not sufficient to lead to LC migration as mice deficient in mast 
cells who had intradermal histamine injections did not demonstrate LC migration. 
(237)
 Thus the following mast 
cell functions: activation (and pro-allergic cytokine secretion), migration to skin-draining LNs, recruitment of 
Th cells to LNs via MIP-1β and local degranulation and histamine release (leading to LC migration to LNs) 
provides a multitude of ways in which mast cells are important in bringing together the elements required for 
induction of a primary immune response in the LN: LCs (carrying antigen), Th cells and a Th2 cytokine milieu.  
 
3.9.4.2 Role of mast cell migration and proliferation in allergic elicitation following epicutaneous 
sensitization 
In the study by Bartnikas et al. (2013) epicutaneous sensitization to OVA and / or peanut through tape stripped 
skin led to OVA and /or peanut anaphylaxis respectively following oral exposure; this was prefaced by a 
proliferation of mast cells in the gastrointestinal submucosa. 
(177)
 In the mouse model of epicutaneous 
sensitization by Wang et al. (2014), 
(235)
 mast cells were detected in the spleen 24 hours after epicutaneous 
antigen exposure, which is consistent with subsequent migration from LNs to the blood stream. 
(235)
  Thus it is 
plausible that activated mast cells in the skin could migrate to the gastrointestinal submucosa. The mechanism 
by which mast cells could lead to allergic elicitation is as follows: in murine oral antigen challenges, antigen in 





this is followed by massive antigen transport dependent on mast cell activation. 
(238)
 Mast cell activation leading 
to degranulation results in the release of various pro-inflammatory mediators (histamine, prostaglandins and 
mast cell proteases) that would increase intestinal permeability and could therefore allow large passage of 
antigen across the intestine, cross-linking the FcεRI receptor on mast cells and leading to allergic 
manifestations.
(238)
  Moreover, routes of mast cell migration, together with local IL9 induced proliferation at 
local tissue sites could potentially explain the different manifestations of allergic symptoms; such as 
predominantly respiratory or gastrointestinal allergic symptoms in addition to cutaneous symptoms.  
 
3.10 Summary of mechanism of epicutaneous sensitization 
The interplay between skin barrier function, EPE, LC, TSLP, mast cells and Th2 and Th9 cells proposed in this 
PhD is depicted in Figure 13 (p106). To summarize, skin barrier impairment through FLG loss-of-function 
mutations and atopic eczema predisposes to mechanical injury of the epidermis, through irritants and allergens 
in the environment and the itch scratch cycle of eczema. Mechanical injury to the skin results in TSLP secretion 
from keratinocytes; this leads to LC maturation and migration to skin-draining LNs and mesenteric LNs. When 
LCs encounter peanut allergen passing through an impaired skin barrier, they present this to naïve Th cell in 
skin draining LNs and induce Th2 differentiation of CD4+ naïve Th cells. These peanut-specific skin-homing 
Th2 cells migrate back to the skin and secrete Th2 cytokines (IL4, IL5 and IL13) which attract eosinophils and 
other pro-inflammatory cells leading to the typical eczematous flare and further skin barrier impairment. 
Through facilitated antigen presentation on mature LCs (by FCεRI expression) very tiny amounts of peanut 
allergen might be enough to activate and differentiate naïve peanut specific CD4+ Th cells into a Th2 biased 






IL9 may also play an important role in inducing PS following epicutaneous peanut exposure through its effects 
on mast cell activation, trafficking, cytokine secretion and its effects on B cell IgE class-switching in the 
presence of IL4. IL9 additionally enables allergic reactions to occur since the main allergy effector cell – the 
mast cell – requires IL9 to proliferate. Activated mast cells migrate to different areas in the body following 
epicutaneous sensitization, and gastrointestinal mast cells expansion is required for allergic elicitation oral 
challenges in mice. Thus the hypothesised pathway for IL9 mediated PS and PA following EPE is as follows 
(Figure 13):  TSLP (secreted following skin barrier disruption) enhances Th9 differentiation and IL9 secretion 
in the skin which can then exert its effects on mast cells. Thus IL9, stimulated by skin barrier disruption 
activates mast cells, thereby initiating migration of mast cells to LNs and subsequent Th2 skewing of naïve Th 
cells within the LN. Activation and local degranulation of mast cells following epicutaneous peanut exposure 
could also lead to migration of the LC APC to skin-draining LNs thereby facilitating interaction between Th 
cells and LCs, leading to PS. Once Th2 skewed, the secretion of IL4 drives IgE class switching by B-cells 
which is enhanced by IL9. In mouse models, peanut applied onto disrupted skin leads to mast cell expansion in 
the gut and induces peanut anaphylaxis on subsequent oral exposure to peanut. Following this model in humans, 
EPE could lead to epicutaneous PS, and on subsequent oral exposure to peanut, peanut specific mast cell 
expansion and degranulation in the intestine could lead to increased intestinal permeability and IgE mediated 


















Chapter 4 The skin barrier  
In order to better understand how sensitization may be occurring through the skin it is important to understand 
the skin structure and function of the proteins and enzymes within the skin. Human skin has three layers, 
starting with a layer of fat and connective tissue, followed by the dermis and then the outer layer of the 
epidermis. In most regions of the body, skin thickness ranges between 1-2mm, but can range from 0.5mm 
around the eyes to 5mm between the shoulder blades. The difference in thickness of the skin is generally due to 
variation in the thickness of the dermis.  
 
The dermis is a layer of fibrous and elastic tissue comprising sweat glands and sebaceous glands, hair follicles, 
blood vessels, nerve endings, collagen and elastin. The epidermis acts as a barrier to prevent infectious and 
antigenic material gaining entry into the body and is usually around 0.5 mm in thickness. The epidermis is in a 
constant cycle of desquamation (skin shedding) and regeneration by terminally differentiated keratinocytes so 
that the skin remains the same thickness. Each keratinocyte has a life span of 30-40 days as it makes its way 
through the layer of the epidermis through a process called keratinization. The bottom layer of the epidermis is 
the basal layer where keratinocytes divide and push upwards to renew the epidermis. The next layer is the 
spinous layer where cells start to synthesise keratin. Above this is the granular layer where keratinocytes lose 
their nuclei and are filled with cytoplasmic material. Lamellar bodies are formed within the keratinocyte in the 
granular layer; these are released in the cornified layer (stratum corneum) as lipid lamella (ceramides, 
cholesterol and fatty acids). The lucid layer is only present in areas of thick skin (such as soles of the feet) and 
its role is to reduce shear forces between the cornified layer and granular layer. The outermost cornified layer 
comprises up to 30 layers of flattened cells which comprise keratin (corneocytes) and are bound together by 
corneodesmosomes and surrounded by the lipid lamella. This has been compared to a bricks and mortar 





the masonry ties between the bricks. 
(239)
 Figure 14 displays the normal anatomy of the epidermis and skin 




Figure 14: Structure of the epidermis and EDC proteins  
Epidermal differentiation is characterised by the expression of specific proteins, which are listed in this Figure. 
The smaller black dots in the cells of the granular layer represent keratohyalin granules. Reprinted from 





The cornified layer acts as a barrier to prevent water loss and prevents the reduction of skin lipids. The cornified 





and thigh area, measured using fluorescence spectroscopy, videomicroscopy and confocal laser scanning 
microscopy, 
(241;242)
 ranges between 7-35µm, whereas it is slightly thicker in adults. Desquamation of the 
cornified layer is promoted by degrading proteases which break down corneodesmosomes.
(243)
 The most 
intensely studied protease family in the skin are the kallikrein family of which there are at least 8 in the human 
cornified layer. Other proteases include trypsin-like serine proteases like pro-urokinase and plasminogen, 
cysteine and aspartic proteases and matrix metalloproteases.
(239)
 Proteases are tightly regulated by protease 
inhibitors which include metal ions, cholesterol sulphate, the lympoepithelial Kazal-type 5 serine protease 
inhibitor (LEKTI-1), secretory leukocyte protease inhibitor (SLPI) and elafin, α2-macroglobulin-like-1 
(A2ML1), Plasminogen activator inhibitor-2 (PAI-2) and cystatin protease inhibitors.
(239)
 Proteolytic activity is 
higher in facial skin, which would account for the cornified layer being thinner on the face than elsewhere on 
the body. In acute atopic eczema lesions there is an increase in serine proteases
(244)
 and matrix metalloproteases 
(245)
 which results in thinning of the cornified layer.  
 
4.1 Role of filaggrin in skin barrier maintenance 
Filament aggregating protein (filaggrin) is a complex polypeptide which is vital for the strength and integrity of 
the cornified layer of the epidermis. Much progress has been made in identifying the mechanisms by which 
filaggrin facilitates epidermal differentiation and maintains the skin barrier. 
(243;246;247)
 The FLG gene codes for a 
~ 400kDa profilaggrin polyprotein which is found in the keratohyalin granules of keratinocytes within the 
granular layer of the epidermis. Profilaggrin undergoes cleavage to yield 10, 11 or 12 tandem repeats of the 
filaggrin peptide during the process of terminal differentiation of keratinocytes as they migrate towards the 






As keratinocytes undergo apoptosis (programmed cell death) in the granular layer and cornified layer, filaggrin 
forms an aggregate with keratin intermediary filaments and facilitates collapse and flattening of the keratinocyte 
to become cornified cells. This layer of collapsed corneocytes is then enclosed within a structure of proteins 
cross-linked by transglutaminases and surrounded by a lipid envelope, called the cornified cell envelope. 
(243)
 
Using immunoelectron microscopy Manabe et al. (1991) demonstrated the function of filaggrin on filament 
aggregation in mice and humans cells. They showed that filaggrin peptides in the lower cornified cells which 
correlated precisely with the formation of aggregated keratin filaments, and  a reduction in filaggrin levels in the 
upper cornified cells was associated with loosening of keratin filaments. 
(246)
   
 
In the top layer of the cornified layer, filaggrin is degraded into free amino acids that form major components of 
natural moisturizing factor (NMF). 
(247)
 NMF has hygroscopic effects (drawing in water) and reduces skin pH. 
Low skin pH reduces the activity of serine proteases which in turn reduces skin shedding by desquamation. 
(248)
 
Low skin pH also promotes the action of lipid converting enzymes, which produce lipid factors such as 
sphingosine and ceramides which maintain the cornified layer. 
(33)
  Ceramide-dominant, physiologic lipid–based 
emollients (Triceram, Osmotics, US and Epiceram PuraCAP) have been shown to accelerate the restoration of 
barrier function after tape stripping in a murine model and have comparable efficacy to moderately potent 
steroids in children with moderate to severe eczema. 
(249;250)
   
 
4.2 FLG and the epidermal differentiation complex (EDC) 
Profilaggrin (which is cleaved into filaggrin) is encoded by the FLG gene which resides in the EDC on 
chromosome 1q21.  Although FLG has received the most attention since its successful genotyping in 2007,
(251)
 
the EDC comprises is a cluster of three gene families which are all involved in the terminal differentiation of 





(1) Precursor proteins of the cornified envelope: involucrin, loricrin and small proline-rich proteins and late 
cornified envelope proteins  
(2) Calcium binding proteins (S100)  
(3) Fused gene proteins include profilaggrin (FLG), trichohyalin, hornerin and repetin. (243;252)  
 
Although how the FLG gene relates to eczema is now well understood (see Section 4.1 and 4.4), the biological 
function of other EDC gene variants and their relation to eczema is less well understood. 
 
Table 2: Genes involved in terminal differentiation of the human epidermis 
Name of gene Epidermal 
expression 
Structural role Phenotype with mutations 
in the EDC gene 
Involucrin Upper spinous and 
granular layer 
Cross-linked to membrane proteins by 
transglutaminase enzyme to form the 
cornified envelope.  
Involucrin forms the outermost 
protein layer of the cornified envelope 
to which lipid ceramides attach. 
Minor component of 
cornified envelope.  
Mice lacking involucrin 
have normal cornified 
envelopes  
Loricrin Cornified layer 
Late granular layer  
Cross-linked to membrane proteins by 
transglutaminase enzyme to form the 
cornified envelope. 
Represents more than 70% of 
epidermal cornified envelope 
Loricrin deficient mice 
are born with 
erythroderma but 
normalizes after 





Cornified layer Cross-bridges receivers and donors of 
amino groups during cornified 
envelope formation by 
transglutaminase enzymes 
SPRR polymorphisms 
involved in atopic eczema 
Transglutaminases 
1,3 and 5 
Spinous and 
granular layer 
Enzyme which crosslinks keratin 










Late upper granular 
layer 
Protein crosslinking functions similar 
to SPRR 
Polymorphisms involved 
in psoriasis  
 S100A family S100A7 in 
differentiated 
keratinocytes / 
S100A15 present in 
all epidermal layers 
Regulatory proteins involved in 
calcium signal transduction pathways 
regulating cell shape, cell cycle 
progression, and differentiation. 
S100A7 and S100A15 are 
antimicrobial peptides  
S100A7 and S100A15 are 
present in chronic eczema  
Profilaggrin (FLG) Granular and 
cornified layer 
Profilaggrin is cleaved into filaggrin 
subunits which aggregate keratin 
filaments into tight bundles and 
promote collapse of the keratinocyte 
into flattened corneocytes. Filaggrin is 
then degraded in the cornified layer to 
free amino acids (NMF). 
Ichthyosis vulgaris and 
atopic eczema 
Trichohyalin Component of 
keratohyalin 
granule of hair 
follicle / granular 
and cornified layer 
Cross-linked to membrane proteins by 
transglutaminase enzyme to form 
cornified envelope. 
Involved in alopecia 
areata, molluscum 
contagiosum 
Hornerin Granular and 
cornified layer  
Cross-linked to membrane proteins by 
transglutaminase enzyme to form 
cornified envelope. 
Involved in psoriasis and 
atopic eczema 
Repetin Granular and 
cornified layer 
Cross-linked to membrane proteins by 









4.3 FLG gene variations and impact on filaggrin protein expression 
The FLG gene comprises three exons and two introns. The first exon is non-coding and the protein translation 
initiates within exon 2 but the bulk of the profilaggrin protein is encoded by exon 3 (Figure 15). Exon 3 
comprises repetitive sequences called tandem repeats and individuals have between 10-12 tandem repeats.  
Figure 15: Structure of FLG gene on chromosome 1q21  
(A) Profilaggrin gene structure (B) Profilaggrin protein structure contains 10, 11 or 12 tandem repeats of 
filaggrin which are flanked on either side by partial imperfect repeats.  Reprinted from Sandilands et al.(2009) 




4.4 FLG loss-of-function mutation phenotypes 
Loss-of-function mutations in the genes which code for profilaggrin were originally identified as the underlying 
genetic cause for the most common form of ichthyosis: ichthyosis vulgaris. 
(251)
 Ichthyosis vulgaris is 
characterised by dry, flaking skin appearing in the postnatal period followed by hyperkeratosis pilaris 
(roughening of skin around hair follicles predominantly on extensor surfaces) and hyperlinearity of the palms 





absence of epidermal keratohyalin granules, whereas heterozygous (i.e. one allele) mutations lead to 
approximately 50% less filaggrin expression. 
(240)
 Individuals with homozygous or compound heterozygous 
FLG loss-of-function mutations have 100% penetrance for the severe ichthyosis vulgaris phenotype whereas 
heterozygotes have a milder phenotype with 90% penetrance.
(253)
  
Approximately 37-50% of patients with ichthyosis vulgaris have eczema, which is characterised by dryness but 
not hyper-linearity or hyperkeratosis pilaris and has an itchier inflammatory phenotype. The estimated 
penetrance of FLG mutations, i.e. the likelihood of a person with at least one FLG mutation developing eczema, 
is between 42-79%; 
(254-256)
 this may explain, in part, why not all children with FLG mutations develop eczema. 
FLG was assessed as a candidate gene for eczema due to the co-existence of these two dermatoses. Since then 
FLG loss-of-function mutations have been replicated in multiple candidate gene studies for eczema in both 
children and adults in the US, UK, Ireland, France, Germany, Italy, Sweden, Denmark, South Asian, China, 
Singapore and Japan. 
(255;257-259)
 In the 21 studies from the above mentioned countries, FLG gene mutations 
were implicated in 14-56% of patients with eczema with a 1.2 to 13.0 fold increased risk of eczema.
(259)
  
Two FLG mutations, R501X (a SNP) and 2282del4 (a 4 base pair deletion) are present in 6.1% to 9.6% of 
Caucasian European populations. 
(251;260-263)
 Less common SNPs leading to FLG loss-of-function mutations 
include R2447X, S3247X, and 3702delG; these were found in 188 Irish paediatric eczema patients (Figure 
Figure 16a).  
(251)
 A further study found these less common FLG mutations plus 3673delC in 186 adult eczema 
patients from London and Newcastle Upon Tyne. 
(264)
 Other FLG loss-of-function mutations, such as 441delA, 
1249insG, 3321delA, Q2147X, E2422X, S2554X and 7945delA, are associated with ichthyosis vulgaris and 
eczema in South-East Asian populations.
(265;266)
 In children with wild-type FLG, there may be reduced filaggrin 
expression depending on the number of tandem repeats of filaggrin in exon 3 (see Section 4.3); the intragenic 
copy number variation (from 10-12 tandem repeats) reduces the odds ratio of atopic eczema by 0.88 (95% CI: 







Figure 16: Profilaggrin molecule (a), skin immunohistochemistry (b) and Immunoblot (c) 





(a) Schematic of profilaggrin molecule (from 10 tandem repeat allele) showing positions of known loss-of-
function FLG mutations. Variations in red are common in European or Oriental populations. Variations in black 
are family specific.  
(b) Immunohistochemistry staining of skin biopsy for filaggrin with keratohyalin granules in normal epidermis 
and in R501X/R2447X compound heterozygote.  
(c) Immunoblot shows reduced truncated profilaggrin molecules (arrow) in the R501X/R2447X compound 
heterozygote and no processed filaggrin compared to healthy control and a R501X homozygote showing  






4.5 Filaggrin deficient mouse models 
The flaky tail (ft) mouse has the autosomal recessive frameshift mutation (5303delA) analogous to the common 
human FLG loss-of-function mutations within the murine FLG gene. 
(269)
 The homozygous (ft/ft) flaky tail 
mouse phenotype comprises dry, flaky skin, matted hair and disorganised scales on the tail. These mice have 
truncated profilaggrin which is not cleaved into tandem repeats of the filaggrin peptide; immunoblot analysis 
reveals virtually absent filaggrin protein within the cornified layer of the epidermis.
(270)
 Topical application of 
OVA to intact skin in homozygous (ft/ft) mice leads to a significant cellular infiltration (predominantly 
lymphocytes and eosinophils) and increased transepidermal water loss at the site of allergen exposure after 24 
hours.
(269)
 In fact several studies using the homozygous (ft/ft) flaky tailed mouse have shown that antigen 
permeation (such as OVA and/or haptens) through the skin results in an inflammatory infiltrate. 
(269;271;272)
 
Following epicutaneous exposure to OVA, the homozygous (ft/ft) flaky tailed mouse’s spleen cells produce 
OVA specific Th2 cytokines (IL4, IL5 and IL13) but also Th1 (IFN-γ), regulatory/Th2 (IL10) and Th17 (IL17) 
cytokines. Fallon et al. (2012) reported that the homozygous (ft/ft) flaky tailed mouse had similar antibody 
responses to application of peanut onto intact skin;
(273)
 however, immune responses were not seen in the 
heterozygous (ft/wt) or wild type (wt/wt) mice following epicutaneous allergen application.   
 
To confirm that OVA sensitization in the homozygous (ft/ft) flaky tailed mouse was due to skin barrier 
impairment rather than general altered immunity, Fallon et al.(2012)  used IP injections of OVA and alum to 
both wt/wt and ft/ft mice and found that both groups developed comparable OVA specific Th2 biased OVA 
specific cytokine and antibody responses. Surprisingly, ft/ft mice sensitized to OVA via the skin did not develop 
increased airway resistance when subsequently challenged with OVA aerosol into their lungs and there was no 





expressed in the lung (see Section 8.4) in humans; however there are significant differences between mouse 
models and humans (see Section 3.6.7).
(274)
  
More recent murine studies have shown that the flaky tail (ft) mouse contains both mutations in the FLG gene 
as well as the Tmem79 (also known as Matt) gene. Tmem79 is a transmembrane protein that encodes lamellar 
granules required for processing of filaggrin, lipids and proteases (Elias et al Mechanism of abnormal lamellar 
body secretion and the dysfunctional skin barrier in patients with AD. 2014). The Matt gene derives its name 
because mutations thereof also lead to the matted hair phenotype in the flaky tail (ft) mouse. A mouse genetics 
approach was used to separate the Matt and FLG mutations to produce congenic single-mutant strains; authors 
demonstrated that it was the Matt gene mutation rather than the FLG gene that led to spontaneous dermatitis 
over time in pathogen free conditions. (Saunders et al. Tmem79/Matt is the matted mouse gene and is a 
predisposing gene for atopic dermatitis in human subjects jaci 2013, Sasaki et al. A homozygous nonsense 
mutation in the gene for Tmem79, a component for the lamellar granule secretory system, produces 
spontaneous eczema in an experimental model of atopic dermatitis2013). A SNP in the Matt gene in humans 
has also been associated with eczema in humans (Saunders et al. 2013). 
4.6 Filaggrin deficiency and inflammation 
Based on current understanding of filaggrin’s role in the cornified layer, it makes sense that FLG loss-of-
function mutations are associated with the xerosis (dryness) and barrier defect found in eczema. The 
inflammatory component of eczema is less well explained by filaggrin deficiency; as for example filaggrin 
deficient mice do not exhibit spontaneous atopic eczema lesions;
(275)
 however, it may be due to a reaction to the 
entry of irritants, pathogens and allergens.
(271;276)
 Thus skin barrier impairment may itself lead to a maladaptive 
immune system with a predisposition towards atopy: the so-called ‘allergic march’. FLG loss-of-function 







  This highlights the role of the epidermal barrier in the pathogenesis of allergic 




The local cytokine milieu has also been shown to affect filaggrin expression. Filaggrin protein expression was 
assessed in the skin of 69 patients with at least one FLG loss-of-function mutation. Researchers found that acute 
eczematous lesions in these patients had even lower levels of filaggrin protein than non-inflamed skin. Using 
punch biopsies of acutely inflamed eczematous skin, keratinocytes were cultured in the presence or absence of 
IL4, IL13 or IFNγ for 5 days. IL4 and IL13 reduced expression of filaggrin in differentiating keratinocytes and 
down-regulated filaggrin in keratinocytes which were already differentiated.
(280)
 IFNγ increased filaggrin protein 
expression. Thus Th2 inflammation (IL4 and IL13) of the skin of eczematous patients, reduced filaggrin 
expression, whereas the Th1 cytokine IFNγ increased filaggrin expression. (280) The mechanism for filaggrin 
downregulation by Th2 cytokines was two-fold; downregulation of keratinocyte differentiation modulated the 
calcium sensitive protein S100A11, and increased protease activity  broke down filaggrin.
(281)
 Taken together 
these studies show that skin barrier abnormality due to FLG loss-of-function mutations can enhance allergen 
penetration thus favouring Th2 inflammation, however, on the other hand, Th2 inflammation can impair skin 
barrier function via a reduction in filaggrin expression. Thus in children with a heterozygous FLG mutation and 
actively inflamed eczema there could well be significantly less than 50% filaggrin expression in the skin due to a 
vicious circle whereby lower filaggrin promotes allergen entry, further Th2 inflammation and further reduction in 






4.7 FLG loss-of-function mutations and food allergy 
There have been conflicting results for the association between FLG loss-of-function mutations and food 
allergy. In a sample of 3471 Caucasian Danish adults invited to participate in a general health examination, 
FLG loss-of-function mutations represented a significant risk for self-reported egg, cow’s milk, fish and wheat 
IgE-mediated allergy.
(282)
 Other studies, however, found a less clear association between FLG loss-of-function 
mutations and food allergy. In infants recruited to the HealthNuts population study, carriage of a FLG loss-of-
function mutation was associated with sensitization to food (defined as SPT ≥2mm to egg white, peanut, 
sesame, shrimp or cow’s milk) even after adjusting for eczema (OR 3.0, 95% CI: 1.0-8.7; P=0.04, n=428). FLG 
loss-of-function mutations were associated with challenge proven food allergy on univariate analysis (OR 3.2, 
95% CI: 1.2-8.5, P=0.02, n=321); however, after adjusting for eczema this association was no longer significant 
(OR 2.9, 95% CI: 1.0-8.6; P=0.06, n=321). This may have been due to sample size as the OR were very similar 
to those obtained for food sensitization.
(283)
 In the Enquiring About Tolerance (EAT) population based cohort 
study, FLG loss-of-function mutations were not associated with sensitization to one of six foods (cow’s milk, 
egg, wheat, peanut, sesame, cod fish) in infants at 3 months of age (OR 1.27, 95% CI: 0.48-3.38, P=0.7 n=619), 
which is surprising given previous findings. 
(284)
 This may have been due to the low rate (34/619=5.5%) of 
sensitization to one of six foods at 3 months, which is likely to increase at their 1 and 3 year assessments.  
 
Venkataraman et al. (2014) found that FLG loss-of-function mutations were likely to be associated with food 
allergy in later childhood (10 and 18 years) rather than earlier childhood (1, 2 and 4 year). 
(285)
  They showed 
that FLG loss-of-function mutations exerted their action on food sensitization and allergy through eczema, 
rather than having a direct effect on food allergy itself. The impact of FLG loss-of-function mutations on food 
allergy in later childhood, may be because of the propensity for FLG loss-of-function mutations to predispose 





transient food allergies (such as cow’s milk and egg allergy). In the paper by Venkataraman et al. (2014), the 
prevalence of peanut allergy was only 0.08% at one year’s assessment but reached 1% at 18 year’s assessment. 
Tree nut allergy was not present at one year and was 0.5% at 18 years assessment.  Thus at 18 years peanut and 
tree nut allergy made up 37.5% of all food allergies whereas at 1 year they made up only 1.5% of all food 
allergies. The hypothesis for this PhD is that FLG loss-of-function mutations (as a marker of skin barrier 
impairment) increases the risk of peanut allergy, thus the publication by Venkataraman et al. (2014) also 
supports this hypothesis. 
 
Data supporting an association between FLG loss-of-function and challenge proven IgE-mediated PA were 
assessed retrospectively in several populations by Brown et al. (2011)
(286)
 Records of 71 white European 
children with PA (confirmed by diagnostic OFC) from England (ALSPAC birth cohort) (n=35), Netherlands 
(n=20) and Ireland (n=16) were compared against 1000 non sensitized controls from the ALSPAC study or 
controls from their respective population (Dutch and Irish) controls.  The authors performed a replication study 
in 383 white Canadian patients with PA (confirmed by diagnostic OFC or history of allergic reaction on peanut 
exposure and >95% PPV for peanut sIgE ≥15 kU/L or SPT ≥8mm) against 891 non sensitized controls. 
Genotyping for FLG loss-of-function mutations was performed for R501X, 2282del4, R2447X, and S3247X in 
all cohorts except for the ALSPAC cohort where genotyping was only performed for mutations R501X and 
2282del4.  
 
There was a strong and significant association between FLG loss-of-function mutations and PA (OR 5.3, 95% 
CI: 2.8-10.2, P=3x10
-6
) in the 71 patients from the UK, Netherlands and Ireland. The authors adjusted for 
eczema in the LR model as eczema is associated both with FLG loss-of-function mutations and with PA, and 
thus could be an important confounder. Even after adjusting for eczema, a significant association between FLG 





FLG loss-of-function mutations and PA was replicated in the Canadian cohort (OR 1.9 95% CI: 1.2-2.6, 
P=5.4x10
-5
), although no adjustment was made for eczema, as this information was not available for the control 
participants.  
 
On the basis of the data described above it seems that FLG does have a role to play in food sensitization and 
allergy, but that this effect may be more relevant in older children. The positive association between FLG loss-
of-function mutations and PA in the number of cohorts reviewed by Brown et al. (2011) is very convincing, 
thus it may be that FLG loss-of-function mutations are more closely related to PA than food allergy in general. 
This would fit with this association being stronger in older children who are less likely to have outgrown their 
PA than egg or cow’s milk allergy.  
 
4.8 Phenotypic markers of impaired skin barrier 
Although the study by Flohr et al. (2010) did not find an association between FLG loss-of-function mutations 
and food sensitization in infants, they found that a functional assessment of the integrity of the epidermis using 
transepidermal water loss (TEWL) was associated with food sensitization even after adjusting for atopic eczema 
and FLG mutation status (OR 2.23, 95% CI: 1.04-4.76, P<0.05). 
(284)
 TEWL is measured using the non-invasive 
Aquaflux
® 
closed chamber tewameter 
(287)
 which measures evaporation of water from the skin. This measure 
incorporates the spectrum of genetic and environmental factors leading to barrier impairment, such as water 
hardness, frequency of washing and detergents. If the skin barrier is impaired more water can evaporate and 
also allergens, irritant and bacteria can penetrate the skin. 
(248)
 A small French cross-sectional study in children 
aged 3 to 12 months showed that the higher the TEWL, the higher the prevalence of sensitization to 
aeroallergens both in children with and without eczema. This suggests that skin barrier dysfunction, even in the 







A cross-sectional study of 59 children and 40 adults found a trend towards an association between increased 
TEWL and FLG mutations; 
(288)
  however, more recently a study of 88 infants found that carriage of a FLG 
mutation was significantly associated with increased TEWL at three months of age, even in the absence of 
eczema. 
(284)
 The first study 
(288)
 did not separate out adults and children in their analysis which may have 
accounted for the lack of significance as, by adulthood, skin barrier function may have been  affected by many 
other factors (such as long term inflammation or lichenification). 
 
4.9 Summary of evidence on skin barrier function and epicutaneous sensitization 
Taken together, the evidence outlined in Chapter 3 and Chapter 4 demonstrates a good theoretical basis for 
epicutaneous sensitization to peanut especially via an impaired skin barrier. The association between eczema 
and PA in cohort studies, the link between topical peanut exposure on eczematous skin in humans and on 
abraded skin in mice and PA, and the preponderance of CLA+ memory Th cells proliferating in response to PA 
in PA allergic individuals all support the concept that peanut antigen may sensitize via the cutaneous route, 
predominantly where there is concomitant skin barrier dysfunction and inflammation. The discovery of FLG 
loss-of-function mutations and their association with skin barrier dysfunction and eczema, provides a novel 
genetic screening tool to identify children potentially at an increased risk of PS and PA through epicutaneous 
sensitization.  
 
The median onset of PA is 14 months, 
(289)
 therefore sensitization is likely to occur during infancy. Although 
direct epicutaneous peanut exposure during infancy would be very hard to measure in humans, environmental 
levels of peanut antigen may reflect epicutaneous exposure. Infants spend most of their time in the home and so 
it would seem appropriate to look for the possible means of sensitization in the home environment. Publication 





development of PA. However, Fox et al. (2009) used HPC as an indirect marker for EPE and found an 
association with PA (see Section 2.4); 
(104)
 in their study peanut butter consumption versus other ‘covered’ 
peanut containing foods such as chocolates were more likely to be associated with PA. They postulated that 
peanut butter, being stickier, was more amenable to transfer by hands; this could potentially be transferred to 
the infant’s skin directly or onto their bedding or play-area.  In the next theory section I will discuss the role of 







Chapter 5 Environmental exposure and allergic sensitization 
5.1 Environmental exposure to inhalant indoor allergens 
Environmental exposure to inhalant allergens has been evaluated as a risk factor for sensitization and 
development of allergic disease (in particular asthma) in several studies. Data from the Isle of Wight cohort 
study suggested that HDM sensitization was the most potent predictor of respiratory and cutaneous allergic 
disease. Overall 68.4% of children aged 4 years, who were sensitized to HDM, had asthma, eczema or allergic 
rhinitis.
(102)
 In a landmark paper from the Poole cohort, Sporik et al.
(290)
 showed that early environmental 
exposure (at 1 year) to >10μg/g HDM was associated with the development of asthma at 11 years with a 
relative risk of 4.8 (P=0.05). Subsequent studies have investigated the association between early HDM 
exposure and later sensitization and asthma revealed contradictory findings; some studies indicated a positive 
relationship between HDM exposure and asthma, particularly in high-risk children; 
(291;292)
 however, other 
studies negated this association. 
(293-295)
  Implementation of HDM reduction measures have, for the most part, 




In the Childhood Asthma Prevention (CAP) study, high-risk children (at least one family member with a 
diagnosis of asthma) were randomised before birth to HDM reduction measures plus high omega 3 oil 
supplementation (tuna fish oil supplementation and canola oil for cooking) or no HDM reduction measures and 
low omega 3 supplementation (Sunola oil supplementation with polyunsaturated oils for cooking). 
(298)
 HDM 
reduction measures included impermeable mattress covers and an acaricide wash which resulted in a sustained 
low HDM level in the child’s bed in the intervention group at 18 months (6.1mcg/g) whereas in the control 
group this increased from 5.2mcg/g at 1 month to 22.2mcg/g at 18 months. 
(299)





reduce HDM sensitization at 18 months or 5 years, 
(300)
 and did not reduce the incidence of asthma, wheeze, or 




In the Manchester Asthma and Allergy Study (MAAS) (one of the collaborating cohorts for this PhD) rigorous 
HDM reduction measures were applied prenatally (by the 16
th
 week of pregnancy) to the parent’s bedding and 
from 36 weeks pregnancy to the infant’s home environment. HDM reduction measures included pillow, 
mattress and quilt mite-proof bedding to the parental and infant bed, HEPA filter vacuum cleaners, fortnightly 
hot-washing of bed-linen, carpet removal in the infant’s room with vinyl replacement and acaroside application 
to carpets and sofas. The MAAS study showed a significant reduction in HDM levels in the parental mattress, 
living room floor, child's mattress and floor; 
(301)
 however, children randomised to the HDM intervention arm 
did not have a reduced   rate of HDM sIgE sensitization (intervention arm 23.3% versus control arm 8.2%; RR 
2.85; 95% CI: 1.02-7.97; P= 0.05) and SPT sensitization to any allergen (intervention group 34.7% vs control 
arm 21.5%; RR 1.61; 95% CI: 1.02-2.55; P= 0.04).
(302)
   
 
One randomised prospective study, the Isle of Wight study, 
(114)
 did show a protective effect of HDM reduction 
measures on preventing HDM sensitization and allergic disease. One hundred and twenty pregnant mothers 
whose unborn children were at high-risk of developing atopic disease due to family history were recruited. 
HDM reduction measures included impermeable mattress covers for the infant’s cot and acaricide treatment. 
Infants in the intervention group also underwent dietary restrictions (see Section 2.3.3 for further details). 
Follow-up at 1, 2, 4 and 8 years of age showed a reduction in allergic disease and sensitization (both food and 






One reason for the conflicting evidence surrounding indoor allergen exposure is that the use of the allergy 
mattress, duvet and pillow covers, not only reduces exposure to HDM but also to endotoxin, which may be 
protective against atopy. In a high-risk US prospective birth cohort study by Celedon et al. (2007) there was an 
association between postnatal environmental HDM exposure (≥10 mcg/g) and asthma at 7 years of age (OR 3.0 
95% CI: 1.1-7.9).
(303)
 Conversely, early exposure to endotoxin was protective against atopy (defined as 
sensitization to ≥1 allergen and or physician diagnosis of allergic rhinitis or eczema) at 7 years of age (OR 0.5 
95% CI: 0.2-0.9), but was a risk factor for wheeze (OR 1.23; 95% CI, 1.07-1.43);
(303)
 these data suggest that 
interactions between different types of exposure and genetic background may result in the development of atopy 
and asthma. I will discuss this further in the next section. 
 
5.2 Gene-environment interactions for inhalant allergen exposure  
It has long been known that atopy is hereditary and that the impact of environmental allergen exposure is 
modified by parental atopy. For example,  The UK based Ashford birth cohort study (n=625) found that the 
impact of environmental HDM and cat exposure at 8 weeks of age on sensitization to HDM or cat (respectively) 
and atopic wheeze at 5 years of age was modified by paternal atopy and birth order. 
(304)
 High-risk, first-born 
children were most susceptible to HDM and cat allergen exposure. They postulated that reductions in indoor 
allergen exposure would be unlikely to have a major impact on decreasing atopy and asthma if modifying 
factors were not taken into consideration.  Other studies have also shown a selective effect of indoor allergen 
exposure and allergic disease depending on parental atopy. 
(291;292;305)
 Defining risk on the basis of parental 







Since the mapping of the human genome was achieved in 2001 a large number of studies have assessed the 
interaction between genetic variations and environmental exposure.
(306)
 In particular, associations between 
SNPs and allergic disease have been extensively assessed (see Section 1.7.2). The German Multicentre Atopy 
Study found that variations in the gene encoding for IL4 (C-590T) modified the response of HDM exposure 
(Der p 1 allergen in carpet dust) on HDM sensitization, and there was a significant interaction between HDM 
exposure and IL4 genotype (OR 8.56, P=0.002). 
(78)
 This may, in part, account for the discrepant study findings 
described for HDM exposure and sensitization in the previous Section (5.1); as the effect of early HDM 
exposure could be dependent on the IL4 genotype, and potentially other genotypes.  
 
The MAAS group assessed the relationship between a promoter polymorphism in the CD14 gene (innate 
immune system gene) and environmental endotoxin exposure as the effect of endotoxin is mediated through the 
LPS receptor (CD14). Overall CD14 genotype was not associated with  sensitization or eczema; however, in 
children with CD14 genotype CC, increasing endotoxin exposure was associated with a marked reduction in the 
risk of  sensitization and eczema. Conversely, there was an increased risk of non-atopic wheeze with increased 
endotoxin exposure in children with the CC genotype.
(307)
 Thus the CC genotype could explain the discrepant 
findings in the study by Celedon et al. (2007) where environmental endotoxin exposure reduced the risk of 
endotoxin sensitization but increased the risk of wheeze in high-risk US children. 
(303)
 
Custovic et al. (2011) assessed day-care attendance on the development of allergic outcomes in the MAAS and 
Tucson Infant Immune (IIS) birth cohorts. 
(74)
 They hypothesised that the discrepancy found in previous studies 
as to whether day-care attendance protected or was a risk factor for allergic outcomes was due to variations 
(SNPs) in the Toll-like receptor (TLR) family genes.  
(74;308;309)
 TLRs are pattern recognition receptors (PRRs) 
bound to APCs which recognise microbial pathogen associated molecular patterns (PAMPs) and initiate 





the development of allergic disease (see Section 1.7.2). In the study by Eder et al. (2004) children of farmers 
who carried a T allele (AT genotype) for the Toll-like receptor 2 (TLR-2) were significantly less likely to have 
asthma, atopic sensitization (positive SPT or sIgE to common aeroallergens and/or egg, milk, peanut) and 
allergic rhinitis than children with an AA genotype (where there was no protective effect of a farming 
environment). 
(310)
 The interaction between a farming environment and the TLR-2 genotype on asthma was 
independent of other markers of atopy. The TLR genotype could thus be expected to modify the way the 
immune system responds to a higher microbial load in day-care and /or farming environments. Indeed, in 
children carrying the TLR2-AT or TT genotype, day-care attendance reduced atopic sensitization over 4 time 
points (3, 5, 8 and 11 years) in both the MAAS and IIS birth cohort and reduced atopic wheeze in the IIS; 
however, children with the TLR2 AA genotype trended to have an increased risk of sensitization and atopic 
wheeze.  
 
Another example of a gene environment interaction comes from the MAAS and COPSAC birth cohort studies 
where the impact of FLG loss-of-function mutations and environmental cat allergen exposure on the likelihood 
of developing eczema was assessed.
(311)
 In both cohorts, an interaction between FLG loss-of-function mutations 
and environmental cat exposure on the development of eczema in the first year of life was demonstrated 
(COPSAC: OR 11.11, 95% CI: 3.79-32.60, P< 0.0001 and MAAS: OR 3.82, 95% CI: 1.35-10.81, P= 0.01). 
Environmental HDM exposure was not related to eczema or FLG genotype. This may reflect a different 
mechanism of sensitization.  
 
Apart from Publication 3 in this PhD (see Section 7.7) there have been no studies to date assessing the 
interaction between food proteins in dust and variation in specific genes involved in skin barrier function (e.g. 
FLG loss-of-function mutations or SPINK5) or the innate immune system (e.g. CD14, TLRs). This is 





review the available evidence on environmental food exposure in dust and surfaces and discuss the validation 
process that I previously employed to quantify peanut protein levels in the home environment as part of my 




5.3 Food proteins in household dust 
Two studies in 1995 demonstrated quantifiable levels of food proteins in household dust using ELISA based 
methods. Witteman et al. 
(313)
 detected egg (ovomucoid) and milk (β-lactoglobulin) proteins in vacuumed 
samples of settled dust on carpeted and smooth floors in the home; 
(313)
 they found a range of 170 to 6,280 ng 
ovomucoid and 16 to 71 ng β-lactoglobulin per gram of dust. These levels were high enough to give a positive 
radio-allergosorbent test (RAST) with the serum of egg and milk-allergic patients; thus they were considered 
high enough to sensitize patients. Dybendal et al. 
(314)
 also detected ovomucoid and cod-fish protein in the 
vacuumed settled dust of smooth and carpeted homes. They measured percentage inhibition of the same 
allergen added after incubation of patient sera with lyophilized dust extract solution. They found sIgE 
percentage inhibition of 7-74 per metre
2




 Ara h 2 has been 
quantified in settled dust from classrooms and cafeterias of (14/159=8.8%) inner city schools with a median 
concentration of 0.76 µg/g (range 0.47-6.59µg/g) and in bedroom dust of 18/77 (23.4%) student’s homes with a 
median concentration of 1.13 µg/g (range 0.4-9.79µ/g). 
(315) 
More recently there seems to be resurgence in 
interest in food proteins in household dust. In 2013-2014 two articles were published measuring fish, egg, milk 
and peanut allergens in the mattress dust of 13 year old Norwegian adolescents, 
(316)
 and in different areas of the 




Using a polyclonal ELISA against whole peanut protein (Veratox, Neogen, Europe), I have previously shown 





containing meal (peanut butter sandwich). 
(318) 
Median peanut protein level increased from below the lower 




) on the 
following day (n=10, P=0.017). In other pilot work, which was submitted as part of my Allergy MSc at the 
Univserity of Southampton,  I assessed where peanut butter was most likely to be found in the bed the day after 
peanut butter consumption. Peanut levels were highest was in the middle third of the bed (1.05μg/m2), followed 
by the top (0.88μg/m2) then the bottom of the bed (0.53μg/m2). This gives important information as to the likely 
means of transfer (hands for the middle of bed and saliva for the top of the bed), which I will mention further in 
the discussion. The persistence of peanut protein on bedding following peanut protein consumption over 5 days 
was also assessed. Peanut protein levels were present for 48 hours after peanut butter consumption after which 




5.4 Peanut proteins on surfaces 
In previous work, Perry et al. (2003) 
(319)
 assessed the amount of peanut allergen remaining on tables after 
‘spiking’ surfaces with peanut butter and subsequently applying different methods of cleaning. They used their 
own commercial monoclonal ELISA against Ara h 1 (range of detection, 30-2000 ng/ml) as a marker for peanut 
protein in the environment as previously described. 
(320)
 Arachis hypogaea 1 (Ara h 1) is a major peanut allergen 
which belongs to the vicilin family of seed storage proteins and is recognized by serum sIgE of over 90% of 
peanut-allergic patients. 
(321;322)
 However, Ara h 2 is considered to be the most important peanut allergen for the 
diagnosis of PA on the basis of IgE binding and cell activation, 
(323;324)
 intracutaneous testing and diagnostic 
oral peanut challenges. 
(324;325)
  Peanut butter (5ml) was placed onto table surfaces and then wiped/washed off 
with water, cleaners with bleach, sanitizing wipes, liquid soap or a bar of soap. Glass-fibre filter wipes were 
moistened with extract solution (PBS and 1% Tween) to sample the area before cleaning. The wipes used were 





on table surfaces peanut protein levels decreased from 0.7-6.4μg/ml to 40-140ng/ml in 25% of tables (post 




I have shown that peanut protein levels increase on kitchen surfaces immediately after and 18-24 hours after a 
single peanut containing meal. 
(312)
 Using a polyclonal ELISA against whole peanut protein (which measures 
both Ara h 1 and 2 as well as other peanut allergens), peanut protein increased from below the lower limit of 
quantitation to 3.95 (range 0-29.3) µg/wipe on taps (P=0.043); to 4.42 (range 0-223.4) µg/wipe on fridge 
handles (P=0.018); to 5.58 (range 0-42.5) µg/wipe on dishwasher handles (P=0.018) and to 134 (range 0-816) 
µg/metre2 on kitchen tables (P=0.043). Peanut protein levels remained elevated on kitchen table surfaces with 
median 8.4 (range 0-116) mcg/m2 18-24 hours after exposure but were not significantly raised on other kitchen 
appliance handles and surfaces. This is probably because most of the peanut antigen had been removed with the 
first wipe I had performed to sample peanut levels immediately after peanut consumption. On the kitchen tables, 
which were often wood, it is likely that there was still some residual peanut remaining even after obtaining a 
wipe sample.  
 
On the basis of finding persistent peanut protein on tables 24 hours after peanut butter consumption, as part of 
my Allergy MSc project I proceeded to explore residual peanut protein after usual detergent cleaning of three 
types of table surfaces following spiking of peanut protein.
(326)
 I chose to spike table surfaces with only 0.5ml of 
smooth Sunpat peanut butter which was 10 times less than the study by Perry et al. (2003) to provide a more 
realistic representation of environmental contamination of peanut that was likely to occur.
(319)
 Kitchen laminate, 
unpainted wood and granite table surfaces (n=3) were 'spiked' with 0.5ml of peanut butter, then wiped with 








Wipe samples were taken before, after peanut spiking and following cleaning. I also spiked surfaces with plain 
butter to determine any false positives or contamination of samples. Prior to spiking with peanut butter there 
was no detectable peanut on any table surface. After spiking with 0.5ml smooth peanut butter median levels of 
peanut protein ranged from median 7.86-9.21μg per wipe sample of the wood, granite and laminate table. The 
highest amount of peanut protein post application of 0.5ml of peanut was detected on one of the granite table 
samples (15.5µg peanut protein/wipe). Following a single wipe with water there was only a small reduction of 
peanut protein ranging from a median of 6.56-7.92 μg per wipe sample. Following vigorous detergent cleaning 
peanut protein was undetectable on granite table surfaces but still detectable on the laminate surface; median 
0.47μg/wipe (range 0.42-0.55 μg per wipe) and wood surface; median 1.75μg/wipe (range 1.62-3.33 μg/wipe) 
(Figure 17). These results are also shown in Publication 1 (see Section 7.4). Peanut was undetectable before and 
after plain butter spikes. These results showed that peanut was resistant to usual methods of cleaning on 
laminate and wood tables, thus small amounts of peanut on table surfaces from other family members eating 
peanut could potentially come into contact with an infant’s skin and sensitize them to peanut, even after the 
surfaces undergo usual cleaning processes. 






5.5 Routes of transfer of peanut protein into the environment 
5.5.1 Detection of peanut protein in blood 
Whole dietary proteins have been shown to be transported directly into blood, 
(328) 
and there is a reported case of 
anaphylaxis suspected to be from passive transfer of peanut through a blood transfusion from the donor 
consuming peanut several hours before blood donation and administration to a peanut allergic individual.
(329)
 
One study involved measurement of histamine release from passively sensitized basophils, following IgE 
stripping, to investigate the absorption of peanut allergens from the buccal mucosa.
(330)
 Basophils obtained from 
buffy coat bank were stripped of their IgE and passively sensitized with the IgE of patient with confirmed PA. 
Serum from patients who had eaten peanut was then mixed with these passively sensitized basophils and the 
histamine release from these basophils was used to quantify the allergenic activity of absorbed peanut in serum 
following peanut consumption.  Histamine release from basophils were detected using serum collected 30 
minutes after peanut consumption, reached a peak using serum collected 3 hours after peanut consumption and 
persisted up until 24 hours. There was no histamine release from basophils stripped and sensitized with serum 
from non peanut allergic (NA) individuals.  ELISA was also used as a way of quantifying peanut in serum, 
though the authors reported that the ELISA was ‘10 times less sensitive than basophil mediated histamine 
release’ (p. 1322).  
 
5.5.2 Detection of peanut protein in hands and saliva 
Ara h 1 has been measured in saliva in levels up to 40μg/ml (enough to cause an allergic reaction) immediately 
after peanut consumption; however, was undetectable in 87% of participants after 1 hour using a monoclonal 
ELISA against Ara h 1. 
(14)
 Using the same monoclonal ELISA Perry et al. (2004) placed peanut butter (5ml) 
onto the hands of participants which was then wiped/washed off with water, cleaners with bleach, sanitizing 
wipes, liquid soap or a bar of soap.
(319)





and 1% Tween) to sample the area before and after cleaning. They found Ara h 1 levels of 4.8-56.0μg/ml of 
extraction solution before cleaning which decreased to 0.2-8.3μg/ml on 25% of hands (after water clean) and 
0.13-1.7μg/ml of hands (after hand sanitizer) in 50% of participants. All other participants had undetectable 
peanut levels after cleaning.  
 
5.5.3 Evidence for airborne food protein on sensitization and allergy 
Environmental exposure to peanut could lead to sensitization via both epicutaneous and inhalational routes of 
exposure. A classic example of sensitization to foods via inhalation is Baker’s asthma which is one of the most 
common forms of occupational allergy;
(331;332)
 however, there are also reports of occupational asthma to other 
foods such as cow’s milk.(333) Occupational allergen analysis usually reveals high molecular weight type 1 
sensitizers with molecular weights between 6-100kDa, which is the size of many inhalant and food allergens. In 
South-East Asia allergens such as buckwheat (often consumed as soba noodles) may induce sensitization 
through inhalational exposure from cooking or inhalational/epicutaneous exposure from pillows (buckwheat 
chaff-stuffed pillows). 
(334;335)
 Buckwheat allergy predominantly features as allergic rhinitis then asthma 
symptoms but can also lead to anaphylaxis. To date, there are no reports of occupational asthma caused by 
peanut exposure as a primary agent in the UK based SHIELD database (Surveillance Scheme for Occupational 
Asthma). 
(336)
 There was one case of a Turner (lathe wood worker) in 1997 who was reported to have developed 
occupational asthma due to oil mists (oil is rubbed into the wood after it is shaped), which is a common cause of 
occupational asthma. Peanut oil was stated as a secondary cause, however, it is not clear as to whether the oil 
mist that caused the occupational asthma was Arachis oil or another oil, such as pine oil, which is commonly 








There are several reports of certain foods leading to IgE mediated hypersensitivity reactions via inhalation, 
including fish, egg and cow’s milk. (338-340) Aerosolized food proteins have been measured using air sampling 
monitors in egg breaking plants
(341)
 and fish markets.
(342)
 There are anecdotal reports of allergic reactions 
following inhalation of peanut; however, when children with severe or reported inhalational reactions to peanut 
underwent blinded inhalational peanut challenges (peanut butter held 12 inches from the face for 10 minutes) 
these children had no allergic symptoms or signs.
(343)
 An abstract reported peanut protein has been detected in 
the ventilation system filters of commercial airliners after 5000 flight hours using an inhibition assay with 
peanut extract; 
(344)
 however, this abstract was never published. Perry et al. (2003) evaluated airborne peanut 
using Personal Air Monitors attached to adult volunteers whilst eating peanut butter, shelling and eating roasted 
peanut, and opening small packets of dry roasted peanuts (to simulate the type of peanuts consumed in 
commercial flights). 
(319)
Additionally, the room ventilation was switched off in some experiments to decrease 
air exchange so as to simulate the recirculation of air that occurs on commercial flights. Peanut was 
undetectable in all these experiment, even when the amount of peanut in the environment was increased 
artificially by stamping on peanuts on the ground. 
(319)
 However this study used a monoclonal ELISA against 
Ara h 1 which may not have been sensitive enough, given that a monoclonal ELISA will bind specifically to 
only one epitope of only one peanut allergen.   
 
5.5.4 Threshold levels of environmental allergen exposure for sensitization 
It is important to determine not just whether EPE is a risk factor for PA but also what threshold level of peanut 
protein would be sufficient to lead to PS. Allergen exposure threshold levels for sensitization have been 
described for inhalant allergens such as HDM (Der p: >2 μg/g), (345) cat (Fel d 1: 1-8 μg/g), (346;347) and 
cockroach (Bla g 1: >8 μg/g). (348;349)  Witteman et al. (313)  postulated that as 2 µg Der p 1 HDM allergen per 





in dust, this might also be high enough to cause ovomucoid sensitization. No threshold studies for sensitization 
have been performed for food allergens in dust. However direct application of 100μg of peanut protein onto 
tape stripped skin 
(170)
 or via inhalation 
(350)
  is enough to induce a potent Th2 response in mice. For ethical 
reasons this has not been performed in humans.  
 
5.5.5 Threshold levels of peanut exposure to elicit allergic reactions 
It is important not only to consider whether the amount of peanut in the environment is sufficient to lead to PS, 
but also whether levels of peanut in the environment might be sufficient to elicit at allergic reaction in PA 
individuals. Simonte et al. (2003) showed that casual cutaneous contact with peanut was more likely to lead to 
local skin reactions rather than significant allergic reactions;
(343)
 however, given that children may touch their 
mucosal surfaces with their hands after cutaneous contact and that young children may put toys and other items 
contaminated with peanut in their mouths, it is useful to consider what threshold level of peanut might lead to 
clinical reaction after oral exposure.  
 
Studies have assessed the threshold levels of peanut protein required to elicit a clinical response in peanut 
allergic patients in DBPCFCs. In a review article of 12 studies which conducted low dose DBPCFCs to peanut, 
(351)
 the no observed adverse effect level (NOAEL), which is the highest dose observed not to produce any 
adverse effect, and the lowest observed adverse effect level (LOAEL), which is the lowest dose observed to 
produce any adverse effect, were used to create probability distribution models. The lowest doses predicted to 
elicit objective symptoms ranged from 11 mg whole peanut in threshold studies to 18.5 mg whole peanut in 
diagnostic challenges to 65.5 mg whole peanut  in immunotherapy challenges; 
(351)
 some of the most sensitive 
peanut allergic individuals had objective reactions upon consumption of as little as 0.1-5 mg peanut protein 








5.6 Indoor allergen measurement 
Several of the issues surrounding the practicalities of collecting dust, quantifying, sieving, processing and 
extracting dust samples for analysis are discussed in a US Patent. 
(355)
 In this document recommendations are 
made regarding the apparatus, kit and method of dust collection such as using a vacuum adaptor to collect dust 
samples rather than collecting dust into a bag, collecting dust samples over a fixed area for a fixed period of 
time, sieving dust samples to accurately weigh fine dust samples and extracting them in proportional amounts of 
extraction buffer. The standard format to express exposure to environmental allergens in the literature is in μg/g 
of dust (allergen concentration).
(356)
 However, some authors argue that using total recoverable allergen i.e. 
vacuuming the whole living room floor or bed may be a better marker of exposure 
(357)
 and recommend 
expressing environmental allergens in μg/metre2.   
 
5.7 ELISA kits for peanut protein quantitation 
Peanut ELISA kits have been developed predominantly to assess contamination of foods with peanut protein. 
The US Food and Drug Administration Centre for Food Safety and Applied Nutrition and AOAC Research 
Institute conducted a Performance Tested Method Multiple Laboratory Validation Study of three peanut ELISA 
kits: 
(358)
 the Veratox polyclonal ELISA against ‘total soluble peanut protein’ (Neogen Corporation, Lansing, 
MI, USA); the polyclonal Ridascreen ELISA (R-Biopharm, UK)  against ‘total soluble peanut protein;’ and the 
Biokits polyclonal ELISA against Ara h 1 (Tepnel Research Products and Services, Flintshire UK)  
(extrapolated to ‘total soluble peanut protein’). All three ELISAs showed correct identification of test food 
samples which contained 5μg peanut/gram of food and showed no cross-reactivity to a panel of 32 foods 
including cereals, legumes, seeds and tree nuts.  
 
Poms et al. (2005) performed an inter-laboratory validation study of these three commercial ELISA test kits (as 
well as two other peanut ELISAs). 
(359)





peanut per kg of food rather than in the low concentration range (2 or 2.5 mg/kg). The variation in the 
recoveries of peanut between the different test kits had a spread of 44–191% across all concentrations. Biokits 
and Veratox kits were the only two kits which did not give false negative results in dark chocolate but had a 
false negative rate of 1.9% and 2.1% respectively for biscuit. Recovery rate was 116-118% for the Biokits 
polyclonal ELISA against Ara h 1 and 151-188% for the Veratox polyclonal ELISA against peanut.  On the 
basis of the sensitivity of the Biokits and Veratox kits I assessed these ELISAs as potential ELISAs for use in 
measuring peanut in the environment. I also assessed a monoclonal Ara h 1 ELISA (Indoor Biotechnologies, 
Warminster, UK) as this had been used previously in environmental sampling. 
(319)
 This work was performed as 





5.8 Basophil activation test (BAT) to detect biological activity of peanut protein in dust  
Although the Veratox polyclonal peanut ELISA assay was able to reliably quantify peanut protein levels in 
dust, it did not provide us with any information about the ability of peanut allergens in dust to bind to effector 
cells in peanut allergic patients. The BAT was therefore used to confirm biological activity of peanut protein in 
dust in collaboration with Dr Alexandra Santos, King’s College London. The background to this assay is 
described below. 
5.8.1 Basophils 
Basophils are white blood cells which contain large granules inside their cytoplasm. Human basophils have high 
affinity IgE receptors which are antigen specific on their cell surface (FCεRI receptors). Once an antigen cross-
linked antigen specific FCεRI receptors, the basophils degranulate and release proinflammatory allergic 
mediators such as histamine and secrete leukotrienes and cytokines. As such basophils have a similar pattern of 





circulate in the peripheral blood and are therefore readily accessible for in vitro work.   Although basophils are 
the least abundant white blood cell in the peripheral circulation, in sensitized individuals they represent the 
largest population of antigen specific cells in the circulation. 
(361)
 Basophils are therefore ideal cells to evaluate a 
functional biological response to an allergen rather than just an indirect marker such as sIgE.   
5.8.2 Background of BAT  
In previous studies the IgE-cross-linking capacity of Ara h 1, 2 and 3 was examined by measuring histamine 
release after incubating basophils from patients with PA as well as passively sensitized basophils with several 
dilutions of the allergens. 
(324)
 More recently, the BAT has evaluated expression of activation markers CD63 and 
CD203c on the surface of basophils of allergic patients by flow-cytometry (FACS) rather than just measuring 
degranulation products such as histamine or leukotrienes. 
(362)
 CD63 is a 53kDa tetraspanin which is 
translocated from the membrane of secretory granules to the cell surface during basophil activation from FCεRI 
cross-linking.
(363)
 CD63 was originally thought to directly reflect histamine release; however, subsequently it 
has been shown to have differential expression to histamine release, although still being a good marker for 
basophil activation. 
(364)
 CD203c is a 150 kDa transmembrane glycoprotein in basophils and mast cells which is 
expressed in low levels on resting cells and is rapidly upregulated following activation using a distinct pathway 
from CD63.
(364)
 The use of both cell surface activation markers has been argued to increase the sensitivity of 
this assay, as often CD63 upregulation only occurs in a subset of basophils that upregulate CD203c upon 




5.8.3 BAT applications 
Although BAT has previously been used predominantly in the evaluation of drug and venom allergy,
(365;366)
 
BAT has more recently gained application in the diagnosis of food allergy, 
(367)
 including PA.  
(305;368;369)





most recent study by Santos et al. (2014), 
(369)
 using optimal cut-offs, BAT conferred an accuracy of 97%, PPV 
95% and NPV 98% against clinically confirmed PA. PA was confirmed by OFC in 61/104 (58.7%) of children 
(5 had indeterminate challenges so were excluded). In the remaining children, PA was assumed due to a 
convincing history of reaction within the last year and peanut SPT or sIgE above 95% PPV and peanut tolerance 
was assumed if children were able to eat more than 4 grams twice a week (assessed by FFQ). 
(368)
 The BAT cut-
offs and PPV were subsequently validated in an independent population of children in the LEAP study who 
were also undergoing OFCs to determine PA versus tolerance. BAT has also been shown to be a sensitive and 
specific tool to detect trace amounts of peanut in food matrices such as biscuits and chocolates.
(370)
 Basophils 
from peanut allergic patients or peanut tolerant individuals were stimulated with peanut-spiked (0.1ppm, 
0.01ppm, 0.001ppm) biscuits and chocolate extracts and highly significant activation of basophils with 0.1 and 
0.01ppm samples was found.
(370)
 Thus given the relevance of BAT in assessing clinical PA reactivity and its 
highly sensitive assay characteristics, BAT was used to determine the clinical reactivity of peanut protein in 
dust.  The methodology employed for the BAT is described in Section 6.10. 
5.9 Mass spectrometry (MS) 
MS is a powerful analytical tool for protein and peptide analysis. Certain authors argue that MS analysis is 
important to confirm proteins detected by polyclonal ELISAs, as polyclonal ELISAs detect all peanut proteins 
which may or may not include the major allergens (although we confirmed that the Veratox peanut ELISA 
standards contained a protein band of equivalent size to Ara h 1: see Section 10.3). 
(371)
 I therefore wished to 
investigate whether peanut protein found in dust samples from the infants’ bed-sheet and play-area contained 






5.9.1 Background of MS 
MS involves the ionisation of molecules and their subsequent separation and detection based on their mass (m) - 
to -charge (z) ratios (m/z). Ionisation is achieved by knocking one of more electrons off the sample so that the 
molecule has a positive charge.  Ions of different m/z ratios are separated by their interaction with either an 
electric or magnetic field (depending on the type of instrumentation); lighter and more positively charged ions 
(e.g. 2+) are deflected more than heavier or less positively charged ions (e.g. 1+). The mass spectra is then 
produced with the m/z values plotted against signal intensity and this can be used to identify the protein of 
interest using peptide sequence tag analysis and database searching with PeptideSearch or Uniprot (which 
comprises Swissprot).   
 
5.9.2 Sample clean-up requirements and MS analysis 
When assessing complex mixtures of samples, such as food or dust it is necessary to use a sample clean-up 
method in order to isolate the peptides of interest. MS has been used to detect peanut in complex food matrices 
assisted by the use of reversed-phase liquid chromatography (RP-LC) using a gradient mode of separation of the 
complex mixture, 
(371)
 or through a combined ELISA immunoassay and MS assay.
(372)
 In the study by 
Shefcheck et al. (2004), ice-cream was spiked with 0, 10 and 1000 µg/ml of Ara h 1.
(371)
 Following extraction of 
protein from the ice-cream, they used a 50 kDa cut-off membranes to concentrate the Ara h 1 protein in the 
extract and to remove lower molecular weight proteins such as β-lactoglobulin which would interfere with 







The peptide mixture obtained was separated out on a RP-LC column and detected with tandem mass 
spectrometry (MS/MS). In MS/MS collision-induced dissociation with energetic gas (hydrogen) molecules is 
used to generate a set of fragments from a specific peptide ion. The fragmentation occurs across the peptide 
backbone, cleaving the peptide (amide) bond and producing characteristic fragment ions that are indicative of 
the individual amino acids. Using this method Shefchek et al. (2004) were able to identify peptides with m/z 
629.8, m/z 571.3, m/z 606.6 and m/z 869.9; using peptide sequence tag analysis and database searching with 
PeptideSearch, these peptides and their corresponding sequences were unique to Ara h 1. They were able to 
confirm the presence of Ara h 1 in levels as low as 10 ppm (10 µg/ml or 10,000 ng/ml); however, did not assess 
Ara h 1 concentrations lower than this. To date no study has assessed peanut levels in household dust using MS; 
however, I anticipated that using a similar experimental technique it would be possible to identify allergenic 
peanut proteins in dust. 
 
5.10 Overall hypothesis and aims of study 
The overriding hypothesis of this PhD is that early EPE, measured by peanut protein levels in household dust, is 
a risk factor for the development of PS and PA in children with an impaired skin barrier. The aims of this PhD 
were effectively to describe characteristics of environmental peanut exposure, the association between this and 
PS and PA in children with an impaired skin barrier and finally mechanistic work to support the concept that PS 
occurs through the skin using recall responses to peanut from memory Th2 cells. The methods employed to 





Chapter 6 Methods  
6.1 Overview 
There are effectively three themes to this PhD which each require a separate section on the methodology used 
The first is the section where I investigated peanut protein levels in the environment (dust, surfaces, and air), 
characteristics of this exposure (such as how peanut gets into the environment and persistence of peanut in the 
environment) and characteristics of the peanut protein (quantification, major allergen content and biological 
activity). The second is an epidemiological section where I addressed whether early EPE was associated with 
PS and PA (where available) in one atopic and two population-based cohorts and whether this exposure was 
modified by various measures of atopy or skin barrier impairment. In the third section I evaluated in-vitro 
responses to peanut from PA, PS and NA children, assessing memory T helper (Th) cell responses to peanut in 
skin- versus gut-homing Th cell subsets in order to assess whether epicutaneous sensitization was reflected in a 
predominant Th2 response to peanut from skin-homing Th cells.   
 
Various sections to the methods are displayed below. Methods that are described in detail in the publications 
(which comprise the results section for this thesis incorporating publications) are not repeated in this Methods 
section. Where further background, validation or optimisation steps for the methods were taken (which are not 
described in the publications), these are included as Appendices. An overview of the methodology common to 
certain sections of the PhD is required, such as a table comparing the study design of the cohorts employed, 
assessment of potential confounding factors for the relationship between environmental peanut exposure (EPE) 
and peanut sensitization/allergy in the cohorts employed and prevalence of FLG loss-of-function mutations in 
the various populations from which the cohorts are derived. The methodology for sections which have not as yet 





6.2 Environmental peanut protein sampling methodology  
Wipe and dust sample methodology for Publication 1, 2 and 4 (CoFAR cohort) are described in the methods 
sections of these publications. Justification for the methods employed and figures depicting environmental 
sampling are included in Section 10.1 (Appendix 1). The dust collection procedure for publication 3 (MAAS) is 
described in Section 10.11.2 (Appendix 11). 
 
6.3 Dust sample processing  
Methods for dust sample processing (sieving, quantification, weighing, extraction and storage) are described in 
Publication 1 and its online repository. Validation for the minimum weight of dust that could be used without 
affecting peanut protein quantification is describe in Section 10.2 (Appendix 2).  
 
6.4 Peanut protein quantification by ELISA  
The method and validation of the ELISA used in this PhD is described briefly in Publication 1 and its online 
repository. A more detailed description of ELISA methodology, the background, method and quality standards 
employed for the Veratox peanut ELISA as well as assessment of likely Ara 1 in the Veratox peanut standards 
is included in Section 10.3 (Appendix 3).  
 
6.5 Semi-quantitative peanut FFQ  
The peanut FFQ employed is described briefly in Publication 2. A full description of this FFQ’s origins, 





6.6 Participant questionnaire for Publication 2 
A participant questionnaire was used to assess household, demographic and clinical factors which may affect 
levels of peanut protein in the home environment. This questionnaire is described briefly in Publication 2, 
therefore the full rationale and description is detailed in Section 10.5 (Appendix 5).  
6.7 Recruitment of patients for environmental peanut sampling in Publication 1 and 2 
Recruitment and study procedures are described briefly in Publication 1 and 2. Further details are provided on 
participant recruitment including the participant information sheet, participant flow-diagram and study 
procedures in Section 10.6 (Appendix 6). 
6.8 Statistical powering and analysis for Publication 2 
Statistical powering and analysis are described in publication 2. Considerations for depiction of correlation plots 
are explained in Section 10.7 (Appendix 7). 
6.9 Persistence of peanut on human and environmental surfaces  
Given that HPC was shown to positively correlate with peanut protein levels in dust and surface wipes, 
(373)
 it 
was important to determine how peanut might get into the environment, thus persistence of peanut on human 
hands and saliva after peanut consumption were assessed. Given that peanut protein is measureable in the 
infant’s bed and play-area, and that this could be an important source of exposure leading to sensitization, it was 
important to assess whether a detergent wash was sufficient to remove peanut protein from these types of 
household items, for future use in interventional studies thus persistence of peanut on sofa-covers and pillows 
after peanut consumption were assessed. Methods for peanut sampling on human and environmental surfaces 
are described in Publication 1. Participant information sheet for peanut sampling on humans is shown in Section 





6.10 Whole blood basophil activation test (BAT)  
This work was conducted in collaboration with Dr Alexandra Santos. Dust extracts with a known peanut protein 
level incubated with PBMCs of PA ad NA children was used to assess the biological activity of peanut protein. 
Patient selection and methodology of the BAT are described in Publication 2.  
 
6.11 Mass Spectrometry (MS)  
6.11.1 MS analysis at KCL 
I aimed to confirm the presence of peanut using MS in collaboration with Dr. Mark Parkin, Lecturer in 
Analytical Science, Analytical and Environmental Research Division, Franklin-Wilkins Building, KCL and Prof 
James McDonnell, Professor of Molecular Immunology, Randall Division of Cell & Molecular Biophysics, 
KCL. Background of MS use as an analytical tool and previous studies using LC-MS/MS for the detection of 
Ara h 1 peptides in food is discussed in Section 5.9. Trypsin digestion was carried out to create peptides of Ara 
h 1 concentrate (Indoor Biotechnologies, USA) with the SOP described in Section 10.9.1 (Appendix 9).  
 
6.11.1.1 MS validation work  
Before analysing peanut peptides in dust (which contains many other proteins), an aqueous solution was spiked 
with Ara h 1 to determine the LLQ for Ara h 1 using LC-MS/MS. After tryptic digestion and solid-phase 
extraction for sample clean-up, the peptide mixture was separated out by reversed-phase liquid chromatography 
(RP-LC). Selected peptide ions were then bombarded with argon fracturing the peptide ions at the peptide bond 
into fragment ions. The peptide bond is the chemical bond formed between the carboxyl and amino-group of 





fragment ions is the mass of an amino acid. A peptide sequence tag is determined using a 3 or 4 amino acid 
sequence (by calculating the mass difference between fragment ions), the total mass of the peptide and the mass 
of the fragmented peptide at the start and end of the amino acid sequence. These peptide sequence tags were 
then entered into SwissProt protein sequence database to identify the Ara h 1 protein.  Peptides with MS/MS 
spectra corresponding to Ara h 1 were observed in the aqueous solutions comprising 1000 µg/ml and 500 ng/ml 
Ara h 1 with approximately 40% sequence coverage of the Ara h 1 protein.  
 
Two of the more dominant peptide ions found in our aqueous solutions had peptide ions with m/z 607 (Figure 
18) and m/z 630 (Figure 19, p149); these two peptide ions were also dominant in the study by Shefcheck et al. 
(2004) 
(371)
 (see  Section  5.9), where food matrices were spiked with Ara h 1. Additionally, the m/z 607 peptide 
ion in our study had fragment ions with m/z 687.4, m/z 722.9, m/z 745.4, m/z 779.7, m/z 974.5, m/z 1073.5 
(Figure 18); these closely resembled the m/z 607 peptide fragment ions (m/z 687.2, m/z 722.9, m/z 745.3, m/z 
779.3, m/z 974.3, m/z 1073.3) obtained by Shefcheck et al. (2004). 
(371)
  Shefcheck et al. (2004) did not disclose 










Fragment ions of the selected m/z 607 peptide 
ion also found by Shefcheck et al. (2004)  
Fragment ions of the selected m/z 607 peptide 
ion also found by Shefcheck et al. (2004)  
B 
F:\5917 2/11/2011 11:21:02 AM Ara_h_2mg/mL digest
RT: 0.00 - 60.00
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5917 #4974 RT: 24.00 AV: 1 NL: 2.40E4
F: ITMS + c ESI d Full ms2 607.22@cid35.00 [155.00-1225.00]
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Figure 19: Selected ion chromatogram for peptide (m/z 630) (A), MS/MS spectrum of peptide m/z 630 (B) 
 F:\5917 2/11/2011 11:21:02 AM Ara_h_2mg/mL digest
RT: 0.00 - 60.00
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NL: 5.55E5
Base Peak m/z= 
629.50-630.50 F: 




5917 #4358 RT: 21.10 AV: 1 NL: 5.06E3
F: ITMS + c ESI d Full ms2 630.59@cid35.00 [160.00-1275.00]




































577.19359.31 496.36 900.40 971.40
349.15 462.25
288.29207.14
706.27434.23234.99 664.45343.18 542.21 872.50 954.27763.37 1067.78262.17200.17 399.39 1007.60472.26 737.50303.29 832.45661.36 1182.571112.80
Fragment ions of the 
selected m/z 630 peptide ion  
 
Selected peptide ion 







6.11.1.2 Dust sample extract analysis 
Subsequently, biological samples of dust were extracted as per the Veratox extraction protocol (see Section 6.4) 
with or without skim milk; these dust extracts had a peanut protein content below the Veratox ELISA LLQ (<25 
ng/ml peanut protein) and were spiked with 500 ng/ml of Ara h 1. The total peanut content was calculated in the 
biological samples (as they contained other proteins apart from peanut) using a Nanodrop Spectrophotometer 
and proportional amounts of trypsin were added to the sample for the trypsin digest. A 500 ng/ml Ara h 1 
aqueous sample was used as a positive control. Samples were run on the LC-MS/MS (Linear trap quadrupole 
(LTQ), Thermo Scientific). Although peptides were seen in the positive controls of aqueous samples spike with 
500 ng/ml Ara h 1, no Ara h 1 peptides were detected in the dust extracts; however, many keratins were found 




6.11.1.3 Sample clean-up 
Therefore, a strong cation ion exchange method was used for sample clean-up prior to LC-MS/MS. The 
isoelectric point for Ara h 1 is 4.55, which is the point at which positive and negative charges are equal so there 
is no net charge. Dust sample extracts containing no peanut were spiked with 500ng/ml and 1000ng/ml Ara h 1. 
Aqueous solution was also spiked with 500ng/ml and 1000ng/ml Ara h 1 as a positive control. The spiked 
aqueous solution and dust extracts were run through a solid phase extraction cartridge (C18 cartridges, Agilent 
Technologies) on a vacuum manifold is separate experiments. By adding ammonium hydroxide to increase the 
pH of these samples to 11.5 it was anticipated that Ara h 1 would bind to the cartridge given the isoelectric 
point for Ara h 1 of 4.55. Ara h 1 was then eluted off the cartridge using three washes at pH 5.5, pH 4.5 (the 





triple quadrupole MS analyser (TQS – Thermo Scientific, UK) was then used to analyse these samples. 
Following the strong cation ion exchange method clean-up, no peptides were detected in either the dust extracts 
or the positive controls. Therefore further MS analysis was performed in collaboration with Professor Clare 
Mills and Dr Phil Johnson at the University of Manchester.  
 
6.11.2 MS analysis at the University of Manchester 
Three dust samples collected from the homes of families participating in the correlation study (see Section 6.7) 
were sent to the Manchester Institute of Biotechnology for analysis. Two dust samples from an infant’s bed-
sheet (Y175) and play-area (Y231) contained high levels of peanut protein (797.5µg/g and 870 µg/g 
respectively). One dust sample from a maternal mattress (P77) contained peanut protein levels below the LLQ 
of the Veratox peanut ELISA. 
 
6.11.2.1 Dust sample preparation and clean-up 
Dust samples (5mg) were extracted with 50 mM Tris Cl
-





w/v) for 15 min with heating at 60
o
C with continuous sonication and vortex mixing every 5 min. Samples were 
sequentially reduced, alkylated and digested using an in solution protocol designed to reduce volumes of 
reagents and therefore maximise protein concentration in the final sample (see Section 10.9.2). Sample clean-up 
was performed using Pierce C18 spin columns (Thermo Scientific, UK) according to manufacturer’s 
instruction. Samples were stored frozen at -20
o





6.11.2.2 MS analysis 
Dust sample extracts were subjected to reverse phase HPLC electrospray ionisation mass spectrometry (RP-
HPLC-ESI-MS) using a NanoAcquity LC (Waters, Manchester, UK) coupled to an Orbitrap Elite mass 
spectrometer (Thermo Scientific, Waltham, USA). Samples (20µl) were applied to the analytical column 
(1.7µm ACQUITY™ C18 (Waters, Manchester, UK)) and eluted with a 2% (v/v) acetonitrile : water gradient 
for 10min, followed by a linear gradient to 60% (v/v) from 10 to 45min, finishing with a linear gradient to 90% 
(v/v) acetonitrile at 50 min.  Formic acid (0.1% (v/v)) (final concentration) was included throughout. Mass 
spectra were obtained in positive ion electrospray mode. The mass range for the survey scans was m/z 300 – 
2000, resolution 60,000, with m/z values determined by the Orbitrap fourier transform mass spectrometry 
(FTMS) stage. The FTMS fill target was 700,000 ions with a maximum fill time of 1000ms. The resultant 
monoisotopic masses were accurate to better than 10ppm. MS/MS spectra were obtained using collision 
induced dissociation with collision voltage 35V with m/z values determined by the Linear Ion Trap stage. The 
MS/MS was triggered by a minimal signal of 5000 ions with a fill target of 30,000 ions and 150ms maximum 
fill time. A maximum of 6 MS/MS spectra per survey scan were obtained by defaulting to the most abundant 
ions, with m/z values determined to better than ~ 0.5 Daltons (Da).  
 
6.11.2.3 Data analysis 
MS data were analysed using PEAKS Client 6.0 build 2012620 (Bioinformatic Solutions Inc, Waterloo, 
Canada). Analytical variables were set as follows: parent ion mass tolerance 5ppm, MS2 ion tolerance 0.5 Da, 
2+ and 3+ charge states only. Up to 1 missed cleavage (trypsin) was allowed at either end of the peptide. The 





Subsequent analysis consisted of identification of sequences corresponding to those present in a collated, non-
redundant allergen sequence database (personal communication Dr P Johnson, University of Manchester, 
September 2014).   Additional extracted ion chromatograms (EICs) and parent ion spectra were generated using 
the QualBrowser software package (Thermo Scientific) using an m/z range of the theoretical m/z +/- 0.01 Da. 
 
6.12 Airborne peanut (publication 1) 
To determine whether peanut could be aerosolised, experiments were conducted to try to capture airborne 
peanut was captured by glass-fibre filters inserted into the inhalable occupational medicine (IOM) sampling 
head of a personal air sampling monitor (Casella Tuff, Bedford, UK). This method is described briefly in 
Publication 1. A full description with figures of the experiments performed is in Section 10.10 (Appendix 10).  
 
6.13 Influence of early EPE on PS and PA in cohort studies 
6.13.1 Study design 
Cohort studies from the UK, USA and Europe were employed to assess the hypothesis that early EPE, measured 
by peanut protein levels in household dust, is a risk factor for the development of PS and PA in children with an 
impaired skin barrier. A summary of the three cohorts employed are described in Table 3. The MAAS and 
CoFAR study are described in the methods sections of Publication 3 and 4 respectively. Further details on the 
definition of PA (OFC criteria) for MAAS as well as the differences in dust collection procedure for MAAS are 
provided in Section 10.11 (Appendix 11). The third cohort employed (BAMSE) is not yet published thus I 












Full name of study Manchester Allergy and Asthma Study Barn Allergy Milieu 
Stockholm Epidemiology 
Consortium of Food Allergy Research 
Country UK Sweden US 
Study format Observational study but with randomised 
controlled trial within high-risk sub-cohort. 
Observational study Observational study 
Commenced 1995 1994 2005 
Recruitment Antenatal Antenatal 3-15 months 
Atopy status Unselected population based study Unselected population based 
study 
Egg / milk allergy or moderate-severe  
eczema with positive SPT for egg/ milk 
Intervention arm HDM reduction measures Nil Nil 
Sample size recruited 1184 4089 512 
Final sample size 
used in PhD 
623 1878 359 (living room), 173 (bed-sheet) 
Dust site Upholstered furniture Maternal mattress Bed-sheet of infant or living room floor 
Dust collection Antenatally till 12 months Two months after birth 3-15 months 
PS outcomes 8 and 11 years 4 and 8 years 3-15 month 
Definition PS: SPT SPT≥3mm N/A SPT≥3mm 
Definition PS: sIgE/ 
CRD  
>0.35kU/L (CRD) ≥0.35kU/L (sIgE/CRD) ≥0.35kU/L (sIgE) 





6.14 Confounding factors for all cohorts 
The following demographics, clinical outcomes and potential sources of peanut exposure were requested from 
the databases of the cohorts described above (where available) so that the association between these variables 
and PS or PA could be assessed.  
 
1. Parental atopy: PA is more common in children with atopic parents, as atopy is inherited, and PA is 
higher in first degree family members of peanut allergic children (see Section 1.7). 
(63)
 Parental atopy also 
increases the risk of other atopic diseases (eczema, egg sensitization/allergy, allergic rhinitis) and may influence 
behaviour towards peanut consumption during pregnancy, breastfeeding and early childhood given previous 
recommendations,  
(100)




2. HPC: HPC is a known risk factor for PA; however, these data were only available by proxy (peanut 




3. Infant peanut consumption was not available in all three cohort studies, which is unfortunate given that 
this might impact both on PS and PA (potentially via oral tolerance induction) and on environmental peanut 
levels (potentially via epicutaneous sensitization).  
 
4. Sex: Lifetime prevalence rate of PA is higher in male children than female children both in the US (13) 
and the UK. 
(132)
 In the US self-reported allergy to peanut and tree nuts was 1.7% in male versus 0.7% in female 
children aged 0-18 years (P= 0.02).
(13)
  In England, using GP recorded diagnosis of PA, the crude lifetime 
prevalence rate of PA was 1.77/1000 (95% CI: 1.63-1.91) in males versus 1.39/1000 (95% CI 1.27-1.52) in 








5. Ethnicity was included for the following reasons:  
a) Non-Caucasian participants were excluded when analysis of FLG loss-of-function mutations 
(R501X, 2282del4, S3247X, R2447X, 3673delC and 3702delG) were entered into the LR model; these FLG 
mutations have been associated with eczema and other atopic conditions only in Caucasian individuals. 
(258)
 
b) Race (Black ethnicity) has been associated with raised peanut sIgE in several studies; (9;375;376) however, 




6. Number of older siblings: The number of older siblings in the home could reduce the likelihood of PA 
on the basis of increased microbial exposure preventing atopy (as per the Hygiene hypothesis); 
(377)
 however, 
conversely it is possible that a large number of children in the home could lead to more peanut being consumed 




7. Maternal age: Food allergy in the child was associated with a higher maternal age in a Massachusetts 
case control study; the offspring of mothers aged over 30 years of age at the time of their child’s delivery, had a 
3.7- fold (95% CI: 1.67-8.20) increased risk of food allergy defined as a history of an acute allergic reaction and 
positive SPT of sIgE to that allergen. This risk was present after adjusting for socioeconomic status (using 




8. Infantile eczema (presence and severity): Presence and severity of eczema are well known risk factors 
for PS and PA.
(49;143)
 Additionally, it is important to consider including eczema in the statistical model when 
assessing FLG loss-of-function mutations as a predictor of PS and PA as FLG is also a strong predictor of 
eczema. 
(259)










9. Egg SPT or sIgE sensitization: Children with egg allergy are highly atopic and at risk of developing PA, 
with approximately 20% to 30% demonstrating sensitization to peanut on SPT (data from the ALSPAC study). 
(49;104)
 More recently the LEAP study found that infants with egg allergy were 2.3 times [95% CI, 1.39-3.86] 
more likely to be peanut SPT sensitized than children without egg allergy recruited to the LEAP study (with 
moderate-severe eczema). 
 
10. Allergic rhinitis: Tree and grass pollen allergy can lead to cross-reactive antibodies that lead to positive 
in vitro (sIgE) and in vivo (SPT) peanut cross-reactivity, but are not indicative of primary PA. Ara h 8 may be 
raised due to cross-reactivity with birch pollen (Bet v 1). 
(379)
 Ara h 5, a profilin (panallergen) may be raised due 
to cross-reactivity with grass or tree pollen (Bet v 2). 
(380)
 CCD (carbohydrate cross-reactive determinants) may 




11. HDM intervention (MAAS cohort only): Impermeable mattresses and acaricide treatments of soft 
furnishing have the potential to reduce levels of HDM allergen exposure, 
(301)
 and affect exposure to other 




12. Peanut consumption during pregnancy and breastfeeding: The literature surrounding this as a possible 
risk factor for PA is discussed in Section 2.3. 
 
13. Duration of maternal breastfeeding: Many studies have investigated the role of breastfeeding on the risk 





6.14.1 Relationship between variables and potential confounding factors  
To assess potential confounding factors should be accounted for in the statistical analysis I used software for 
Direct Acyclic Graphs (http://www.dagitty.net/dags.html). This method assesses causal networks between  
variables under study to determine potential confounding variables, and has been recommended and used by 
various research groups.
(383;384)
   The conventional method to determine covariates that need to be adjusted for is 
by performing a univariate followed by multivariate LR analysis with the outcome of interest. Figure 20 depicts 
possible associations between predictor variables (demographic, environmental, and behavioural) and the 
outcome variable PS. Figure 20 additionally depicts possible associations between demographic, environmental, 
and behavioural variables on the predictor variable of interest (EPE). An explanation of the hubs and pathways 
is given below: 
1) Green hubs: Exposure variable and ancestor of exposure variables 
2) Blue hubs: Outcome variable and ancestor of outcome variable 
3) Pink hubs: Ancestors of exposure and outcome variables 
4) Green lines: Causal pathways  
5) Pink lines: Biasing pathways  
 
Variables related to both the main predictor (EPE) and outcome variable (PS) were parental atopy, older 
siblings, infant peanut consumption, HPC, maternal peanut consumption during pregnancy and breastfeeding. 
Factors related only to the outcome variable (PS) were infantile eczema, FLG mutations, egg sensitization, 
ethnicity, sex, breastfeeding duration, maternal age and allergic rhinitis. HDM reduction measures were only 










6.15 FLG genotyping  
FLG genotyping was performed using genomic DNA extracted from blood. Although DNA can also be 
extracted from buccal swabs this method is less reliable so only blood for genotyping was used.
(385)
 FLG loss-
of-function mutation prevalence, association with eczema and penetrance in studies from countries similar to 
the cohorts employed in this PhD are described in  
Table 4. FLG genotyping on the following six FLG loss-of-function mutations was performed in MAAS: 
R501X, 2282del4, S3247X, R2447X, 3673delC and 3702delG. The reason for selecting these FLG mutations 
was that in previous literature each of these had been shown to be associated with eczema in the UK or Ireland. 
R501X and 2282del FLG mutations were the most prevalent FLG loss-of-function mutations in the UK and 
Ireland and were more highly associated with eczema than S3247X or R2447X FLG mutations. 
(386;387)
 S3247X 
and R2447X FLG loss-of-function mutations were not significantly associated with eczema in the UK case 
control study (Cumbria); however, in the Irish case control study FLG genotypes S3247X, R2447X and 
3702delG were significantly associated with childhood eczema.
(268)
 These discrepant findings may have been 
because in the Irish study controls were compared against children with moderate to severe eczema, 
(251)
 




Details of FLG genotyping for MAAS and CoFAR are described briefly in Publication 3 and 4. FLG 
genotyping was performed by each respective cohort (except CoFAR where genomic DNA was sent to 
Professor Irwin McLean’s Team at the College of Life Sciences, University of Dundee). Although I did not 





Team at The University of Manchester and University of Dundee. Further description of FLG genotypes, RT-
qPCR background and methods employed in MAAS and CoFAR are described in Section 10.12 (Appendix 12).  
Table 4: Review of FLG loss-of-function mutations in studies from countries from respective cohorts (MAAS: 
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OR 2.21 (1.5-3.25) 
Severe eczema:  
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mutation: 55.6%  
Using allelic model 
R501X:  
OR 1.6 (0.9-2.8)  
2282del4: 
OR 2.0 (1.1-3.7) 
R2447X:  
OR 1.2 (0.3-4.5) 
S3247X: 





6.16 Statistical powering  
Hypothesis: Early EPE in children with FLG loss-of-function mutations is a risk factor for PS 
Simulations were carried out by Professor Andy Grieve (Professor of Statistics, KCL) to determine the power of 
the study to detect a range of values for the slope of the interaction of FLG loss-of-function mutation and 
environmental exposure in the logistic model. The estimated prevalence of PS and PA (where available), FLG 
mutation rate and mean and standard deviation of log transformed peanut protein levels in 20 random dust 
samples from each cohort were used for this simulation (see Table 5).  
 
Table 5: Data used to determine power of each cohort study (using estimated data) 




Mean log transformed 
peanut protein in dust 
Standard deviation of  
peanut protein in dust 
MAAS 4.2%* 6.6% 2.62 1.17 
BAMSE 3.3%* 6.6% 3.11 1.07 
CoFAR 17.5% 15% 3.75 1.15 
*A correction factor of 0.6 in BAMSE and MAAS was included to account for pollen cross-reactivity. 
It was subsequently possible to predict the detectable interaction FLG genotype by environmental peanut 












principle investigators from these cohorts on how much dust was available and how many children had had 
FLG genotyping.  On the basis of the sample sizes below each study had ≥80% power to detect an interaction 
odds ratio of 2.5 (Table 6).  
Table 6: Detectable interaction OR for FLG genotype by EPE on PS  
Study Estimated sample size Detectable interaction OR  
MAAS 750 2.3 
BAMSE 2132 1.9 
CoFAR 140 (bed-sheet) 2.5 
 
6.17 Statistical analysis for MAAS and CoFAR 
Statistical analysis for results obtained for MAAS and CoFAR are described briefly in Publication 3 and 4 
respectively. A detailed description of the statistical methods and the background to these methods is discussed 







6.18 BAMSE study 
The BAMSE study is an unselected Swedish population birth cohort which recruited 4089 children antenatally 
from 1994-1996.
(390)
 The BAMSE study was an observational study to evaluate health conditions over time. No 
intervention was performed. The BAMSE study obtained ethical approval for environmental sampling of dust. 
6.18.1 BAMSE data sources and definition of variables 
Serum sIgE to peanut (ImmunoCAP system, Thermo Scientific, Sweden) was measured at 4 and 8 years and 
children were defined as ‘peanut sIgE sensitized’ if peanut sIgE was ≥0.35 kU/L.  Component allergens (Ara h 
1, 2, 3, 8 and 9) were assessed at 8 years (ImmunoCAP system, Thermo Scientific, Sweden) and children were 
considered to be ‘peanut CRD sensitized’ if Ara h 1, 2 or 3 was ≥ 0.35kU/L and non CRD sensitized if Ara h 1, 
2 and 3 were <0.35kU/L or peanut sIgE was <0.35kU/L at 8 years. Children with positive peanut sIgE at 8 years 
of age but no component allergen analysis were excluded from the peanut CRD analysis. Peanut SPT was only 
available in 49 participants. Peanut SPT sensitization was defined as a mean wheal size ≥3mm. Egg 
sensitization was defined as egg sIgE ≥ 0.35KU/L at 4 years of age. Parental atopy was defined as a doctor’s 
diagnosis of asthma and prescription of asthma medication and/or a doctor’s diagnosis of hay fever in 
combination with furred pets- and/or pollen allergy at the time of questionnaire. 
 
Genotyping was performed for FLG mutations common in Scandinavia by using TaqMan allelic discrimination 
assays for R501X and R2447X and matrix-assisted laser desorption/ionization-time-of-flight MS for 2282del4. 
Children with a mutation in any of these positions were classified as having a FLG loss-of-function mutation. A 
reported history of infantile eczema was assessed by questionnaire and was defined as dry skin, itchy rashes for 





wrists/ankles flexures) and/or doctor’s diagnosis of eczema during the first year of life. Ethnicity was based on 
where the parents were born. Allergic rhinitis at 4 and 8 years was assessed using ISAAC validated 
questionnaires.
(391)
 Clinical symptoms of reactivity to peanut were reported in 3.8% of children at 4 years and 
5% at 8 years in this cohort but no food challenges were performed.  
 
6.18.2 BAMSE dust samples collection procedure 
Dust samples were collected at a median of 2 months of age from the mother’s mattress. The mother’s mattress 
was vacuumed for 2.5 minutes with a small disposable filter bag (Allergy Control Products Inc. Ridgefield CT, 
USA) inserted in the front hose of the vacuum. The dust containing filter bags were sealed in plastic bags and 
stored at -20ºC. Dust samples were sieved and fine dust was weighed and extracted in proportional volumes of 
extraction solution as previously described.
(360)
 Peanut protein in dust was determined using the Veratox 
polyclonal ELISA against whole peanut protein (Neogen Corporation, Lansing, MI, USA). The lower limit of 
quantitation (LLQ) of the assay was defined as 100ng/ml and samples below this value were defined as 50ng/ml 
(LLQ/2).
(392)
 Details of dust processing and extraction are described in Section 6.2.  Peanut protein in dust was 
determined using the Veratox polyclonal ELISA as described in Section 6.4. Results were converted from ng/ml 
into μg peanut protein/gram dust. Due to batch to batch variability of the Veratox ELISA results were batch 
corrected prior to being entered into the final statistical analysis.  
 
6.18.3 Batch correction 
Due to the large number of dust samples in the BAMSE study it was not possible to analyze all dust samples 





was employed to adjust for this when converting from ng/ml to µg/gram peanut protein.  This batch correction 
was feasible because independent positive controls were run along the whole range of the standard curve at 
0ng/ml, 250ng/ml, 500ng/ml and 1000ng/ml with each new ELISA kit. There were four batches which had 
similar results for the independent standards assessed; however, three batches had significantly higher results 
along the trajectory of the standard curve. The results obtained from ELISA batches which had similar results 
for the independent peanut standards were combined into a ‘low batch’ trend line to define the equation for this 
group, which was y = 1.0298x + 30.196.  The three batches which ran higher than the independent peanut 
standard controls had trend equations as described below and in Figure 21: 
1) Batch 26099: y = 1.2901x + 25.592 
2) Batch 26100: y = 1.3411x + 13.036 
3) Batch 26101: y = 1.5258x + 12.762 
 
To correct for the higher results I used the following equations for batch correction: 
1) All samples for Batch 26099:  
a. Subtract 25.59, divide value by 1.2901, multiply by 1.0298 and add 30 
b. INTO EXCEL FUNCTION =((value-25.59)/ 1.2901)*1.0298+30.196 
2) All samples for Batch 26100:  
a. Subtract 13.04, divide value by 1.3411, multiply by 1.0298 and add 30 
b. INTO EXCEL FUNCTION =((value-13.04)/ 1.3411)*1.0298+30.196 
3) All samples for Batch 26101:  
a. Subtract 12.76, divide value by 1.5258, multiply by 1.0298, then add 30 























y = 1.2901x + 25.592 
y = 1.3411x + 13.036 
y = 1.5258x + 12.762 






































ALK independent peanut protein concentration (ng/ml) 
26099 26100
26101 Low batches combined
Linear (26099) Linear (26100)




6.18.4 Statistical analysis for BAMSE study  
Data were entered into an SPSS (SPSS 19.0; SPSS Inc, Chicago, IL, USA) and STATA spreadsheet 
(Timberlake Consultants Ltd London, UK). Peanut protein levels in dust (µg/gram) underwent natural log 
transformation. Initial nested case control analysis was performed with peanut sIgE sensitized cases at 4 
years matched for sex and parental atopy with a 2:1 control (n=274) to case (n=137) matching. Children 
with peanut CRD sensitization defined by Ara h 1, 2 or 3 ≥0.35kU/L at 8 years of age were also matched 
against controls at age 8 years matched for sex and parental atopy with a 2:1 ratio of controls (n=130) to 
cases (n=65). Conditional LR (incorporating matching) was performed for the case control analysis using 
robust standard error for peanut sIgE sensitization at 4 years and peanut CRD sensitization at 8 years.  
 
Subsequently I assessed the relationship between early EPE and PS in children from the whole BAMSE 
cohort with available postnatal maternal bed-dust and FLG genotyping (n=1878). LR analysis was 
performed for peanut CRD sensitization at 8 years of age. Factors associated with peanut sIgE sensitization 
were assessed using Generalized Estimating Equations (GEE) with an exchangeable working correlation 
matrix to account for repeated measures within individuals at 4 and 8 years. Univariate followed by 
multivariate regression analysis was performed including EPE, FLG mutations, infantile eczema and egg 
sensitization at 4 years plus other covariates significantly associated with PS (P≤.05) that improved the 
quality of fit of the multivariate model using the Akaike information criterion (AIC) for LR and the Quasi 
Likelihood Independence models criterion (QIC) for GEE. Where the FLG mutation covariate was entered 
into the statistical model, participants with missing ethnicity data (35/1878=1.9%) and non-Caucasians 
(165/1842=8.8%) were excluded as distinct FLG loss-of-function mutations are present in different 
populations and the FLG loss-of-function mutations assessed in this study have only been associated with 
eczema in Caucasian European populations.
(257;277)
 Peanut levels in dust (µg/g) were compared between 
groups using the Mann-Whitney U test. Proportions between groups (e.g. infantile eczema and FLG 




6.19 Differential gene expression in skin versus gut Th cell recall responses to peanut  
6.19.1 Relevance to PhD hypothesis 
The overriding hypothesis of this PhD is that early EPE, measured by peanut protein levels in household 
dust, is a risk factor for the development of PS and PA in children with an impaired skin barrier. I sought to 
use mechanistic work to support the concept that PS occurs through the epicutaneous exposure using recall 
responses to peanut from memory Th2 that are derived from the skin. The hypothesis for this mechanistic 
section was that memory peanut specific Th2 from the skin would upregulate genes within the Th2 cytokine 
network when cultured in peanut. Conversely memory peanut specific Th2 from the gut would upregulate 
genes within the Th1 or Treg network.  This finding would also support the Dual Allergen Exposure 
Hypothesis, 
(393)
 which hypothesises that allergen exposure via the skin leads to a Th2 phenotype whereas 
allergen exposure through the gut leads to T regulatory function and oral tolerance induction (Figure 22).
(205)
  
Figure 22: Dual Allergen Exposure Hypothesis 
Reprint from Lack et al. (2012)
(394)





6.19.2 Patient selection and methodology  
Children with PA, PS and atopic NA children were recruited from St. Thomas Hospital Children’s Allergy 
Unit to assess differential gene expression in recall responses to peanut from skin versus gut-homing Th 
cells. The methods for PBMC isolation, culture of PBMCs in peanut protein versus medium alone, cell 
staining and FACS, RNA extraction and quantification, cDNA conversion, amplification, quantification, 
fragmentation and biotinylation for hybridization onto the Affymetrix microarray, microarray data 
normalisation and quality check, Partek analysis and automatic classification approach, and confirmatory 
RT-qPCR and intracellular cytokine staining (ICCS) are described in the online repository of Publication 5 
(Section 7.10.1). Various optimisation steps which are not described in the online repository of Publication 
are detailed in Section 10.14 (Appendix 14), including the choice of medium for peanut culture, 
concentration of peanut protein for culture and measures to improve and confirm the quantity and quality of  
RNA extracted from PBMCs. Confirmatory RT-qPCR results are described only briefly in the online 
repository, therefore a more detailed description and justification of the methods employed are displayed in 









Chapter 7 Results  
This PhD incorporates publications as results chapters, thus these publications include a brief introduction, 
method, results section (with associated tables and figures) and discussion. Not all of the work performed 
has been published to date (MS work and BAMSE cohort analysis) thus these results are included as 
separate subsection of the results section. The publications can be grouped into the three themes of this PhD:  
(1) Characterisation of EPE 
(2) Influence of EPE on PS and PA in children with an impaired skin barrier  
(3) In-vitro responses to peanut from PA, PS and NA children, assessing memory T helper (Th) cell 
responses to peanut in skin- versus gut-homing Th cell subsets.  
The publications and sections are listed below according to which theme they belong to: 
7.1 Characterisation of EPE  
1) Publication 1: Brough H.A., Makinson K, Penagos M, Maleki S, Cheng H, Stephens AC, Turcanu V, 
Lack G. Distribution of peanut protein in the home environment. J Allergy Clin Immunol 2013; 132(3):623-
9 
 
2) Publication 2: Brough H.A., Santos A, Makinson K, Penagos M, Stephens AC,  Turcanu V, Lack G. 
Peanut protein in household dust is related to household consumption and is biologically active. J Allergy 
Clin Immunol 2013; 132(3):630-8 
 






7.2 Influence of EPE on PS and PA  
1) Publication 3: Brough H.A., Simpson A., Makinson K., Hankinson J., Brown S., Douiri A et al. 
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7.6 MS findings 
MS was used to determine more detailed analysis of the peanut peptides in dust. The MS methodology and 
validation work used is detailed in Section 6.11.1 (KCL analyses) and Section 6.11.2 (University of 
Manchester analyses). Dust samples from an infant’s play-area (Y175) and bed-sheet (Y231) contained (870 
µg/g and 797.5 µg/g peanut protein respectively). Dust from a maternal mattress (P77) had levels below the 
LLQ of the Veratox peanut ELISA. Initial analysis of the MS/MS data obtained from these extracted dust 
samples and a peanut flour comparator/control is shown in Figure 23. Searches of MS/MS data against a 
decoy database (obtained automatically using the PEAKS software package) was performed to indicate the 
chance of peanut peptide detection through chance alone. In the case of the maternal bed-sheet (P77) 
(suggested by ELISA analysis to contain little or no peanut protein) there was an indication of some peptides 
attributable to peanut with quality scores of 50-100 indicating authentic detection. However, analysis of 
infant bed-dust (Y231) and play-area (Y175) samples indicated a far higher number of detected peanut 
peptides at a higher quality score, indicating an increased presence of peanut proteins in these samples. As 
expected, the peanut flour comparator contained abundant significant peanut peptide hits in greater numbers 




Figure 23: Peptides detected from MS data from dust from (A) maternal bed-sheet (P77), (B) infant play-
area (Y175) and (C) infant bed-sheet (Y231).  
Red spots indicate peptides detected using a decoy database generated by the PEAKS software, blue spots 
peptides detected using the peanut sequence database. Red boxes indicate the range of likely significant 
peptides hits. A roasted commercial peanut flour comparator (D) was used as positive control. 
 
The detection of individual peanut allergens and the sequence accessions (from the database UniProt) which 
comprised them is shown in Table 7. The percentage protein coverage shown was calculated using the 
complete sequences as given in UniProt based on translational start, and therefore included sequences not 
expected in the final protein (e.g. signal peptides). Dust from the maternal bed-sheet (P77) with peanut 
levels < LLQ on ELISA analysis contained poor coverage of the major peanut allergens Ara h 1, 2 and 3. As 
the percentage coverage of isoforms representing these allergens was consistently low the likelihood of 
peanut being present in this sample was low. Conversely, dust samples from the infant bed-sheet (Y231) and 




was also suggested in Figure 23 and from the ELISA analysis performed previously where Y175 had 870 
µg/g and Y231 had 797.5 µg/g peanut protein. Peptides corresponding to the allergens Ara h 1, 2, 3, 6, 7, 8, 
9, 10 and 11 could be detected in dust Y175. The detection of Ara h 8 (Bet v 1 homologue) was poor and in 
no samples could the profilin allergen Ara h 5 be detected.  
Table 7. Detection of allergen sequence isoforms by MS and % of total protein sequence detected (%).  
ND = not detected. 
Allergen UniProt Accession 
(peptide sequence) 
Protein coverage (%) 
  Dust P77 Dust Y175 Dust Y231 
Cupin barrel family     
Ara h 1 P43238  10.2 60.5 35.9 
 P43237 10.3 65.3 36.8 
 E5G076 ND 49.6 28.4 
 Q6PSU3 10.9 ND 39.0 
 Q6PSU4 ND ND ND 
 Q6PSU5 ND 63.9 ND 
 Q6PSU6 ND ND ND 
Ara h 3 O82580 17.0 55.2 30.0 
 Q5I6T2 19.4 66.5 41.2 
 B5TYU1 17.7 65.5 36.4 
 Q9FZ11 16.3 62.8 46.3 
 Q647H4 19.4 72.6 49.8 
 Q647H3 20.3 66.1 48.4 
 Q8LKN1 ND ND ND 
 Q6T2T4 19.4 ND 49.8 
 Q9SQH7 17.4 46.0 37.4 
 Q0GM57 7.8 54.5 ND 
 E5G077 7.8 ND 24.8 
 Q647H2 ND 21.3 ND 
 A1DZF0 17.4 67.3 39.9 
 Q6IQG5 ND ND ND 
Prolamin family     
Ara h 2 Q6PSU2 8.1 57.0 40.1 
 Q6PSU2-2 ND ND ND 
 Q6PSU2-3 ND ND ND 
 Q6PSU2-4 ND ND ND 
Ara h 6 Q647G9  ND 64.1 37.9 
 A1DZE9 ND 37.9 ND 
Ara h 7 Q9SQH1    




 B4XID4 ND 37.2 15.2 
Ara h 9 B6CEX8 ND ND ND 
 B6CG41 ND 76.1 ND 
Bet v 1 family     
Ara h 8 Q6VT83 ND ND ND 
 B2ZGS2 ND ND ND 
 B1PYZ4 ND ND ND 
 Q0PKR4 ND ND ND 
 Q2YHR1 ND ND ND 
 B0YIU5 ND 16.3 ND 
Oleosin family     
Arah10,11 Q647G5 5.3 21.9 ND 
 Q647G4 ND ND ND 
 Q9AXI0 ND 14.2 ND 
 Q9AXI1 ND 14.2 ND 
 Q6J1J8 ND 14.2 ND 
Profilin family     
Ara h 5 Q9SQI9 ND ND ND 
 D3K177 ND ND ND 











7.7 Publication 3: FLG loss-of-function mutation increase the impact of EPE on PS 
and PA  
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7.8 Publication 4: Eczema increases the impact of EPE on PS and likely PA 
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7.9 BAMSE study results 
7.9.1 Demographics and clinical characteristics 
Demographic and clinical characteristics included are described in Table 8.  Median peanut protein [IQR] in 
dust was 4.07µg/gram [1.58, 11.86]. Peanut sIgE sensitization was 6.6% at 4 years (n=103/1572) and 8.6% 
at 8 years (n=161/1876). Peanut CRD sensitization (Ara h 1,2 or 3≥0.35kU/L) at 8 years was 4.1% 
(n=75/1854), of which 74/75 (99%) had Ara h 2 ≥0.35kU/L. 
Table 8: Demographics of BAMSE cohort with dust and FLG genotyping 
 





Peanut sIgE ≥ 0.35kU/L at 4 years  103 1572 6.55% 
Peanut sIgE ≥ 0.35kU/L at 8 years  161 1876 8.58% 
Ara h 1, 2 or 3 ≥0.35kU/L at 8 years vs.  
Ara h 1, 2 or 3 <0.35kU/L or peanut sIgE <0.35kU/L  
(excluding peanut sIgE ≥0.35kU/L with no components) 
75 1854 4.05% 
Avoiding peanut because of previous adverse reaction 73 1878 3.89% 
History of infantile atopic eczema 313 1840 17.01% 
At least one FLG mutation (R501X, 2282del or R2447x) 134 1878 7.14% 
Allergic rhinitis (ISAAC definition) (age 4 years) 215 1828 11.76% 
Allergic rhinitis (ISAAC definition) (age 8 years) 288 1865 15.44% 
Egg sIgE≥ 0.35IU/ml at 4 years of age 82 1575 5.21% 
Male sex  973 1871 52.00% 
Caucasian ethnicity 1677 1842 91.04% 
Biological siblings 1695 1870 90.64% 
Parental atopy – (asthma/AR/AD) 838 1858 45.10% 
Maternal age (mean, SD) 30.9 (SD4.49) 1871 N/A 
Peanut protein in maternal bed-dust (µg/g): median [IQR] 4.07 [1.58-11.86] 1878 N/A 
Exclusive breastfeeding duration (months): mean (SD) 5.19 (2.43) 1838 N/A 





7.9.2 Nested case control analysis for peanut sIgE and CRD sensitization  
Peanut sensitized children were compared against children without PS matched for sex and parental atopy as 
described in the statistical methods; EPE was a risk factor for both peanut sIgE sensitization at 4 years and 
peanut CRD sensitization at 8 years with a 23% and 29% increased risk of PS per natural log (ln) unit 
increase in EPE respectively (Table 9). In children who were peanut sIgE sensitized but not peanut CRD 
sensitized, there was only a trend towards an association between EPE and PS (OR=1.20, 95% CI: 0.97-
1.48, P=0.09). Differential relationship between EPE and primary peanut CRD sensitization (Ara h 1,2 or 3 
≥0.35kU/L) and non-clinically significant PS (peanut sIgE ≥0.35kU/L but negative results for Ara h 1,2 or 
3<0.35kU/L) is displayed in Figure 24.  
 
Figure 24: Mean predictive probability of peanut CRD sensitization versus non-clinically significant PS as a 
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Table 9: Univariate conditional LR incorporating matching for peanut sensitized cases versus non-sensitized controls.  
Peanut sIgE sensitization (≥0.35kU/L) at age 4 years and peanut CRD sensitization (Ara h 1, 2 or 3 ≥0.35kU/L) at age 8 years. 
  
Peanut sIgE sensitized at age 4 years 
(n=411) 
Peanut CRD sensitized at age 8 years 
(n=195) 
OR 95% CI P-value OR 95% CI P-value 
EPE (µg/gram ln transformed) 1.23 1.06-1.43 <.01 1.29 1.04-1.61 .02 
No. of biological siblings  1.38 0.63-3.03 .42 2.50 0.77-8.16 .13 
≥1 FLG loss-of-function mutation 
(excluding non-Caucasians) 
2.67 1.18-6.04 .02 3.00 0.84-10.75 .09 
History of infantile eczema 7.35 4.20-12.83 <.001 6.39 2.95-13.83 <.001 
Egg sIgE sensitization: 4 years 18.91 7.50-47.66 <.001 12.85 3.78-43.67 <.001 
Allergic rhinitis: 4 years (ISAAC) 3.44 1.90-6.23 <.001 2.53 1.04-6.18 .04 
Allergic rhinitis: 8 years (ISAAC) 11.44 5.68-23.07 <.001 12.97 4.54-37.05 <.001 
Exclusively breastfed (months) 0.95 0.88-1.03 .22 0.98 0.87-1.11 .77 
Breastfed (excl/partial) (months) 0.99 0.93-1.05 .74 1.01 0.93-1.11 .76 






Median peanut protein in dust was higher in peanut sIgE sensitized children (3.39 µg/g, IQR 1.41-11.01, 
n=137) than non-peanut IgE sensitized controls (2.28µg/g, IQR 0.88-5.14, n=274) (P<.01); and higher in 
peanut CRD sensitized children (4.64µg/g, IQR 1.58-12.77, n=65) than non-peanut CRD sensitized controls 
(2.24µg/g, IQR 0.88-4.74, n=130) (P<.01). 
 
On multivariate conditional LR analysis, EPE was significantly associated with peanut sIgE and peanut 
CRD sensitization with a 1.41- and 2.1-fold increased risk per unit increase EPE respectively (Table 10). 
Infantile eczema and egg sensitization were both significantly associated with peanut sIgE and CRD 
sensitization.  FLG loss-of-function mutations increased the risk of peanut sIgE sensitization 3.78-fold and 
peanut CRD sensitization 7.33-fold. Allergic rhinitis at age 4 and 8 years was associated with both peanut 
sIgE at age 4 years and peanut CRD sensitization at age 8 years in the multivariate analysis. The number of 
biological siblings, duration of exclusive and total breastfeeding and maternal age at baseline were not risk 
factors for PS. There was no significant interaction between EPE and infantile eczema or egg sensitization 
on peanut CRD sensitization, and only a slight trend for an interaction with FLG loss-of-function mutations 





Table 10: Multivariate conditional LR incorporating matching for peanut sensitized cases versus non-
sensitized controls.  
Peanut sIgE sensitization (≥0.35kU/L) at age 4 years and peanut CRD sensitization (Ara h 1, 2 or 3 
≥0.35kU/L) at age 8 years. Non-Caucasians were excluded due to inclusion of FLG mutations as a covariate.  
  




Peanut CRD sensitized at age 8 
years (excluding non-Caucasians) 
(n=143) 
*AIC: 49.19 
OR 95% CI P-value OR 95% CI P-value 
EPE (µg/gram ln transformed) 1.41 1.05-1.90 .02 2.11 1.38-3.22 .001 
≥1 FLG loss-of-function mutation 3.78 0.93-15.36 .06 7.33 1.21-44.21 .03 
History of infantile eczema 2.53 0.98-6.51 .05 3.93 1.03-15.00 .05 
Egg sIgE sensitization: 4 years 28.00 5.24-149.39 <.001 39.9 1.47-1081.68 .03 
Allergic rhinitis: 8 years (ISAAC) 12.57 4.164-37.98 <.001 28.93 3.77-221.61  <.001 
*Smaller AIC is better 
 
7.9.3 Whole cohort analysis for peanut sIgE and CRD sensitization  
On univariate (Table 11) and multivariate analysis (Table 12, p235) infantile eczema, egg sensitization, FLG 
loss-of-function mutation (trend for CRD) and allergic rhinitis at age 8 years were associated with peanut 
sIgE and CRD sensitization; however, EPE was no longer associated with PS. There was no interaction 
between EPE and FLG mutations, infantile eczema, egg sensitization or parental atopy on PS. On subgroup 
analysis peanut CRD sensitized children were compared against children who were sensitized to egg 





Table 11: Factors associated with peanut sIgE sensitization at age 4 and 8 years and peanut CRD 
sensitization at age 8 years. 
  
Univariate GEE for peanut 
sIgE sensitization   
at 4 and 8 years 
Univariate peanut CRD 
sensitization at age 8 years  
OR 95% CI 
P-value OR 95% CI P-value 
EPE (µg/gram ln transformed) 0.95 0.86-1.06 .39 1.01 0.86-1.19 .89 
Sex 1.14 0.83-1.56 .43 1.41 0.88-2.26 .15 
Full older siblings  1.08 0.63-1.85 .77 0.86 0.40-1.81 .68 
≥1 FLG loss-of-function mutations 
(excluding non-Caucasians) 
1.85 1.08-3.16 .03 1.76 0.82-3.77 .15 
History of infantile eczema 6.49 4.66-9.02 .001 7.94 4.91-12.83 <.001 
Egg sIgE sensitization at 4 years 13.58 8.55-21.58 <.001 11.04 6.13-19.90 <.001 
Allergic rhinitis aged 4 years (ISAAC) 2.82 1.92-4.13 <.001 2.16 1.22-3.83 <.01 
Allergic rhinitis aged 8 years (ISAAC) 8.05 5.78-11.22 <.001 5.87 3.66-9.42 <.001 
Parental atopy  
(asthma and/or hay-fever) 
1.77 1.28-2.44 <.001 1.77 1.10-2.83 .02 
Non-Caucasian ethnicity 1.58 0.97-2.57 .07 1.09 0.49-2.43 .79 
Exclusively breastfed in months 0.98 0.94-1.06 .92 0.97 0.88-1.06 .49 
Breastfed (exclusive/partial)  
in months 
0.99 0.94-1.03 .57 0.97 0.91-1.04 .43 




Table 12: Multivariate analysis of peanut sIgE sensitization aged 4 and 8 years.  
Generalised estimating equations (GEE) used to account for repeated measures within individuals at 4 and 8 
years and LR analysis for peanut CRD sensitization at age 8 years in the BAMSE cohort excluding non-
Caucasians. Goodness of fit was assessed by QIC and AIC. 
  
Multivariate peanut sIgE sensitization 
(excluding non-Caucasians) (n=1388) 
QIC:1094 




OR 95% CI P-value OR 95% CI P-value 
EPE (µg/gram ln 
transformed) 
 0.98 0.84-1.13 .75 1.08 0.88-1.32 .48 
≥1 FLG loss-of-function 
mutations 
2.37 1.22-4.60 .01 1.82 0.72-4.57 .20 
History of infantile eczema 3.81 2.44-5.94 <.001 5.51 3.03-10.03 <.001 
Egg sIgE sensitization at 4 
years 
8.12 4.35-15.15 <.001 6.61 3.16-13.80 <.001 
Allergic rhinitis aged 8 
years (ISAAC) 
5.57 3.57-8.71 <.001 3.05 1.65-5.63 <.001 
 
EPE was a risk factor for peanut CRD sensitization on both univariate (OR=1.33 95% CI: 1.01-1.74, P<.05, 
n=134) (Table 13) and multivariate analysis (OR=1.56, 95% CI: 1.14-2.12, P<.01, n=132, AIC: 331) 
adjusting for allergic rhinitis at age 8 years and infantile eczema. Peanut levels in household dust were also 
significantly higher in peanut CRD sensitized children (n=75, median 4.79µg/g, IQR 1.63-12.00) versus egg 
sensitized, non-peanut CRD sensitized children (n=59, median 2.35µg/g, IQR 1.23-6.15) (P=.03). The 
impact of EPE on PS was compared against other high-risk groups of children who did not become peanut 





Table 13: Univariate LR analysis of factors associated with peanut CRD sensitization versus non peanut 
CRD sensitization in children with preceding egg sensitization. 
  
Peanut CRD sensitization at aged 8 years compared against 
children who are not peanut CRD sensitized patient at aged 8 
years but who were sensitized to egg at 4 years (n=134) 
OR 95% CI P-value 
EPE (µg/gram ln transformed) 1.33 1.01-1.74 <0.05 
Sex 1.90 0.95-3.80 0.07 
Full older siblings  0.61 0.17-2.13 0.44 
≥1 FLG loss-of-function mutations  
1.09 0.33-3.56 0.89 
(excluding non-Caucasians) 
History of infantile eczema 2.51 1.24-5.08 0.01 
Allergic rhinitis aged 4 years (ISAAC) 0.87 0.38-1.96 0.73 
Allergic rhinitis aged 8 years (ISAAC) 2.65 1.26-5.56 0.01 
Parental atopy (asthma and /or hay-fever) 1.34 0.67-2.65 0.41 
Non-Caucasian ethnicity 2.55 0.93-6.98 0.07 
Exclusively breastfed in months 0.89 0.77-1.04 0.14 
Breastfed (exclusive/partial) in months 0.99 0.89-1.09 0.76 















7.10 Publication 5: IL9 is a key component of memory Th cell peanut-specific responses from 
peanut allergic children 
Brough H.A., Cousins D.J., Muntaenu A., Wong Y.F., Sudra A, Makinson K., Stephens 
A.C., Arno M., Ciortuz L., Lack G., Turacnu V.  IL9 is a key component of memory Th cell 
peanut-specific responses from peanut allergic children. J Allergy Clin Immunol. 
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Chapter 8 Discussion 
8.1 Summary of principal findings 
This is the first study to assess the impact of EPE, measured in household dust, on the development of PS 
and PA. The findings from this PhD showed that peanut proteins are present in household dust and are 
widespread throughout the home (publication 1) and that HPC is the single most important factor which is 
associated with peanut levels in dust in an infant’s bed-dust and play-area (publication 2); this is of 
significant importance as HPC has been shown to increase the risk of PA, particularly when compared 
against high-risk infants with eczema and/or egg allergy.
(104)
 Whole amino acid sequences of major peanut 
allergens were identified in dust using the highly specific MS assay, thus confirming the findings of peanut 
allergen in dust from the Veratox peanut ELISA employed to quantify this exposure.  In-vitro work using 
BAT demonstrated a dose response of CD63+ upregulation from basophils of peanut allergic patients mixed 
with serial dilutions of peanut dust extracts (publication 2), providing biological plausibility that peanut 
protein in dust is able to cause allergen-specific activation and thus has the capability to induce PS. Peanut 
in the environment is more likely to sensitize through the skin than the respiratory tract, as peanut does not 
easily aerosolise. This was shown in a number of experiments using a personal Air Monitor sampling 
device; in particular there were undetectable levels of airborne peanut over 22 hours in homes with high 
levels of peanut protein in dust.  
 
Following work to establish the characteristics of peanut protein in dust, I subsequently employed 
international cohort studies to determine the impact of peanut antigen in dust in early life on clinically 
relevant outcomes of PS and PA. Early environmental exposure to peanut in household dust significantly 
increased the risk of PS and PA in longitudinal studies in children with an impaired skin barrier (defined by 
carriage of a FLG loss-of –function mutation) (MAAS: publication 3) or when compared against egg 
sensitized children (BAMSE study). In a high-risk study (CoFAR: publication 4) where infants were 




cow’s milk, EPE was a risk factor for PS and likely PA. The effect of EPE on PS was augmented further in 
children with a history of infantile eczema and even further in infants with a history of severe eczema. These 
results, taken together suggest that the route of PS may be via the presentation of peanut antigen via an 
inflamed disrupted skin to antigen presenting cells; this in turn could lead to a Th2 skewing of naïve Th cells 
in the skin-draining LNs and subsequent development of a peanut allergic response.  
 
In order to further evaluate the hypothesis that PS occurs through the skin, I anticipated that recall responses 
to peanut in Th cells from peanut allergic children would be predominantly derived from the skin (rather 
than the gut which is predominantly a tolerising organ) and would be Th2 skewed. I used Th cells from NA 
children as controls and anticipated showing that recall Th responses to peanut in these children were 
predominantly derived from the gut (rather than the skin) and would be Th1 skewed or of a Treg phenotype. 
I therefore recruited peanut allergic and NA children and cultured their PBMCs in peanut then sorted their 
PBMCs according to their memory Th cell phenotype, activation status and homing markers (skin: CLA+ 
versus gut: β7+) (publication 5). Differential gene expression between children with PA or NA children was 
assessed in an explorative gene microarray then confirmed by RT-qPCR. I then compared gene expression 
in Th cells from peanut allergic children against gene expression in Th cells from peanut sensitized children 
to assess whether similar results were obtained. There were no differences in CLA+ versus β7+Th cells from 
peanut allergic children in terms of Th cell counts or Th2/Th1 or Treg cytokine gene expression. This is in 
contrast to previous research findings which showed higher Th cells proliferative recall responses to peanut 
antigen in CLA+ versus β7 + Th cells from peanut allergic children and Th2 cytokine predominance in 
CLA+ memory Th cells cultured in peanut antigen from peanut allergic children.
(203)
  Possible reasons for 
this discrepancy are discussed in Section 8.11.6. 
 
Using microarray and confirmatory RT-qPCR gene expression analyses I demonstrated that the IL9 gene 
(encoding IL9 which is a mast cell activation and proliferation IL) was the most highly differentially 




individuals (publication 5). IL9 production was also confirmed on a protein level using ICCS in Th cell 
recall responses to peanut from PA versus PS children. IL9 was produced by different Th cells to those cells 
producing IL5 which suggests that IL9 producing cells are not Th2 cells but may be produced by the 
recently described Th9 cell. Although further studies are required to understand the role of IL9 in PA, the 
findings from this PhD suggest that IL9 may provide a useful biomarker for clinically relevant PA (rather 
than PS). 
 
8.2 Overview of discussion of results 
The primary hypothesis of this PhD was that early EPE, measured by peanut protein levels in household 
dust, is a risk factor for the development of PS and PA in children with an impaired skin barrier.  The 
epicutaneous route of PS was then further investigated using in-vitro memory responses from skin versus 
gut derived Th cells in PA, PS and NA children to elucidate where PS may have originated. The work 
assessing EPE characteristic and its association with PS and PA is epidemiological in nature whereas the in-
vitro section is mechanistic; I will therefore separate out these two sections in the discussion for the purpose 
of reviewing the relevant findings, limitations and future research.   
 
8.3 Relationship between peanut consumption and peanut protein levels in dust 
8.3.1 HPC and infant EPE 
The premise of this PhD arose due to the findings from the study by Fox et al. (2009) where they showed 
that HPC during the child’s first year of life was a risk factor for PA, especially when compared against 
atopic controls.
(104)
 The study by Fox et al. (2009) was criticized by the reviewers because an objective 
measure of EPE had not been used. This led to my establishing the methodology to quantify peanut protein 
in dust, and in this PhD I showed HPC was highly correlated with peanut-dust levels in an infant’s home 




multivariate LR analysis. The findings from this PhD therefore provide further support for the findings by 
Fox et al (2009), that HPC during infancy may be a risk factor for PA in the child via EPE. 
 
8.3.2 HPC of hand-held peanut-containing foods and EPE 
Fox et al. (2009) hypothesized that EPE was more likely to lead to PA was through hand transmission from 
members of the family eating peanut then placing their peanut contaminated hands onto both the child and 
the environment that the child inhabits. They based this hypothesis on their finding that high household 
consumption of peanut butter (which is sticky and easily transferred by hands) was associated with a higher 
risk of developing PA than household consumption of covered peanuts (e.g. chocolate covered peanut food). 
In publication 1, I demonstrated that peanut persisted on hands after consumption of whole peanuts for at 
least three hours which gives plenty of time to contaminate the infants’ skin and/or various areas in the 
home. In order to corroborate whether certain hand-held types of peanut-containing foods were more closely 
related to peanut-dust levels in the infants’ environment, I assessed whether peanut protein levels in the 
infant’s bed and play-area were more closely linked to household consumption of peanut butter and ‘hand-
held’ peanut-foods (whole peanuts) than all types of HPC (Table 14).  
 
Table 14: Spearman rank (rs) correlations between HPC and peanut levels in dust 
 Peanut protein in infant bed-
sheet (µg/g)  
Peanut protein in infant play-
area (µg/g) 
All types of HPC over 6 
months 
rs=0.71                             
95% CI: 0.51-0.84      
P<0.001, n=38 
rs =0.72                             
95% CI: 0.52-0.84      
P<0.001, n=38 
Household peanut butter and 
whole peanut consumption 
over 6 months 
rs =0.72                             
95% CI: 0.52-0.85      
P<0.001, n=38 
rs =0.77                             






The correlation between peanut-dust levels in the infant’s bed and play-area and household consumption of 
‘hand-held’ peanuts (including peanut butter and whole peanuts) was marginally stronger than the 
correlation with all forms of HPC, but this did not reach statistical significance (Fisher r-to-z  transformation 
P>0.05). However, with an increased sample size, this might have reached statistical significance.  
 
8.3.3 EPE distribution and relation to individual peanut consumption 
The highest correlation between peanut protein levels in the home was between the mother and father’s bed-
sheet (rs=0.864, P<0.001); these dust samples were usually obtained from opposite sides of the parental bed 
and I have shown previously that there is cross-transference between both sides of the parental bed.
(312)
 This 
high correlation was followed closely by peanut protein levels in the infant bed-sheet and play-area 
(rs=0.862, P<0.001), which were usually in different areas of the home (child’s bedroom and living-room 
respectively). This suggests that the baby, the baby’s clothes or the person carrying the baby was 
transferring peanut to these locations. There was a higher association between peanut levels in the infant 
bed-dust and the maternal bed-dust rather than paternal bed-dust; this is probably because infants often slept 
in the maternal bed. Paternal peanut consumption was more highly associated with peanut levels in the 
infants’ bed and play-area than maternal peanut consumption, which is likely due to the finding that fathers 
tended to have higher peanut consumption than mothers.   
 
8.4 EPE: which route is likely to lead to PS? 
Routes of exposure to food antigens appear to be crucial in determining whether food allergy or tolerance 
develops. Peanut containing dust is bound to be in contact with the child’s skin in their bed or play-area 
(which is where infants spend most of their time) but could also be inhaled or consumed by the infant. 
Inhalation and epicutaneous exposure have been shown to lead to allergic sensitization in mice (usually only 
with co-administration of an adjuvant or active skin barrier disruption), whereas high dose oral exposure 




CT with concomitant oral food antigen exposure usually leads to allergic sensitization regardless of the dose 
administered, which may be due to barrier impairment in the gastrointestinal tract by CT.  
 
8.4.1 EPE leading to PS via the skin 
The hypothesis that EPE results in PS through the skin is supported by the increased susceptibility that 
children with FLG loss-of-function mutations had to EPE, and by the exposure-response observed in 
children with a history of eczema and severe eczema, as discussed in Section 8.7. Not all children with 
peanut allergy have a history of overt eczema; these children may have had dry skin and an impaired skin 
barrier even though they did not have overt eczema; in combination with EPE this could have been the route 
through which transcutaneous peanut sensitization occurred. Alternatively children could have had a 
transient abrasion of the skin allowing peanut to enter the epidermis. Finally, an impaired gut barrier, 
following, for example rotavirus gastroenteritis might also be an alternative route of sensitization. 
 
Filaggrin is predominantly expressed in the skin, and FLG loss-of-function mutations lead to an impaired 
skin barrier (as described in Section 4.1). However, filaggrin is also expressed in other parts of the body, 
such as the upper respiratory tract and upper gastrointestinal tract which has important ramifications for the 
potential mechanism of PS. The available literature on the expression of filaggrin (either as mRNA and/or 
histological staining of the protein) in various parts of the human body is summarized in Table 15. Although 
filaggrin is not expressed in the lung, the presence of FLG loss-of-function mutations modifies the risk of 
smoking on the development of asthma, which may be through the impact of FLG loss-of-function mutation 
in the nasal mucosa. 
(398)  
In summary, on the basis of these findings, although mutations in the gene that 
codes for filaggrin could potentially predispose to barrier impairment in the upper respiratory and 
gastrointestinal tract, FLG loss-of-function mutations are far more likely to affect the skin where filaggrin 











Epidermis of skin  
(Presland et al. 2000, Sandilands et al. 2009, Wu et al. 2009)
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Proximal, mid and distal esophageal mucosa  















Small intestine and colon  







Cornified epithelium of the nasal vestibulum  







Epithelium covering inferior nasal turbinate  







Respiratory and bronchial mucosa  







*N/A: not available. If protein detected then need for mRNA obviated  
There is observational data in humans which supports the concept of epicutaneous sensitization: in the 
ALSPAC study children with eczema who had Arachis oil applied onto their skin within the first 6 months 
of life were 6.8 times more likely to develop PA. Another important argument which supports the concept of 




the skin (eczema presence, severity and duration) and PS. 
(9)
 For ethical reasons it would not be possible to 
demonstrate unequivocally that cutaneous exposure to peanut in children with an impaired skin barrier leads 
to PS and PA; this would require tape stripping of the skin in infants without eczema followed by topical 
application of peanut (or peanut containing dust) or application of peanut (or peanut containing dust) onto 
eczematous skin followed by analysis of the immune response and follow-up of these children with peanut 
OFCs.  
 
8.4.2 EPE leading to PS via the gastrointestinal tract 
During the oral mouthing phase of development between 4-8 months one could argue that the infant is likely 
to ingest some of peanut in the dust in its environment. In mouse models, low dose oral exposure to peanut 
was shown to lead to PS and PA (see Section 2.5). One argument against small levels of peanut exposure 
predisposing to allergic PS was shown in the ALSPAC study by Lack et al.(2003) where infants that 
breastfed after maternal application of nipple cream containing Arachis oil did not have an increased risk of 
PA. 
(49)
 This may, however, also be because Arachis oil was presented in combination with breast milk 





8.4.3 EPE leading to PS via the respiratory tract 
The possibility that sensitization occurs in the respiratory tract via inhalation of peanut containing-dust 
cannot be excluded; however, an argument against inhalation being the route of exposure is that peanut was 
very difficult to aerosolise.  Peanut protein levels were below the LLQ in a variety of experiments using a 
personal Air Monitor running at 2L/min (equivalent to an infant’s minute respiration) only 1cm away from 
peanut-rich foods (peanut butter, satay sauce, whole peanuts) and in homes with high levels of peanut in 
vacuumed dust. Even when peanut was forced into the air by breaking peanut shells directly underneath the 
Air Monitor sampling head, there was only a transient surge in airborne peanut detected, which disappeared 




Previous studies have found that the allergen concentration from vacuumed dust correlates poorly with 
airborne allergen concentration; 
(399-401)
 this is due to the size and shape of the allergen which affects its 
aerosolizeability when disturbed in the environment and how long it remains airborne. For example, HDM 
allergen (Der p 1 and 2) and cockroach allergen (Bla g 1) are mainly associated with particles >10 µm in 
diameter; 
(402-404)
 this means that even after becoming airborne most HDM allergen falls back onto the 
ground due to gravity. After 15 minutes only 10-20% of HDM allergen remains airborne and several hours 
later <0.1% remains airborne. 
(405;406)
 Similarly, cockroach allergen is only detectable for up to 30 minutes 
after vigorous dust disturbance. 
(404)
 In contrast, more than 20% of cat and dog allergens are less than 5 µm 
in diameter and these can be measured in the air for days after disturbance of dust in the environment. 
(407)
 
The nature and size of the inhaled particle as well as the way that it is deposited and cleared from the airway 
are important determining factors for disease pathogenesis. 
(408)
 Particle sizes above 30 µm are non-
respirable as they are trapped by the nasal hairs and upper respiratory tract mucous. Particles between 4-10 
µm usually reach the trachea, primary and secondary bronchioles, particles up to 4 µm reach the terminal 




In order to determine the particle size of peanut in dust one could determine in which fraction of the dust the 
peanut resides. In the online repository of Publication (see Section 7.4.1, Fig E3), I showed that there were 
similar peanut protein concentrations in the larger structures of vacuumed dust samples (e.g. hair and bed-
cotton) as compared to fine dust; this could be explained by peanut being transferred via hands onto the bed-
linen or onto hair. Within the fine dust post sieving (less than 300 microns in diameter), I would expect 
peanut to be found in larger particle sizes (>10 µm) given its lack of sustained aerosolizeability. One 
problem with separating out particle sizes in dust is humidity: if there is humidity in dust (especially if the 
dust sample has been frozen and then thawed) then dust particles could stick together and be more difficult 
to separate. One way to reduce the humidity would be to heat the dust samples prior to particle separation; 
however, use of such a technique could result in changes to the peanut protein structure. As PS could also 




peanut protein captured by personal nasal filter devices in a bed with known high levels of peanut in dust. 
Personal nasal filter devices measure inhaled allergens with a particle sizes of 5 µm, 
(410)
 and have been used 
to measure allergen exposure and the efficacy of protective masks. 
(411)
   
 
8.4.4 Is peanut in dust responsible for PS or just a marker of cutaneous exposure? 
Environmental peanut levels in dust reflect only a proxy marker of the actual amount of peanut that the 
infant is exposed to in their environment. This would be extremely difficult to quantify. Additionally, the 
question remains whether peanut contained in dust could induce PS or whether is it simply a marker of 
cutaneous exposure to peanut through household hand to infant body contact, given that peanut persists on 
hands 3 hours after peanut consumption.
(360)
 Another mechanism of transfer of peanut consumed by other 
household members onto the skin of the infant and PS is through kissing, given that peanut remains 
detectable in saliva for at least 3 hours after peanut consumption as shown in Publication 1.   
 
8.5 Peanut protein levels in household dust using ELISA, MS and BAT 
This PhD confirmed that peanut protein can be measured in dust through a variety of approaches (ELISA, 
MS and BAT). Each of these analytical methods provided different information about the peanut antigen 
found in dust but also had certain limitations.  
 
8.5.1 ELISA 
The main advantage of the Veratox polyclonal whole peanut ELISA was that it was able to quantify the 
concentration of peanut protein in dust using a relatively simple and quick procedure. However, the Veratox 
peanut ELISA had the following drawbacks:  
1) The LLQ of the Veratox peanut ELISA was 100ng/ml which is satisfactory for an ELISA; however, 
this resulted in a truncated EPE variable in MAAS when a fixed LLQ/2 calculation was assigned to 




in MAAS were performed, using all peanut-dust values obtained below the LLQ and using the 
LLQ/2 calculation. Using these two different peanut dust variables did not make a material 
difference to the results obtained, thus it is less likely that this introduced error or bias. 
 
2) The results obtained by the Veratox peanut ELISA did not reveal which peanut (Ara h) allergens in 
dust were present or most prevalent as both capture and detection antibodies in the Veratox ELISA 
are directed against whole peanut protein (see Section 6.4).  
 
 
3) Although the Veratox peanut ELISA demonstrated that peanut protein in dust bound to the ELISA 
capture and detection anti-peanut antibodies, thus showing allergen specific binding, this did not 
show that peanut in dust could interact with the immune system of a peanut allergic individual.  
 
8.5.2 Mass Spectrometry 
MS superseded ELISA analysis in its ability to identify major peanut allergen sequences in dust. The 
University of Manchester demonstrated the presence of peptides corresponding to the major peanut allergens 
Ara h 1, 2, 3, 6 and 9, with protein coverage of up to 65.3% for Ara h 1, 57% for Ara h 2, 64.1% for Ara h 3 
and 76% for Ara h 9 in an infant play-area (see Section 7.6). MS is highly specific, as peptide sequences are 
determined from amino-acid sequences within a peptide. Therefore, the MS findings supported the potential 
for peanut protein in dust to lead to sensitization to major peanut allergens which is more likely to lead to 
PA. Drawbacks of MS were the labour intensive sample preparation and clean-up, in particular to remove 
keratins from dust samples that interfered with MS. Given the laborious preparation required for each dust 
sample it would not have been feasible to analyse thousands of dust samples from the homes of different 
participants as was performed in this PhD.  Additionally MS did not quantify peanut protein concentration in 
dust (although work is ongoing to try to achieve this) and did not provide evidence that peanut allergens in 






This brings me to the final assay, BAT: the LLQ of the BAT for dust extracts was 1ng/ml peanut protein 
which was 100 times lower than the LLQ for the Veratox peanut ELISA. Additionally BAT demonstrated 
that peanut protein in household dust induced a dose-dependent activation of basophils from children with 
PA but not in NA children, thus confirming a peanut-specific basophil response. This provides biological 
plausibility for the ability of environmental peanut levels in dust to interact with immune cells in young 
children and sensitize the individual to peanut. Drawbacks of BAT were also laborious sample preparation 
time and that BAT did not quantify peanut protein concentration.  
 
In summary the various methods employed as part of this PhD confirmed the presence of major peanut 
allergen in dust able to stimulate effector cells of children with PA. In future experiments it would be useful 
to explore how peanut in dust interacts with Th cells and APC as this would be most relevant in terms of the 
ability of peanut in dust to cause PS. This could be performed by mixing serial dilutions of peanut-
containing dust extracts with the PBMCs of peanut allergic individuals versus NA individuals to determine 
Th cell activation, interaction between APC and Th cells and Th cell cytokine secretion. 
 
8.6 Factors associated with PS and PA 
8.6.1 Overview 
The relationship between PS and PA and EPE, infantile eczema, FLG loss-of-function mutations and egg 
sensitization for all three cohorts are displayed in Figure 25 and Figure 26 (p271). In both population based 
studies (MAAS and BAMSE), EPE was not a risk factor for PS or PA in the whole population, whereas in 
the high-risk CoFAR study, EPE was associated with both PS and likely PA (trend on univariate, significant 
on multivariate analysis). The most likely reason for the discrepancy in the effect of EPE in the population 
versus high-risk cohort is due to atopy and/or skin barrier impairment modifying the individual’s response to 
EPE in the high-risk cohort. Both infantile eczema and FLG loss-of filaggrin mutations were associated with 




8.6.3); however, they were not associated with PS or PA in CoFAR. The lack of association between FLG 
loss-of-function mutations and PS in CoFAR is probably because children with known PA were excluded 
from inclusion into the CoFAR study; thus the FLG mutation rate was very low (14.7%) for this highly 
atopic cohort. The lack of association between infantile eczema and PS in CoFAR is probably because 
moderate to severe eczema was one of the inclusion criteria for the study thus 92.5% of children had 
infantile eczema.  
 
Figure 25: Forest plot of main factors associated with PS on univariate LR analysis. 
MAAS: Peanut SPT sensitization at 8 and 11 years, CoFAR: Peanut SPT sensitization at 3-15 months, 
BAMSE: peanut sIgE sensitization at age 4 and 8 years. EPE: OR per unit increase in EPE. Egg 








































Figure 26: Forest plot of main factors associated with PA on univariate LR analysis. 
MAAS: Challenge proven PA at 8 or 11 years, CoFAR: Likely PA (sIgE≥5kU/L) from 3-15 months. EPE: 
OR per unit increase in EPE. Egg sensitization: Yes vs. No 
 
 
8.6.2 EPE levels in different cohorts 
Although the most likely cause for the discrepancy in the impact of EPE on PS and PA between the 
population based studies (MAAS and BAMSE) and high-risk studies (CoFAR) is the different atopic status 
of these population, it should also be noted that peanut-dust levels in the three cohorts were significantly 
different (Mann-Whitney U P<0.001 for each comparison), which may have also influenced the relationship 
between EPE and PS/PA. Different EPE levels (median [IQR]) between cohorts are shown in Table 16 and 
































Table 16: Level of peanut protein in dust (µg/g) in three cohort studies. 
 
  
Peanut protein in living 
room dust  
 
Peanut protein in 
maternal mattress 
 
Peanut protein in infant 
bed-dust 
 
MAAS (including values 
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n/a (not analysed) 
 
Figure 27: Comparison of peanut protein in dust (µg/g) in three cohort studies. 








Participants in the CoFAR (USA) study had the highest levels of peanut in household dust followed by 
participants in the BAMSE (Sweden) study, then MAAS (UK). It is known that peanut butter is widely 
consumed in US households; furthermore, 373 out of 421 (86%)  families of children recruited to the 
CoFAR observational study had peanut-containing food in the home during breastfeeding. 
(98)
 This is the 
most likely explanation for the higher levels of peanut protein in dust found in US homes. The difference 
between peanut levels in dust in BAMSE versus MAAS could be explained by differences in peanut 
consumption levels in Stockholm versus Manchester respectively; however, no information on HPC was 
available in these two studies. The difference in peanut levels in dust between these two cohorts could also 
potentially be explained by different locations of dust samples in these two studies (sofa in MAAS and 
maternal mattress in BAMSE) as the mattress might provide a larger reservoir of peanut. However, in 
Publication 1 I showed that there was high within-home distribution of peanut protein in dust, thus one 
would expect that if peanut levels are high in the maternal mattress they would also be high in the sofa.  
 
Finally, the difference between MAAS and BAMSE peanut levels in dust could be explained by the fact that 
I was sent peanut dust extracts (liquid extract with dry ice to prevent thawing) from MAAS whereas I was 
sent dust samples from BAMSE. Peanut protein in extracted dust may be less likely to remain stable over 
prolonged period of time (these dust samples were collected between1996-1997), than in dust itself.  
 
8.6.3 Infantile eczema and FLG loss-of-function mutations as risk factors for PS / PA 
In both population based cohorts included in this PhD (MAAS and BAMSE), infantile eczema was a risk 
factor for PS and PA (where available), over and above the effect of FLG loss-of-function mutations. 
Infantile eczema has been shown to be a stronger risk factor for PS and PA than FLG loss-of-function 
mutations in other studies. In three month old infants enrolled to the EAT (Enquiring About Tolerance) 
population based study (www.eatstudy.co.uk), infantile eczema increased the risk of PS 4-fold after 
adjusting for FLG loss-of-function mutation and sex. 
(412)
 FLG loss-of-function mutations did not increase 




a 2.2-fold increase in risk of food sensitization (cow’s milk, egg or peanut SPT ≥1mm) after adjusting for 
FLG loss-of-function mutations, infantile eczema and sex. 
(412)
 Thus although FLG loss-of-function 
mutations were not associated with food sensitization in the EAT study, a more general measure of skin 
barrier function was associated with food sensitization at 3 months.  
 
In a recent publication from the Isle of Wight study, Venkataraman et al. (2014) found that FLG loss-of-
function mutations were likely to be associated with food allergy in later childhood  (10 and 18 years) rather 
than earlier childhood (1, 2 and 4 years). 
(285)
  The effect of FLG loss-of-function mutation on food allergy 
was mediated through eczema and food allergic sensitization in the earlier years. FLG loss-of-function 
mutation carriage was associated with early childhood eczema at 1, 2 and 4 years, early childhood eczema 
was associated with food allergic sensitization at 4, 8 and 10 years, and food allergic sensitization was 
associated with food allergy at 4, 10 and 18 years.  The authors therefore postulated that FLG loss-of-
function mutations had an indirect effect on food allergy mediated by eczema rather than a direct effect on 
food allergy. 
 
Entering infantile eczema into the multivariate LR model reduced the association between FLG loss-of-
function mutations and PS and PA (where analysis available) in MAAS and BAMSE. FLG loss-of-function 
mutations predispose an individual towards developing eczema;
(259)
 however, the inflammatory milieu of 
eczema (IL4, IL5) also down-regulates the expression of filaggrin protein in the skin.
(281)
 Thus, even without 
FLG loss-of-function mutations, eczema may reduce filaggrin expression and alter skin barrier function 
through this and other pathways (e.g. the itch scratch cycle). It is therefore difficult to tease out the 
difference in the effects of FLG loss-of-function mutations and eczema as both lead to skin barrier 
impairment and each independently lead to reduced filaggrin levels in the skin.  
 
The two landmark papers that first described the association between FLG loss-of-function mutations and 








Caucasian children with moderate to severe eczema. Studies since then have shown lower associations 
between FLG loss-of-function mutations and eczema ranging from between 14.2% (using R501X only in 
Germany) to 42% (in England) in adults and children of Northern European descent (n=15, median 22.75% 
[IQR 18.4-35.0%]).
(259)
 FLG loss-of-function mutations vary according to the number of mutations screened, 
ethnicity, disease ascertainment (population, primary or secondary care) and eczema disease severity. The 
findings of these studies suggest that around 80% of eczema is not dictated by the individual’s FLG 
genotype. There are various other epidermal proteins (Section 4.2), which also contribute to skin barrier 
function but, in essence, atopic eczema seems to be multifactorial and was a more potent risk factor for PS 
and PA than FLG loss-of-function mutation in population based cohorts.  
 
8.6.4 Egg sensitization as a risk factor for PS and PA 
In all three cohorts preceding egg sensitization was the strongest risk factor for PS and PA (see Figure 25, 
p270 and Figure 26, p271); this remained significant in the majority of multivariate analyses. Although it 
has long been known anecdotally that egg allergy is a risk factor for PA, as reviewed by Sampson (2002), 
(27)
 there had been no original data to prove this until the LEAP study screening data showed that egg 
sensitization and severe infantile eczema were the strongest determinants of PS.
(9)
 In the MAAS, CoFAR 
and BAMSE cohorts I found that the inclusion of egg sensitization in the multivariate model strengthened 
the association between EPE and PS / PA. The influence of egg sensitization in the multivariate model for 
EPE and PS/PA is not entirely surprising as Fox et al. (2009) found that the impact of HPC (used as an 
indirect marker of EPE) on the rate of PA in young children was far stronger when comparing peanut 
allergic cases against egg allergic controls as opposed to comparing peanut allergic cases against population 
controls.
(104)
 I therefore postulate that egg SPT sensitization reflects the earliest and strongest atopic 
indicator and that adjusting for this atopic marker increases the positive association between EPE and PS 
and PA. In this respect it should be noted that most common sensitization in children with eczema is egg 
(see Figure 7 (p80) and Figure 8 (p80)),
(146)







8.7 Factors that modify the relationship between EPE and PS and PA 
There were differences between the three studies with regards to the factors that modified the impact of EPE 
on PS/PA; PS was modified by FLG loss-of-function mutations in MAAS, eczema and eczema severity in the 
CoFAR study and EPE was only associated with PS in the BAMSE study when compared to the relevant 
control groups (egg sensitized children or children matched for parental atopy and sex).  Whereas one might 
have expected more homogeneity in the interactions observed in these three studies, given the important 
differences in demographics, peanut allergic outcomes measured, and atopic risk between the populations it is 
not surprising that these differences existed. In the sections below I will discuss the differences in the results 
obtained from the three cohort studies and reasons as to why this may have occurred. 
 
8.7.1 Interaction between FLG loss-of-function mutation and EPE on PS and PA 
Although there was a very impressive interaction between EPE and FLG loss-of-function mutation on PS and 
PA in MAAS this was not replicated in the CoFAR or BAMSE study. In both CoFAR and BAMSE, FLG 
mutation rates were low which may have in part resulted in the lack of association. In CoFAR the FLG 
mutations rate was 14.9% which is very low given the high rate and severity of eczema in this cohort as 
previous studies have shown that FLG loss-of-function mutations are present in up to 56% of children with 
moderate to severe eczema. 
(259;260)
 The low FLG mutation rate in CoFAR can be explained predominantly by 
the fact that children with confirmed PA prior to study enrolment were excluded from the CoFAR study. 
Given the known association between FLG loss-of-function mutations and PA, this would have excluded a lot 
of the FLG mutation carriers.
(286)
 In the BAMSE study the rate of FLG mutation was only 7.14% which is low 
in comparison with other cohorts (average 9-10%); 
(257;286)
 however, eczema rates in BAMSE were not 
particularly high (17%) in comparison to MAAS (33.7%) and CoFAR (92.5%) thus BAMSE was a relatively 
non-atopic cohort. In the CoFAR study another explanation for the lack of FLG interaction with EPE on PS 
and PA may be that, as 54% of children already had severe eczema, the skin barrier was already impaired and 
had reduced filaggrin levels secondary to eczematous inflammation thus the addition of FLG loss-of-function 




8.7.2 Interaction between a history of eczema and EPE on PS and PA 
In a similar fashion, although CoFAR found that a history of eczema augmented the impact of EPE on PS 
and likely PA, this modifying effect of eczema was not found in the MAAS or BAMSE study. These three 
cohorts evaluated the period prevalence of infantile eczema in different ways which may have led to 
different levels of eczema ascertainment. In MAAS, parental report of a history of infantile eczema was 
assessed using a modified ISAAC questionnaire to apply the UK working party’s diagnostic criteria for 
atopic eczema.  The UK working party’s diagnostic criteria is derived from the Hanifin and Rajka criteria 
for eczema,
(144;415)
 and has been validated against physician diagnosed eczema in both hospital and 
population based settings (as per MAAS). 
(144;415;416)
 Diagnostic criteria for the UK working party consist of 
an itchy skin condition in the last 12 months plus three of more of the following criteria: 1) history of 
flexural involvement, 2) onset under the age of 2 years, 3)  a personal history of other atopic disease (in 
children aged under 4 years history of atopic disease in a first degree relative may be included), 4) history of 
a generally dry skin,  and/or 5) visible flexural dermatitis as per a photographic protocol. 
  
 
In the CoFAR study, history and maximum severity of eczema was assessed and graded by a non-validated 
tool comprising (1) extent of disease (by “rule of 9”), (2) course of disease (by history), and (3) intensity of 
disease (disturbance of night's sleep by itching), each on a 3-point scale.
(417)
 The “rule of 9” is used to 
calculate the area of the body’s skin affected for SCORAD (scoring AD) assessment, where the head and 
neck amount to 9%, upper limbs 9% each, lower limb 18% each, anterior trunk 18%, back 18% and genitals 
1%.
(418)
 In the BAMSE study infantile eczema was assessed using the following set of criteria; dry skin, 
itchy rashes for ≥2 weeks and specific localisation (face or arms/legs extension surfaces or arms/legs 
flexures or wrists/ankles flexures) of rash and/or doctor’s diagnosis of eczema up to 1 year of age.(419) 
 
Studies have shown that the UK working party diagnostic criteria for atopic eczema had a high negative 
predictive value (NPV) for eczema of 97% but a low PPV of 47% when compared against a doctors’ 




incorrectly diagnoses atopic eczema where it is not present.
(144)
 PPV rises with increasing prevalence of 
disease, thus the positive pick-up and reported diagnosis of atopic eczema was likely to be higher in a high-
risk population such as CoFAR. Given that eczema was more severe in the CoFAR study, individuals with 
eczema were more likely to have been assessed by a physician and thereby be correctly diagnosed, whereas 
in the general population (particularly in the non-atopic BAMSE population), the broader spectrum of 
eczema is likely to have been missed. The interaction between EPE and eczema on PS and PA is likely to 
require the spectrum of mild to severe atopic eczema in patients, and the lack of pick-up of mild-moderate 
cases of eczema in BAMSE and MAAS  may therefore have resulted in a reduced synergistic interaction 
with EPE.  
 
Although BAMSE did not show an interaction effect between eczema or FLG loss-of-function mutations and 
EPE on PS, there was a significant impact of EPE on PS when peanut sensitized cases were compared against 
non-peanut sensitized, egg sensitized controls and when peanut sensitized cases were compared against non-
peanut-sensitized high-risk controls matched for sex and parental atopy. Thus this represents a similar picture 
of EPE having a greater impact when compared against high-risk children. The exposure-response relationship 
between EPE and PS (when compared against atopic controls) was stronger between EPE and peanut CRD 
sensitization (Ara h 1,2 or 3≥0.35kU/L) than between EPE and non-clinically relevant PS (peanut sIgE 
≥0.35kU/L but negative results for Ara h 1,2 or 3<0.35kU/L) (Figure 24, p230); this supports the concept that 
EPE increases the risk of clinically relevant PS.  
 
Fox et al.(2009) showed that HPC was more significantly associated with clinical PA when compared against 
egg allergic controls than when compared against non-atopic controls.
(104;143)
 Egg sensitization was highly 
associated with PS in BAMSE; thus it may be that egg sensitization shows a predisposition to mount allergic 
antibodies to other allergens as egg allergy is highly associated with the development of other food allergies, 
asthma and aeroallergen sensitization.
(414;420)




early onset eczema, up to 50% are sensitized to egg;
(146)
 thus egg sensitization may be a marker of eczema 
severity and thus also an indirect marker of skin barrier impairment.  
 
8.7.3 Summary and clinical implications 
In summary, although differences were present in population, study design, characteristics of the population 
and results obtained a common theme emerges; namely in children with evidence of skin barrier dysfunction 
e.g. history of infantile eczema or indirect correlates of skin barrier dysfunction e.g. FLG loss-of-function 
mutations or egg sensitization, EPE increases the risk of sensitization to peanut.  
The different effect of EPE in the three cohorts assessed highlights the importance of choice of population 
when designing an interventional study to prevent PA or indeed other food allergies. Should neonatal 
screening for FLG loss-of-function mutations be considered as a screening tool for enrolment or should 
family history of atopy or eczema be used as an assessment of risk? In the case of PS and PA it seems that it 
would be better to target eczema rather an FLG loss-of-function in an interventional study, given its stronger 
association with the outcome of interest. There are, however, drawbacks to using infantile eczema as a 
screening tool for an interventional study as, once eczema is visible, the skin barrier will already be impaired 
and transcutaneous sensitization is likely to have already occurred, In the LEAP study 20% of infants with 
eczema already had sIgE to peanut from 4 months of age.
(17)
 If FLG mutations were used as a screening tool, 
one could identify at-risk infants for environmental modifications prior to them developing overt eczema. 
However, many children without FLG mutations develop eczema, whether due to mutations in other skin 
barrier proteins (Section 4.2) or other inflammatory processes leading to the eczema phenotype thus FLG 
genotyping would miss these children. Additionally, more sophisticated markers of skin barrier impairment 
could be included in the design of the study: for example in children with FLG loss-of-function mutations, 








8.8 Limitations of studies assessing EPE  
 
8.8.1 Limitation of study comparing HPC and peanut protein levels in dust 
In the semi-quantitative FFQ, peanut consumption in day care or other locations where the child might be 
exposed to peanut was not included; additionally, participants were only asked to document peanut 
containing foods consumed in the home. Limitations of this were highlighted by one family where there was 
very little apparent HPC but surprisingly high levels of peanut in household dust; on further questioning it 
was revealed that the child’s grandmother ate Crunchy Nut Cornflakes every day in the car as she did not 
want to expose her grandchild (who had confirmed PA) to peanut. This is interesting on two accounts:  
1) Peanut consumption may not need to be in the home to be associated with high household peanut 
levels in dust and further supports the route of hand to environment transfer. 
 
2) The fact that this child was peanut allergic raises the question as to whether the grandmother eating 
Crunchy Nut Cornflakes was in part responsible for the child’s PA.  
 
In future FFQs I would therefore not limit the participant’s consumption of peanut-containing foods to those 
consumed in the home but would also include those consumed outside the home, as peanut foods consumed 
outside the home may also impact on peanut levels in dust.  
 
8.8.2 Limitation of cohort studies 
In the discussion section of publications 3 (MAAS) and 4 (CoFAR study) the limitations of these cohort 
studies are provided in detail. There are three limitations which affected all cohorts (including also BAMSE) 
which I will discuss: (1) the lack of information on infant peanut consumption, (2) the lack of available dust 





8.8.2.1 Lack of infant peanut consumption  
The lack of information on the child’s peanut consumption in the first year of life was a significant 
limitation in all studies. This was due to the retrospective nature of analysis in this PhD and because the 
cohort studies involved were not designed to answer the questions asked in this PhD.  There are two ways in 
which infant peanut consumption could confound the association between EPE and PS/PA:  
1. Infant peanut consumption increases peanut protein levels in household dust, as shown in publication 
2. In the cohort studies, peanut levels in dust were used as a measure of exposure to peanut in the 
environment through other members in the home eating peanut rather than being a reflection of what 
the infant or young child ate. Given that oral peanut consumption should protect against PS/PA, even 
in children with high levels of HPC by other family members as shown by Fox et al. (2009),
(104)
 if 
the child’s peanut consumption was contributing to peanut protein levels in household dust this 
would negate the risk relationship between EPE and PS/PA.  
 
With regards to the first potential confounding effect, this is not relevant for the MAAS and BAMSE 
cohort as dust samples analysed for peanut were collected either antenatally or in the first 6 months 
of life (bar 2 dust samples at 1 year in MAAS) when infants would not have been consuming peanut. 
However, in the CoFAR study dust was collected at a median age of 9 months [IQR 7-12] when it is 
possible that children would have started eating peanut containing foods such as peanut butter 
(especially in a US cohort where peanut butter consumption is very high). 
 
2. Peanut consumption occurring after exposure to peanut in the environment during the first year of 
life could also protect against PS and PA 
 
It is possible that despite high EPE around the time of birth, that the introduction of peanut as a 
weaning food could prevent PS or prevent PS progressing to PA. In order to address this second 




randomised to eating peanut after dust samples were collected versus continued avoidance of peanut. 
The Enquiring About Tolerance (EAT) study is a population based RCT assessing whether early 
introduction of peanut and other allergenic foods (from 3 months of age) with concomitant 
breastfeeding versus exclusive breastfeeding until 6 months reduces food allergy at 3 years of age. 
Consumption of peanut after 6 months of age in the control arm has not been forbidden but has also 
not been actively encouraged. A detailed evaluation of peanut consumption by the child and other 
household members has been obtained by validated dietary questionnaires. Dust samples have been 
collected at 3 months of age in the bed-sheet and play-area of infants recruited to the EAT study 
(www.eatstudy.co.uk). The 1302 children recruited to this study have been followed up and are 
currently undergoing OFCs to peanut and other allergenic foods. The EAT study design will 
therefore assess whether EPE at 3 months of age increases the risk of  PS and PA at 3 years of age, 
and whether this effect is modified by the infant consuming peanut from 3 months of age in the 
intervention arm of the study. These data will be available for analysis towards the end of 2015 once 
all year 3 EAT study visits have been completed thus is not included in this PhD. 
 
8.8.2.2 Lack of available data for analysis 
Dust for peanut protein analysis was only available in a proportion of patients from each cohort. 
Additionally only data from children with available FLG genotyping were included in the final analysis for 
MAAS and BAMSE (which also therefore excluded non-Caucasians). Excluded data ranged from 54.1% 
(2211/4089) for BAMSE, to 47.4% (561/1184) for MAAS to 29.9% (359/512) for CoFAR. Although in 
MAAS and CoFAR there were differences between various population demographics between those 
participants included versus excluded in the studies, there were no significant differences in the rate of PS or 
PA (where available), thus these differences are less likely to have influenced the results. Demographics of 
included versus excluded participants were not compared in BAMSE as the final sample size obtained was 
large (n=1878), therefore it is more likely that this large number of participants would adjust for any bias 




8.8.2.3 Lack of comprehensive PS and PA assessments  
PS and PA outcomes in the cohorts were not comprehensive except for the MAAS. In MAAS PS status was 
available from testing with SPT, peanut sIgE and peanut component allergens and PA was also assess by 
OFC. In the CoFAR study PS was assessed by SPT and sIgE. The CoFAR study has performed peanut 
component allergen testing and also has assessed PA by OFC at 3 years of age; however, this information 
was not made available for incorporation into this PhD as the CoFAR group have not yet published these 
findings. The main limitation in the CoFAR study was therefore that only PS and a ‘likely’ diagnosis of PA 
could be assessed using the serological cut-off of sIgE to peanut ≥5kUA/ml. The CoFAR group defined this 
group of children as having likely PA,
(98)
 given that 70-90% of 5-7 year old children have positive 
diagnostic peanut challenges with this level of peanut sIgE.
(18;149;421)
 Once peanut CRD and OFC based PA 
outcome data are made available if will be interesting to see whether the association found between EPE and 
PS and PA remains. Additionally, the 3 year PA outcome data will show whether early EPE is associated 
with later onset PA, whereas at present only contemporaneous EPE and PS/ likely PA have been assessed. In 
the BAMSE study, only peanut sIgE and peanut component allergen testing was available as only 2.6% 
(n=49/1878) of children in BAMSE underwent peanut SPT testing therefore peanut SPT sensitization was 






8.9 Further research for EPE 
8.9.1 Impact of dust containing peanut in a mouse model 
In order to assess a more causal role of EPE on the development of PS and PA, a mouse model could be 
employed where neonatal mice with an impaired skin barrier (using the flaky tail mouse or by tape stripping 
wild-type BALB/c mice) were exposed to peanut protein in dust. Peanut containing dust could be 
compressed into the bedding of young mice (torn tissue hankies) which they do not usually eat (personal 
communication Dr Sophie Wavrin, French National Institute for Agricultural Research (INRA), June 2013). 
Immune responses from spleen and LNs as well as anaphylactic responses to oral peanut gavage could 
subsequently be assessed in this group of mice versus control to determine whether early EPE could drive 
Th2 sensitization and /or clinical manifestations of PA. 
 
8.9.2 Randomised controlled study for reduction in EPE 
The data obtained in this PhD provides useful information to determine what levels of peanut reduction are 
required to reduce the risk of PS and PA. Data from publication 2 demonstrated that peanut protein levels in 
household dust from an infant’s home environment were highly correlated with HPC (grams/week) over 6 
months. Using the raw data from Publication 2, I calculated the conversion factor for HPC at certain levels 
of peanut protein in dust in the infant’s play-area. Using this conversion factor I was able to assess the 
impact that a reduction in HPC would provide on EPE. According to this calculation, a reduction in HPC 
from 20 g/week (ln 3.0 g/week) to 5 g/week (ln 1.6 g/week) would result in a reduction in peanut protein 
levels in the infant’s play-area from 144 µg/g (ln 5.0 µg/g) to 5 µg/g (ln 1.61 µg/g). 20 grams per week of 
HPC is equivalent to a household of  4 people each eating 1-2 slices of peanut butter on bread (3.75 grams 
peanut protein) per week. A reduction of HPC to 1g/week would reduce EPE to below the LLQ of the 
Veratox peanut ELISA (<25 ng/ml peanut protein). Using data from the CoFAR study (Figure 28) I assessed 
the impact of reducing HPC and peanut protein levels in household dust on the predictive probability of 




HPC would reduce the risk of PS in children with atopic eczema (ranging from from mild to severe) from 
64% to 39% (a 39% risk reduction). Thus the findings obtained from this PhD could be used towards 
estimating the effect size in reducing PS with a reduction in HPC and therefore EPE, and this could then 
provide information towards powering an RCT with the aim to reduce PS by reducing HPC. 
 
There may be a long lag-time between reducing HPC and a concomitant reduction in peanut levels in 
household dust as per the findings in studies to reduce cat allergen levels in the home once the pet cat has 
been rehoused.
(422)
 The time-course for the reduction of peanut levels in dust following a reduction in HPC 
would have important influences on the design of an interventional study i.e. measures to reduce peanut 
protein levels in household dust such as reducing HPC might need to start before conception which would 
make patient selection complex.  
 
Figure 28: Mean predictive probability of PS dependant on HPC or EPE in all children, children with a 








Table 17: Reduction in HPC on EPE and the probability of PS in high-risk infants. 
 HPC  
(6 months) 
EPE Probability of PS 
All children 20 g/week (ln 3) 150 µg/g (ln 5) 62% 
Children with history of 
infantile eczema 
20 g/week  
(ln 3) 
150 µg/g (ln 5) 64% 
Children with history of  
severe infantile eczema 
20 g/week  
(ln 3) 
150 µg/g (ln 5) 67% 
 
All children 10 g/week  
(ln 1.6) 
50 µg/g (ln 3.9) 57% 
Children with history of 
infantile eczema 
10 g/week  
(ln 1.6) 
50 µg/g (ln 3.9) 59% 
Children with history of  
severe infantile eczema 
10 g/week  
(ln 1.6) 
50 µg/g (ln 3.9) 59% 
 
All children <1 g/week (ln 0) <LLQ 42% 
Children with history of 
infantile eczema 
<1 g/week (ln 0) <LLQ 39% 
Children with history of  
severe infantile eczema 




8.9.3 Peanut in dust extinction study 
If a RCT were to show that a reduction in EPE (through reduction in HPC) was to reduce the incidence of PS 
and PA, then, to be able to translate this into public health measures, it would be important to know how 
quickly peanut protein levels could be removed from the home environment after household members 
discontinue eating peanut.  Findings from publication 1 showed that a significant reduction in peanut protein 
levels could be achieved by washing soft furnishings (sofa covers had median 1000-fold reduction in peanut 
protein levels) and bedding (pillows had median 40-fold reduction in peanut protein levels) with a single 
machine wash at 60 ºC using normal detergent.  
 
It would also be important to know how quickly peanut levels disappear from the home after peanut 
consumption is discontinued without resorting to intensive cleaning measures. On the basis of currently 
available data from publication 1, the correlation between peanut in dust and HPC over 1 and 6 months was 
similar. This may be because eating habits do not usually change (unless there is a specific reason for this such 
as a new diagnosis of PA in a household member), but also due to peanut protein persisting in the environment 
due to its resilient nature. In results from my MSc study a single peanut meal led to 48 hours duration of 
detectable peanut in the participant’s bed-dust, however this could have been confounded by removing peanut 
from the bed surface every time the bed-sheet was vacuumed.  
 
To date there is no study which has assessed the rate of extinction of peanut levels in dust after HPC is 
discontinued. In the LEAP and LEAP-ON study dust samples have been collected from the child’s bed before 
their peanut OFC at 5 years (LEAP study completion) and 6 years (LEAP-ON study completion). In the LEAP 
study, infants were randomised to peanut consumption or avoidance for the first 5 years and following this 




subsequently recruited to the LEAP-ON study and asked to avoid all peanut for 1 year and called back for 
another peanut oral food challenge to determine whether high dose oral peanut consumption in the first 5 years 
of life led to oral tolerance induction or merely transient desensitization. It is hoped that there will be a 
significant reduction in the level of peanut protein in the bed-dust of previous LEAP peanut consumers after one 
year of peanut avoidance. Results of the LEAP-ON study will be available in 2015; they will only show 
whether peanut levels in dust reduce after one year of peanut avoidance. However, they will not show whether a 
more short term avoidance of peanut leads to reduction of peanut levels in household dust. Therefore I am 
currently recruiting 20 adult volunteers into a study where they will be asked to eat peanut regularly for 2 
months and then avoid peanut for 6 months (other household members are also asked to avoid eating peanut). 
Dust samples from their bed will be collected before commencing peanut consumption and will then be 
obtained every month thereafter until the end of the study (8 months). This will allow a more accurate estimate 





8.11 Discussion of findings from in-vitro work 
The purpose of this mechanistic section of the PhD was to assess the compartmentalization of Th2 recall 
responses to peanut from skin (CLA+) versus gut (β7) homing Th cells in children with PA; this would have 
supported the concept that PS occurs through the skin which is the overriding concept for this PhD. Although 
there was no predominance in Th2 cytokines from CLA+ Th cells in peanut recall responses, we postulated that, 
whilst the original Th2 gene expression profile is limited to the skin-homing CLA+ Th cells, over time Th2 
responses became dominant in all lymphocyte homing compartments. Although the findings from this 
mechanistic work were not what had been expected, they did reveal a potential novel biomarker for PA, IL9, 
which furthermore ties in with the concept of epicutaneous sensitization (see Section 3.9). The gene with the 
highest differential expression between PA and PS was not one of the usual Th2 signature genes (e.g. IL4, IL5 
or IL13) but the more recently described IL9 gene (publication 5). IL9 induces mast cell proliferation and 
production of IL4 induced IgE thus may have an important role in the pathogenesis, severity and persistence of 
PA. Although, IL9 was also expressed in both skin and gut-homing memory Th cells in children with PA, the 
role of IL9 in the skin provides an argument for its contribution in epicutaneous PS as discussed in the 
introduction (Section 3.9) and in the discussion below (8.11.5).  
 
8.11.1 IL9 as the best differentiator of PA in children 
IL9 was shown to be the best differentiator of PA in children using Affimetrix gene microarrays analysed by 
ANOVA and Random Forest classifiers and using RT-qPCR (publication 5). Although IL9 had the highest 
differential gene expression when recall responses from PBMCs from children with PA were compared against 
NA children and peanut sensitized children, IL9 was not actually the most highly expressed gene in peanut 
allergic children (RT-qPCR analysis). IL5, a classical Th2 cytokine, was more highly expressed in peanut 




expressed in peanut sensitized and atopic NA children than IL9 (see Table 18). Thus IL9 expression in PA had a 
lower false positive rate and a higher specificity than IL5 which is why IL9 was the highest differentially 
expressed gene for PA. 
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*AU: Arbitrary units 
The lower specificity of IL5 may be because IL5 is stimulated more non-specifically in both PS and atopic NA 
children, thus has a higher background level, making it less useful in ruling in PA. IL9 was able to classify PA 
using the Random Forest classifier with 100% accuracy, even when selecting only 10, then 5, then 2 genes, 
which is quite remarkable. Although we did not proceed further to evaluate IL9 as a predictive tool in the 
diagnosis of PA, this would be interesting research and further mechanistic assessments of IL9’s role in PA are 
warranted. There is a need for novel biomarkers that will improve diagnostic testing for PA so as to be able to 
avoid the risk of undertaking a diagnostic OFC, as well as the inconvenience to the family and cost to the 
healthcare system. There is already a patent on file by Jordana M and Waserman S (2011) for a diagnostic 
classification algorithm to diagnose PA which incorporates the age of the individual, SPT size, total IgE and the 
cytokines IL9, IFNγ, IL10, IL13 and IL5.(423) Additionally, biomarkers could be used to monitor efficacy of 





8.11.2 IL9 and Th9 cells 
IL9 is secreted by a variety of cells, including mast cells and innate lymphoid cells,
(424)
 as well as Th cells (Th2, 
Th9 and inducible T regulatory cells[iTregs]).
(425)
 Until recently IL9 was described as a Th2 cytokine as it was 
thought to be produced by Th2 cells and was involved in various Th2 responses; however, ICCS of cytokines in 
naïve Th cells from mice cultured in Th9 conditions (TGFβ and IL4) showed that these cells produced IL9 (and 
IL10) but did not produce IL4, IL5 or IL13, suggesting a distinct lineage of Th cells.
(426)
 In publication 5 we 
also found evidence that IL9 was being produced by cells that did not produce IL5; this suggests that the cells 
producing IL9 in response to peanut antigen were not Th2 cells. I would have liked to further characterise the 
lineage of IL9 producing Th cells in order to strengthen the argument that IL9 is produced by the newly 
discovered Th9 cell; however, this was difficult due to the lack of confirmatory characteristics of the Th9 cell.  
 
There are generally two ways to identify Th cell phenotypes: (1) by their immune function and cytokine 
secretion and (2) by their lineage specific transcription factors. Murine data have demonstrated that Th9 cells 
produce IL10;
(427)
 however, the evidence for Th9 production of IL10 in humans is lacking. 
(425;428)
 Th9 cells 
produce IL9 but, as described above, so do Th2 and iTregs, 
(425)
 thus it may be more prudent to define Th9 cells 
by the cytokines that they do not secrete (Th2: IL4, IL5 and IL13 and iTreg: IL10, TGF-β). Th cells are often 
defined by their lineage specific transcription factors; for example Tbet for Th1 cells,
(429)
 GATA3 for Th2 
cells
(430)
 and RORγT for Th17 cells.(431) These transcription factors, which determine the T-cell phenotype, are 
stimulated in naïve Th cells by cytokines in the surrounding milieu via the T cell receptor complex and co-
stimulatory molecules (see Section 1.6 and Figure 29).  
 
The development of IL9 secreting Th cells is promoted by the cytokines IL4 and TGFβ; if only IL4 signalling 




produced (via induction of Foxp3).
(432)
 The lineage specific transcription factors for IL9 secreting Th cells in 
murine models are a mixture of transcription factors downstream of IL4 (STAT6,
(433)
 GATA3, and IRF4
(434)
) 
and TGFβ (PU.1).(433;435)  
 
Figure 29: Development of Th effector subsets from Th precursors (Thp).  
Cytokines and STAT proteins required for the differentiation into each Th phenotype. A sliding scale TGF-β or 
inflammatory cytokines is shown to display the variable concentration of cytokines in the microenvironment 








8.11.3 Lineage transcription factors for Th9 in mice  
PU.1 is a transcription factor which binds to the PU-box, a purine rich sequence found near the promoters of 
target genes and regulates their expression in coordination with other transcription factors. 
(435)
 In murine 
models, TGFβ switches off GATA3 (the master transcriptional regulator  of Th2 cells) with a resulting switch in 
Th cytokine secretion from IL4, IL5 and IL13 to IL9.
(426)
 Murine models have also shown that TGFβ prevents 
expression of the transcription factor Tbet in favour of PU.1; 
(437)
 PU.1 then induces an open chromatin 





8.11.4 Lineage transcription factors for Th9 in humans  
Less data exist regarding lineage specific transcription factors for IL9-producing T-cells in humans. When Th9 
cultures from human PBMCs were transfected with PU.1-specific small interfering RNAs (siRNAs) there was 
decreased IL9 production.
(438;439)
 In atopic human subjects, PU.1 was only found in a proportion of IL9 
producing Th cells (median 52%; range 5%-90% of Th9 cells). The authors postulated that whilst PU.1 might 
be necessary for the differentiation of naïve Th cells into Th9 cells, once the Th cell was polarized this 
transcription factor was no longer expressed. 
(440)
 In the study by Cortelazzi et al. (2013) staining for PU.1 was 
present in 23.4% of total lymphocytes in the epidermis of individuals with atopic eczema versus 5.8% of total 
lymphocytes in the epidermis of individuals with contact dermatitis; some of the epidermal PU.1 + cells co-
expressed CD4, thus could have represented Th9 cells.  IL9 staining was also higher in the skin of patients with 
atopic eczema than contact dermatitis; however, the authors did not state whether cells that stained positive for 
IL9 cells also stained positive for PU.1.
(226)
 In the Asthma, Allergy and Respiratory Science Department at 




Th cells (personal communication: Professor David Cousins, King’s College London, October 2012), thus I did 
not evaluate PU.1 as a lineage specific transcription factor for the Th9 cell phenotype. 
 
8.11.5 Biological relevance of IL9 for PS and PA 
8.11.5.1 IL9 and its role in epicutaneous sensitization and clinical reactivity 
The biological relevance of IL9 in epicutaneous sensitization is likely to be related to the mast cell function of 
IL9 which includes mast cell activation, release of inflammatory mast cell mediators (e.g. histamine) and 
expression of mast cell protease, pro-allergic cytokines (IL4, IL5, IL6, IL9, IL13) and FcεRIα receptors. 
(236;441;442)
 IL9 additionally potentiates IL4 induced IgE production by B cells.{Dugas, 1993 964 /id} The 
interplay between IL9, mast cells, Langerhans cells and TSLP in the process of epicutaneous sensitization is 
discussed in Section 3.9.4.1.
(233)
  The role of IL9 on mast cell migration and proliferation in the skin and gut 
may also play a role in clinical reactivity following epicutaneous peanut sensitization as discussed in Section 
3.9.4.2. Mast cell IgE cross-linking of the high affinity FCεRI receptor by specific antigens results in the release 
of pro-inflammatory mediators such as histamine and prostaglandins resulting in the immediate effects of an 
allergic response and recruitment of other inflammatory cells  (see Section 1.6).   
 
8.11.5.2 IL9 and its role in oral sensitization and clinical reactivity 
In mouse models IL9 has been shown to be a crucial factor for anaphylaxis following oral antigen exposure. 
(443;444)
 IL9 deficient mice failed to develop experimental oral antigen–induced intestinal anaphylaxis (acute 
diarrhoea, intestinal mastocytosis and mast cell activation) after being sensitized with IP OVA with aluminium 
adjuvant. Following sensitization IL9 deficient mice had reduced intestinal mast cells and serum mMCP-1 






 developed  OVA specific IgG1 and total IgE, intestinal IL4 (mRNA and 
protein),  intestinal mast cell expansion, leakage and anaphylaxis (diarrhoea and increase in mMCP-1) 
following oral exposure to OVA.
(443;446)
 In the mice with intestinal IL9 overexpression intestinal anaphylaxis 
occurred after repeated oral doses of peanut without the need for prior IP OVA sensitization, whereas in wild-
type BALB/c mice prior IP OVA sensitization was required with aluminium adjuvant to mount Th2 responses 
or symptoms upon rechallenge. These findings suggest that in mice with IL9 overexpression in the intestine, 
there is a phase of sensitization that occurs through the gut which then leads to intestinal anaphylaxis.  
 
In humans, intestinal mast cell expansion has also been reported in subjects with food allergy; 
(447)
 this may play 
a role in increasing intestinal permeability and transcellular passage of large amounts of antigen across the 
intestinal epithelium leading to food sensitization and subsequently food allergic reactions. 
(446)
  The mast cell 
stabilizer cromolyn has been used to prevent intestinal permeability and mast cell activation in mice which 
constitutively overexpress IL9 in the enterocytes of the gastrointestinal tract. In the study by Forbes et al. (2008) 
pretreatment with cromolyn prevented orally induced antigen sensitization (OVA sIgE) and anaphylaxis.
(443)
 
These findings suggest that mast cell mediated intestinal activation and degranulation may be an important 
factor for specific antigen sensitization and subsequent anaphylaxis through oral exposure.  
 
 
8.11.5.3 Mechanism why IL9 differentiate between PS and PA 
The importance of IL9 for mast cell for mast cell proliferation in the gut may explain why this cytokine 
differentiates between PS and PA. PS occurs via both Th2 and Th9 pathways; however, lack of IL9 means that 
there will be lower densities of mast cells in the skin and gut; this in turn may mean that the threshold for 




8.11.6 Homing markers of Th2 and Th9 cells in peanut allergic children 
Th9 cells (CD4+IL9+IL13-IFNγ-) have been shown to circulate in the blood of allergic patients, but not in non-
allergic patients, and a significant population of these Th cells have CLA+ homing markers.
(448)
 Thus it is 
surprising that in PMBCs from peanut allergic patients we did not find a CLA+ predominance in IL9 secreting 
Th cells and Th2 cells; however, given the murine literature that epicutaneous sensitization leads to migration of 
mast cell and mast cell expansion in the gut, it may be that, that whilst the original Th2 and Th9 gene 
expression profile is limited to the skin-homing CLA+ Th cells, over time Th2 and Th9 responses became 
dominant in all lymphocyte homing compartments. This could be as a consequence of migration of mast cells 
from the skin to both skin and mesenteric LNs following mechanical injury to the skin; once the mast cells are 
in these LNs the MIP-1β recruits Th cells into both skin and mesenteric LNs. 
 
8.12 Limitations of mechanistic work 
8.12.1 Further characterization of IL9 and its role in PA 
The main limitation of the mechanistic work was the need to further evaluate IL9 as a biomarker for PA. By 
increasing the sample size of participants and employing statistical models it may have been feasible to evaluate 
IL9 as a predictor for correctly diagnosing PA and to define PPVs and NPVs for optimum IL9 cut-offs. 
Additionally, evaluation of downstream signalling pathways for IL9 in children with PA would have been very 
useful to understand the role of IL9 in PA.  
 
8.12.2 Further characterization of IL9 secreting Th cells  
Although the findings from this PhD suggested that IL9 was secreted by Th cells which were not Th2 cells (due 




were Th9 cells.  Further work still needs to be done to identify lineage specific transcription factors for Th9 
cells in humans in order to identify whether IL9 secreting Th cells are indeed Th9 cells.  
8.12.3 PBMC culture conditions  
One limitation in the in-vitro work performed was that several patients’ blood was cultured in RPMI with 
autologous serum before the decision was made to switch to the culture free AIM-V medium to increase the 
amount of cells and RNA obtained for microarray analysis. Initially the low RNA obtained was thought to be 
solely due to the technique of RNA extraction. Thus several patient blood samples that had been cultured in 
RPMI could not be used in the final analysis. Another limitation was that PBMCs were cultured for only 18 
hours rather than over a period to time to assess kinetics of IL9 expression.  In previous microarray studies 
using recall responses to HDM in atopic versus non atopic controls, IL9 had the highest differential expression 
between 24-48 hours rather than at 12-24 hours.
(79)
 Xie et al. (2012) found that IL9 from PBMCs of peanut 
allergic versus non atopic controls started to increase predominantly after 2 days of culture up to a maximum 
fold increase at 5 days.
(449)
 Thus culturing PBMCs for at least 48 hours may have led to even higher differential 
expression of IL9 in the microarray and RT-qPCR experiments used in this PhD.  
 
8.13 Further mechanistic research 
8.13.1 Kinetics of IL9 expression 
IL9 differential gene expression in Th cells from peanut allergic children was found after 18 hours peanut 
culture, whereas Bosco et al. (2006) found IL9 upregulated in recall response from PBMCs of HDM allergic 
individuals at 48 hours.
(79)
 Kinetic experiments using microarray gene expression analysis following PBMCs 
cultured in peanut for 18, 36 and 54 hours would evaluate whether IL9 continued to be the predominant gene 




8.13.2 Longitudinal studies to assess Th homing markers as PS progresses to PA. 
Given the lack of predominance of CLA+ Th cells in peanut recall responses in peanut allergic children, I 
postulated that the CLA+ Th cells might predominate initially during PS and then spread to other Th cells 
subsets (i.e. include β7+ Th cells) once PA is established. Longitudinal analysis following up immune responses 
in children at high-risk of developing PA would elucidate whether there is migration from CLA+ Th cell to both 
CLA+ and β7+ Th cell predominance in recall responses to peanut as children progress from PS to PA.  
 
8.13.3 IL9 as a biomarker for PA prediction and prognosis  
It would also be interesting to conduct a longitudinal study assessing IL9 expression in peanut sensitized 
children to determine whether memory Th cells from peanut sensitized children who go on to develop PA have 
higher IL9 expression in the presence of peanut than memory Th cells from PS children that do not go on to 
develop PA. This would provide evidence in support of IL9 being used a predictive biomarker for PA. 
Assessment of IL9 as a biomarker of anaphylaxis in humans would also be valuable given its central role in 
anaphylaxis in mouse models (see Section Error! Reference source not found.). 
 
8.13.4 Anti-IL9 antibody therapeutics 
The obvious direction for any research on biomarkers of disease is to evaluate whether a monoclonal antibody 
directed against this biomarker could reduce the severity or cure the disease. Given the success of anti-IL9 
antibodies in mice on the prevention and reduction in severity of food anaphylaxis, there may be a role for IL9 
antagonists in the prevention of PS and PA in humans. Although no studies to date have evaluated humanized 
anti-IL9 antibodies for the prevention or treatment of PA, there have been studies assessing anti-IL9 




safety of a humanized anti-IL9 antibody (MEDI-528), there were positive effects on asthma symptom control, 
reduction in exacerbations in adults and reduced exercise induced bronchoconstriction.
(450)
 Unfortunately, in a 
larger RCT (n=327), addition of an IL9 antagonist was not associated with any improvement in asthma 
symptoms scores, exacerbation rate or forced expiratory volume in one second (FEV1) in adults with severe 
asthma.
(451)
 The authors concluded that given the heterogeneous nature of asthma, in particular severe 
uncontrolled asthma, that the identification of subgroups of patients would be key in delivering an optimal 
response to anti-IL9. However, disappointingly when they assessed subgroups with atopic asthma, peripheral 
blood eosinophilia and patients taking moderate to high doses of inhaled corticosteroids, the researchers did not 
find a response to anti-IL9.  
 
The efficacy of biologicals directed against specific cytokines or transcription factors (using monoclonal 
antibodies) is often disappointing, which may be due to the network of signals which are responsible for a 
particular clinical outcome and redundancy within immunological systems. It may be, therefore, that 
combinations of biologicals (including for example anti-IL9 and anti-IL5 monoclonal antibodies) need to be 
used to achieve the outcome of interest. However, biologicals have drawbacks due to the requirement for 
subcutaneous or intravenous injection and the risk of adverse effect given that nature reuses signalling pathways 





8.14 Summary and conclusions 
This PhD is the first study to evaluate the role of environmental exposure to a food antigen on the development 
of food sensitization and allergy. Although Fox et al. (2009) showed that HPC was a risk factor for PA, this was 
only an indirect measure of EPE, whereas now this PhD confirms that HPC does indeed lead to higher levels of 
EPE and therefore provides the ‘missing link’ in the study by Fox et al. (2009).(104) The findings in this PhD 
reveal previously unknown characteristics of peanut antigen in dust, such as the ability of the peanut allergens 
in dust to elicit antigen specific responses in immune effector cells of peanut allergic children, and the presence 
of major peanut allergens in dust. It would be interesting to assess whether other food allergens maintain their 
biological activity and major allergens once distributed in the environment as dust.  
 
This PhD is also the first study to evaluate the impact of EPE on PS and PA in cohort studies and to determine 
factors that modify this such as atopy and markers of skin barrier impairment. The finding that a FLG loss-of-
function mutation and a history of eczema interacts with EPE to increase the risk of PS and PA provides an 
exciting avenue to identify high-risk children from birth (using genetic markers) or early infancy (in children 
with eczema or raised TEWL) and target them with environmental modifications. On the basis of the 
publications arising from this PhD to date, this approach has been cited as an avenue of interest in a recent 
review by Leung et al. (2014): 
(452)
 ‘…environmental peanut might drive sensitization to peanut allergy in 
patients with atopic dermatitis (AD), particularly in those with FLG mutations, which is a clinically relevant 
example of the importance that environmental exposure in house dust might contribute to allergen sensitization 
in patients with AD.’ (p. 771)… ‘These articles suggest the possibility that controlling environmental peanut 





Additionally in the study by Tordesillas et al. (2014) evidence that epicutaneous application of peanut antigen 
was able to induce PS and PA in mice without the need for skin abrasion or an adjuvant led these authors to 
postulate ‘Our results with peanut allergen support the hypothesis that environmental exposure to peanut is an 
important risk factor for sensitization.’ (p. 2).  In this PhD, I demonstrated that HPC is the factor most highly 
associated with peanut levels in dust in an infant’s bed and play-area (where infants are most likely to be 
exposed in their environment). These findings therefore also provide the strategy by which EPE could be 
reduced in interventional studies. It is, however, important to consider that children may be exposed to peanut 
outside the home, such as in nursery or at their grandparent’s home. 
 
Finally, this PhD supports the role of IL9 as a potential biomarker for PA, which has only been previously 
shown in one study in adults by Xie et al. (2012). 
(449)
 My PhD supports the findings from the Xie et al. (2012) 
manuscript but also extends them by assessing children, and by comparing PA versus PS (rather than just PA 
versus NA). In this PhD IL9 was the most highly differentially expressed gene in PA compared both to atopic 
NA children and PS children. A biomarker that was able to differentiate between PA and PS would be useful 
due to the limitations of current SPT and sIgE testing which often requires OFC to differentiate between PA 
versus tolerance in PS individuals. Further research is required to evaluate IL9 in predictive models to assess 
sensitivity, specificity and reliability of IL9 in PA diagnosis and prognosis (by natural resolution or to monitor 
outcome in peanut desensitization studies). The interplay between Th9 and Th2 subsets may clarify whether the 
success of preventative therapeutic approaches aimed at PA resolution could be evaluated on the basis of IL9 
secretion and/or Th9 suppression in peanut-specific in vitro responses. Future research into the role of Th9 cells 
in the development of PS and PA via epicutaneous sensitization is warranted in both murine and human studies, 
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10.1 Appendix 1: Environmental peanut protein sampling methodology 
Wipe sampling methodology 
‘Benchkote’ filter paper (Whatman Ltd, Maidstone, UK) measuring 4x4cm was moistened with PBS to wipe 
different surfaces for peanut protein as shown in Figure 30. The Benchkote wipes were decided upon because 
alternative wipes were not appropriate; Cellulose wipes became fragmented and glass fibre filter wipes were 
thought to potentially release glass fibres which might be harmful for infants when sampling near their bed. A 
different pair of gloves was used to collect each wipe sample. Wipes were weighed before and after sampling to 
calculate results in μg peanut protein/gram filter.  
Figure 30: Wipe sampling 
 
Dust sampling methodology 
Philips cylinder vacuum FC8262 (1600 Watts) was connected to a Dustream adaptor and collector (Indoor 
Biotechnologies Inc., Warminster, UK) with a nylon collection filter (pore-size 40µm) for dust samples 
collected for Publication 1,2 and 4 (Figure 31 and Figure 32). For vacuuming indoor allergens in dust, motor 
power wattage of over 1000 Watts is recommended (personal communication Dr Jill Warner, Imperial College 




enough motor power to have enough suction power to sample sufficient quantities of dust, and should be used at 
full power. The Indoor Biotechnology Dustream Collector kit has been shown to be compatible with most 
Commercial U.S. vacuum cleaners (n=48). 
(453)
 The dust collector was able to fit 9 vacuums tested without the 
adaptor, 18 vacuums with the adaptor and 21 vacuums with the adaptor reversed. In this study they also showed 
that this method of dust collection resulted collection of a mean of 326 mg of dust from carpets and 254 mg of 
dust from beds and mattresses.  
Figure 31: Dust collection apparatus 
        
 
Figure 32: Vacuuming bed 
 
Disposable nylon collection 
filter 
Dustream vacuum adaptor 
Dustream collector 
Assembly of Dustream 





10.2 Appendix 2: Dust processing 
Weight of dust validation work  
To assess the minimum weight of dust that could be used for peanut protein analysis, one dust sample with 11.9 
µg/g peanut protein was separated out into dust weights of 100mg, 75mg, 50mg, 25mg, 10mg, 5mg, 4mg, 2mg 
and 1mg. Peanut protein was quantified using the Veratox peanut ELISA kit against whole peanut protein (see 
Section 6.4). Results obtained for peanut protein (ng/ml) were extrapolated to µg/gram of dust taking into 
consideration the initial weight of dust extracted. For example 5mg of dust was multiplied by 10 in order to 
compare with the results obtained for a 50 mg dust sample. Dust sample weights extracted down to 5mg gave 
similar peanut protein levels to dust samples weighing 10mg, 25mg, 50mg, 75mg and 100mg; however, dust 
samples weighing 4mg, 2mg or 1mg significantly overestimated (Figure 33). For this reason, all dust samples 
less than 5mg were excluded from analysis. 





10.3 Appendix 3: ELISA Background, methodology and validation 
 Background of ELISA methodology 
The ELISA is common antibody-based laboratory technique that is used to measure the concentration of antigen 
or antibody in solution. There are three common ELISA formats: direct assays, indirect assays and sandwich 
assays.  
1) Direct assays have an antigen or antigen-specific antibody directly immobilized to a multiwell plate; the 
antigen or antigen-specific antibody are detected by an antibody or antigen (respectively) which is directly 
conjugated to an enzyme.  
2) Indirect assays also have primary antigen-specific antibodies immobilised to the multiwell plate; 
subsequently, secondary enzyme-linked antibodies are bound to the primary antibodies. The secondary antibody 
is usually an anti-species antibody (for example anti-rabbit IgG) and is often polyclonal thus increases the 
sensitivity of the assay as more than one secondary antibody can bind each primary antibody.  
3) Sandwich assays comprise matched antibody pairs that are specific for non-overlapping different 
sections (epitopes) of the antigen of interest. The primary ‘capture’ antibody is immobilized to the multiwall 
plate, then the antigen is added to each well and a secondary antibody directed against the antigen of interest 
measures the concentration of the antigen. This type of assay has a higher specificity as the capture and 
detection antibody bind two different epitopes of the antigen of interest. 
a. In a direct sandwich ELISA the capture antibody is conjugated to an enzyme 
b. In an indirect sandwich ELISA the detection antibody is conjugated to an enzyme and the 






Veratox ELISA kit background 
The Veratox ELISA is a polyclonal indirect sandwich ELISA. The Veratox ELISA comprises polyclonal IgG 
‘detection’ (that line the bottom of the ELISA well) and ‘capture’ antibodies (within the conjugate antibody 
ELISA solution) against whole peanut protein. This means that it detects multiple different peanut allergens and 
multiple different epitopes within those allergens. This results in a very sensitive assay. The Veratox ELISA is a 
commercially available ELISA; Neogen (Europe) use the following methodology to produce the components of 
the ELISA. The detection and capture antibodies are synthesized using rabbits immunized with a blend of 32 
raw and roasted peanuts. The rabbits are then bled and the antibodies obtained are screened for activity and 
purified before use. The Veratox ELISA has been validated for sensitivity, specificity, reliability and efficacy of 
extraction for determining peanut protein contamination in food. 
(358;454)
 In Section 5.7  I discussed the 
validation previously performed on ELISA kits to measure peanut protein in food in terms of accuracy and 
reliability.  As part of my MSc and in the online repository of Publication 1 the Veratox polyclonal peanut 
ELISA (Neogen Corporation, Europe) was compared against two other peanut ELISAs and assessed 
performance characteristics of the Veratox peanut ELISA. Following this validation step the Veratox polyclonal 
peanut ELISA (Neogen Corporation, Europe) was used to quantify peanut protein levels in dust and wipes.  
 
In this PhD, each 24-well ELISA run was able to analyse 6 extracted dust samples performed in duplicate 
(n=12) and five peanut standards also performed in duplicate (n=10). Additionally one positive control 
(250ng/ml) from the independent peanut standard and one negative control (plain extraction solution) were also 
analysed. First 150 µl of standards and samples were individually pipetted into the red transfer wells. A multi-
channel pipette was used to transfer 100µl of each sample from the transfer wells to the corresponding antibody 
coated well.  Following a ten-minute incubation period antibody coated wells were emptied into the sink and 




remove the excess wash buffer and were visually inspected to ensure no air bubbles remained.  The polyclonal 
anti-peanut IgG conjugated horse-radish peroxidase (100 μl) was subsequently added to each well and 
incubated for ten minutes. Wash steps were performed as previously described. The substrate TMB was then 
added to each well (100 μl) and incubated for ten minutes. The ELISA wells changed from pink to blue 
dependent on the amount of TMB cleaved by the enzyme horse-radish peroxidase, which in turn was dependent 
on the amount of peanut bound to the antibody-coated ELISA well (see Figure 34). Sulphuric acid (100μl) was 
added to the solution to halt the horse-radish peroxidase enzymatic breakdown of TMB and the colour change 
was analysed on the spectrophotometer within ten minutes.   
 
Figure 34: Veratox peanut ELISA colour change  
The first 5 wells are peanut standards (0, 100, 200, 400 and 1000 ng/ml whole peanut) provided by the Veratox 
peanut ELISA kit. Subsequent 7 wells are individual samples.  
 
 
Optical density (OD) measurements were made on a Precision EMax microplate reader (Molecular Devices Inc. 
USA) at 650 nm wavelength. Results were compared against the standard curve run with each plate. Log-log 
analysis of the standard curve and samples was selected as recommended by the Veratox peanut ELISA kit. To 
accept the OD values obtained, the correlation coefficient of standard curve (ranging from 0ng/ml to 
1000ng/ml) had to be ≥0.98, or the ELISA was repeated. Results were converted from ng/ml whole peanut into 




peanut protein by dividing the results by four as recommended by the manufacturer. Results were converted 
from ng/ml to μg peanut protein/gram dust in a manner proportional to the amount of extract solution used for 
each sample. Dust samples weighing 50-100 mg after sieving were extracted in proportional amounts of 
extraction solution between 1-2 ml respectively. Thus to obtain results of peanut protein per gram dust, the 
results in ng per ml were multiplied by 20 to convert from 50 mg to 1gram. To convert peanut protein results 
from nanograms to micrograms the results were divided by 1000. Dust samples less than 50 mg were all 
extracted in 1ml of extraction solution as it was not possible to use less extraction solution or there would be 
insufficient volume to perform the ELISA analysis.  In order to account for the fact that a dust sample weighing 
5mg through to 50 mg would be extracted in 1ml of extraction solution, peanut protein results (μg/g) were 
multiplied up according to the weight of dust extracted i.e. 5 mg was multiplied by 10 to become 50 mg.   
 
Protein band corresponding to Ara h 1 in Veratox ELISA standard 
The Veratox ELISA has been shown to detect peanut allergens Ara h 1 and 2 using Sodium Dodecyl 
Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Densitometry by other investigators. 
(455)
 SDS-
PAGE is the most common type of gel electrophoresis which employs a polyacrylamide gel and buffers loaded 
with Sodium Dodecyl Sulphate (SDS). The SDS-PAGE maintains proteins in a denatured state once they have 
been treated with strong reducing agents to remove secondary and tertiary structures (such as disulphide bonds) 
and thus allows separation of proteins by their molecular weight. These proteins become negatively charged as 
they are covered with SDS and when a current is run through the polyacrylamide gel they migrate towards the 
positively charged electrode. Small proteins migrate faster through the polyacrylamide gel mesh than larger 
sized proteins. Thus the proteins are separated according to size, and a molecular weight which runs 




To confirm the presence of major peanut allergen in the independent peanut standard and the Veratox peanut 
ELISA standards an SDS-PAGE was run on the independent peanut standard (Lane 4: which was used in 
various validation experiments and as an independent positive control in the Veratox ELISA analysis) and on 
the Veratox 1000 ng/ml standard (Lane 2 and 3 duplicate) which was used for the standard curve analysis. The 
standards used in the Veratox peanut ELISA were the same blend of raw and roasted peanuts used to sensitize 
the rabbits and create the detection and capture antibodies.  A molecular weight marker Coomassie Brilliant 
Blue staining was run in Lane 1 and the monoclonal Ara h 1 standard from the Indoor Biotechnologies ELISA 
was run in Lane 5. Figure 35 shows the presence of a protein around 70 kDa in size in the independent peanut 
standard (Lane 4) and Veratox ELISA peanut standard (Lanes 2 and 3 in duplicate), which corresponded with a 
protein band in the independent peanut extract and monoclonal Ara h 1 concentrate. Anti-Ara h 1 antibodies 
were not used to confirm that the protein band was Ara h 1(as per Western Blot) which is a limitation. 
Figure 35: SDS-PAGE to evaluate Ara h 1 content in the maximum peanut standard 
 
 




Independent positive peanut standard and negative standard  
All ELISAs suffer from batch to batch variability because different batches of peanuts are used to create the 
standards for the ELISA. To ensure consistency of results for each cohort, an independent positive standard, 
created from one single batch of aliquoted lyophilised defatted peanut protein, was used throughout all dust 
analyses. An independent peanut standard was provided by ALK Abello (Hørsholm, Denmark) and created 
as described in the online repository of Publication 1. This peanut extract was used as an independent 
positive standard (at 250ng/ml) with each ELISA plate that was run in addition to the standards provided by 
the Veratox ELISA kit. An independent negative peanut standard which consisted of plain extraction 
solution was also employed so as to ensure that the extraction solution used to extract peanut protein from 
dust had not already been contaminated with peanut protein. For each ELISA these independent positive and 
negative standards were assessed and if they were within allotted range acceptable for the ELISA (calculated 
as one standard deviation from the mean) then the results for that ELISA were included in the analysis, 
otherwise the ELISA was repeated. Additionally, every time a new Veratox peanut ELISA kit batch was 
received from Neogen Europe, we ran all the Veratox peanut standards (0-1000ng/ml) and compared them 
to the ODs obtained for the independent peanut standard (0-1000ng/ml).   
 
Analysis of extracted dust samples above the upper limit of the standard curve  
All samples above the upper limit of the standard curve (1000ng/ml) were diluted so that results were 
interpreted on the basis of OD results obtained along the linear part of the standard curve. Samples were 
therefore diluted 2-fold, 5-fold, 10-fold. 20-fold then up to a maximum of 30-fold in a step-wise approach so 
that the results obtained ranged between 0-1000ng/ml. Results obtained in ng/ml were then multiplied up 






Analysis of extracted samples below the lower limit of quantitation (LLQ)   
There are several ways in which results below the LLQ are usually dealt with: either using imputation or by 
diving the LLQ by two or the square root of two.
(392)
 I chose to divide peanut protein levels below the LLQ 
by 2 as this has been shown to be more applicable to skewed data (all of the EPE data were skewed before 
log transformation). 
(392)
 All results below the LLQ of the Veratox peanut ELISA (100 ng/ml whole peanut) 
were therefore assumed to be 50 ng/ml; however, in the case of the MAAS study, given that 37% of samples 
were below the LLQ and thus would be censored, it was felt by the reviewers at the JACI that it would be 





10.4 Appendix 4: Semi-quantitative food frequency questionnaire 
To assess the relationship between environmental peanut protein levels in household dust and surfaces with 
peanut consumption in the home, a semi-quantitative peanut FFQ was employed. The FFQ used in this study 
was previously compiled using paediatric dietitians’ peanut avoidance dietary sheets from a tertiary allergy 
centre and from the Anaphylaxis Campaign (a charitable organization that offers support to the families of 
children with allergies). 
(456)
 The peanut-containing foods compiled were categorized into a variety of food 
groups including spreads, snack, cereal bars, chocolate bars/sweets and miscellaneous foods, which included 
many savoury foods from different ethnic backgrounds (e.g. peanut soup, satay sauce). The FFQ did not 
include peanut oils as these have not been shown to lead to sensitization or allergy (see Section 2.6), or 
foods containing ‘trace’ amounts of peanut as these would have not contributed significantly to overall 
peanut consumption. Peanut containing foods were mixed in with other types of foods, including foods 
typically associated with food allergy (cow’s milk, sesame, wheat, soya and fish) so as to prevent too much 
emphasis on peanut and thus potential recall bias. Peanut containing foods were favoured towards the 
beginning of the FFQ as evidence suggests that accuracy may reduce towards the end of FFQs due to 




To calculate how many grams of peanut protein were in each serving of food in the FFQ, both the peanut 
content of the food and a standard portion size needed to be determined (see Table 19). People have 
difficulty estimating portion sizes in all forms of dietary assessments,
(458)
 including when relating their 
consumption to pre-defined reference portion sizes as is the case in FFQs.
(459)
 Therefore, for pre-packaged 
food such as chocolate bars the portion size was defined in terms of this standard unit, however, for other 
foods standard portion sizes were obtained from the Ministry of Agriculture,
(460)
 and converted into 
household measures such as a slice, bowl, cup or handful. The actual peanut protein content in each product 
on the FFQ was obtained from the manufacturer directly. The frequency of peanut consumption was 




the food and what the typical amount of the food was (in terms of household measurements). Using this 
information average weekly peanut protein consumption over 1 week, 1 month and 6 months could be 
calculated. HPC was the sum of peanut protein consumed by all household members. Moderate to high 
peanut protein consumption was defined as ≥10 grams/week as previously described. (28)  
 
The gold standard in dietary questionnaire assessments is the 7 day food diary; however, this is time-
consuming and laborious for the family as all foods consumed needs to be documented. The peanut FFQ 
employed in this PhD was validated against a 7-day food diary for maternal recall of her own diet and of her 
infants’ diet over six months; thus was relevant to the study design.(461)  In the study by Sofianou et al.(461) 
mother and infant peanut protein consumption was divided into three groups of none/low, moderate and high 
peanut consumers. Although there was considerable variation at the individual level between the two tools, 
when diary responses were grouped into small numbers (5 and 7) of mother and child ‘units’, the FFQ 
responses were very close to the diet monitored by the 7-day food diaries. 
(461) 
This was the case not just for 
peanut but also for other foods that were also assessed by this dietary questionnaire.  
 
Table 19: Peanut containing foods in FFQ and peanut protein content  
Food % Peanut composition 
(26% of peanut is 
protein) 
Peanut protein/serving (g) 
Spreads:   
Peanut butter (Sunpat) 95% 3.75g/spreading (15g) on bread slice  
Snickers spread 20% 0.8g/spreading (15g) on bread slice  
Snacks:   
Bamba peanut snacks 49% 3g per packet (25g) 
Whole peanuts        100%  2.6g per  handful (10g) 




Snickers flapjack (Mars) 12% 1.1g per bar (34g) 
Tracker Roasted nut bar (Mars)   16 %  1.1g per bar (26g) 
Eat natural- fruit and nut bars  11% 1.4g per bar (50g) 
Breakfast cereals:   
Crunchy Nut Cornflakes 7%   0.6g per bowl (30g serving) 
Crunchy Nut Red 5 %   0.4g per bowl (30 g serving) 
Crunchy Nut Nutty 6% 0.6g per bowl (40g serving) 
Crunchy Nut Clusters 5% 0.5g per bowl (40g serving) 
Honey Nut Branflakes (Tesco) 5% 0.5g per bowl (4og serving) 
Weetabix Minis: honey nut crisp 7% 0.7g per bowl (36g serving) 
Chocolate bars/sweets:   
Snickers (Mars) 17% 2.9g per bar (64.5g) 
Peanut M&Ms 22% 2.6g  per 45g pack 
Cadbury’s Star Bar 20%  2.8g per bar (53g) 
Cadbury’s Fuse 7% of 49g bar 3.43g per bar 
Cadbury’s Picnic 10%  1.2g per bar (48g) 
Reese’s Peanut Butter Cups 29%  1.3g per cup (3 cups in 51g packet) 
Reese’s nutrageous bar 28% peanuts 
23.5%peanut butter 
7.7g.per bar (60g) 
Miscellaneous:   
Satay sauce  25g peanut in typical serving 
Snickers ice cream (Mars) 12% 1.5g per bar (48g) 
Peanut soup (one bowl)  54g peanut in typical serving 
West African dish   27g (range 8.5 - 45g) 
Thai dish     7g  (range 7 - 10g) 























































10.5 Appendix 5: Participant questionnaire 
A participant questionnaire was created in order to be able to account for factors independently affecting 
peanut levels in dust and for factors that might create discrepancies between the dietary questionnaire and 
environmental peanut levels in dust and wipes. The number of families living in the home was recorded, as I 
sometimes visited homes with more than one family living together who shared the same kitchen. In such 
situations, although there was shared EPE, the main carer of one family was not able to document how many 
peanut-containing foods members of the other family were eating. In our preliminary work I also ascertained 
that sometimes pets were fed peanut. In one particular home the family owned a pet parrot who ate peanuts, 
thus although the family was a low peanut consuming family there were still detectable levels of peanut in 
their home.   
 
The accuracy of the peanut data were at risk of compromise by whether, as requested, the family had left the 
bed-sheets in place for at least 5 days prior to vacuuming. For example a clean bed-sheet would be less 
likely to have peanut levels in dust which reflect peanut levels in dust in the rest of the home. Age of the 
parental and infant mattress was captured as this has been shown to affect the concentration of inhalant 
allergens (i.e. the older the mattress the more HDM was found).
(462-464)
 As maternal mattresses are usually 
older than infant mattresses, information was collected on whether the infant slept in the mother’s bed or in 
their own cot. Use of an ‘anti-allergy’ mattress cover was also recorded as this has been shown to reduce 
indoor allergen exposure (in particular HDM) in previous studies. 
(299;301)
 The material of the parent and 
infant eating table was assessed as previously I found that the type of table surface influenced persistence of 
peanut protein despite cleaning with detergent (peanut persisted more on wood followed by laminate 
followed by granite surfaces). 
(465)
 The questionnaire used for household and demographic factors is 





Table 20: Participant questionnaire on household and demographic factors 
Flat or house 
 
 Number of bedrooms: 
 
All household members sampled? 
 
 Reason 
Number of siblings of infant 
 
 Ages: 
Number of ‘other’ household members 
 
 Day/ Day and night time 
household members 
Number of families in home 
 
 Kitchen Use Yes/No 
Bed-linen left for >/=5 days? 
 
  
Infant sleeps in maternal bed or cot 
 
  
Location of infant’s cot 
 
  
Age of infant’s mattress 
 
 Type of Mattress 
Mattress cover? 
 
 Type of Mattress cover 
Age of parent mattress 
 
 Type of Mattress  
 
Mattress cover?  
 
 Type of Mattress cover 
Location of infants’ play area 
 
  






Infant eating table used 
 
 Material 
Parent eating table used 
 
 Material 










10.6 Appendix 6: Recruitment and study procedures for publication 1 and 2 
Recruitment and consent process  
Details of the participant recruitment process are provided in Figure 37. Participants were recruited from a 
tertiary allergy clinic. During the clinic consultation they were asked whether they would be interesting in 
participating in this study and, if so, provided with a participant information sheet (Figure 38, p367). During 
their appointment they were given time to read through the information leaflet (whilst waiting for allergy 
testing or dietetic review) and had the opportunity to discuss the study with the researcher (myself). If they 
agreed to participate then written consent was obtained in clinic and a copy was given to the parent. If 
parents wanted more time to consider the study then they were called 2-3 days later and a home visit was 
arranged at this point. In this scenario the consent form was signed in the parent’s home and a copy of the 
consent form was sent in the post following the home visit. Families were asked to avoid washing their bed-
sheets and vacuuming their infant’s play-area for 5 days prior to the home visit. 
 
Home visit 
For safety purposes and to abide with the Lone worker Policy, the date, time and location of the home visit 
were recorded either with Professor Lack’s secretary or a member of the laboratory team.  If the family had 
not yet given written informed consent, this was obtained prior to any environmental sampling or 
questionnaire completion. Once the consent form was signed the family were asked to complete the FFQ 
and household factor questionnaire whilst dust and wipe samples were collected.  Wipe samples were 
obtained from the parent table, infant high-chair table, tap, dishwasher-handle, fridge-handle and infant cot-
rail. Dust samples were obtained from the beds of all household members and from the infant’s play area. 
Parents usually slept in the same bed, thus dust samples were taken from each side of the bed. The infant’s 
play-area was designated as the place where the infant spent most of their day such as the Moses basket, 




minute within a 0.5m
2
 surface area. Other bed-sheets and the infant’s play-area were vacuumed for 2 
minutes within a 1m
2
 surface area. After environmental samples were collected, the FFQ was reviewed with 
the family to ensure that it had been filled out correctly.  




















Figure 38: PIS for HPC and EPE study 

























10.7 Appendix 7: How to depict correlation plots for Publication 2 
A review of the British Medical Journal, The Lancet and the New England Journal of Medicine during 1997 
found that correlation scatterplots were often incorrectly represented. 
(466)
 Porter et al. (1999) found eight 
errors (detailed below) which they deemed to be important either because they considered them to be major 
errors or due to the frequency with which they occurred.  
 
1. Failure to state in the text the number of cases used in a correlation coefficient.  
2. Citing a correlation coefficient without a 95% confidence interval 
3. The inappropriate use of a regression line through a scatterplot of a correlation 
4. Failure to justify the inclusion of outliers 
5. Use of correlation when numbers were very small 
6. Use of Pearson correlation in non-parametric data 
7. Progressive increase or decrease in spread of dots around the regression line  
8. Attaching importance to a significant P-value with a low correlation coefficient.  
 
I adopted these principles when constructing the scatterplots published in Publication 1 and 2; for example, 
the highest peanut consumers in the correlation plots in Publication 2 (where both parents and infants were 
consuming peanuts) were removed and the correlation coefficients were repeated to assess the impact of 





















10.9 Appendix 9: Tryptic digest SOP 
10.9.1 KCL SOP: Trypsin digest for Ara h 1 to use on Mass Spectrometer 
1. 50 µL of (2 mg/ml Ara h 1 protein stock in H2O) was prepared.  
2. Serial dilutions were prepared: 
 100µg/ml (50 µl of 2000µg/ml solution) 
 10 µg/ml (add 450µl water to 50 µl protein and take 50 µl of this) 
 1 µg/ml (add 450µl water to 50 µl protein and take 50 µl of this) 
 500 ng/ml (add 50µl water to 50 µl protein and take 50 µl of this) 
 250 ng/ml (add 75µl water to 50 µl protein and take 50 µl of this) 
 50 ng/ml (add 50µl water to 50 µl protein and take 50 µl of this) 
 10 ng/ml (add 40µl water take 10 µl of this) 
3. 50 µl of tetrafluoroethylene (TFE) was added to the protein solution to denature the protein and the 
solution was vortexed (protein concentrations may vary but the volume of 50 µl remains the same).  
4. The addition of 11 µl of 150mM Dithiothreitol (DTT) to give 15mM DTT was then carried out and 
the solution was heated to 55
o
C for 45 min. This breaks up disulphide bonds. To make up DTT 
(154g/L=1M) need 0.23g (flakes) in 10ml deionised water (make up fresh every time) 
5. The samples were cooled to room temperature (~5min) and then 12 µl of 550mM iodoacetamide 
(IAM) was added to give 55mM IAM.  IAM stabilises the mixture whilst preventing any new 
disulphide bonds by binding to the thiol group of the cysteine residue. To make IAM 550mM need 
0.501g of stock (184.96g/L=1M) in 5ml deionised water  (make up fresh every time) The solution 
must then be incubated in the dark at room temperature  for 30 minutes.  
6. The sample was diluted by adding 880 µl of 50mM Tris + 2mM CaCl2 pH 8.0 (to achieve 5% TFE 
concentration). For Promega sequencing grade calcium is not required. TRIS available is at pH 10.5 




7. Trypsin (Promea sequencing grade) was then diluted with TRIS (1:500) in order to have a dilute 
sample enough to pipette down to 10ng of Ara h 1. If 10 µg=20µl of original solution then add 12 µl 
to 2988µl of TRIS to make up 1:500 fold dilution. Final concentration of 1:50 enzyme:protein was 
made and the solution was incubated at 37
o
C overnight.  
8. Following overnight incubation, 10 µl of formic acid (to get 1% v/v total) was added to stop the 
digestion. Formic acid 0.25M was multiplied up by 32 (0.25x32=8M which is 100%) 
9. The sample was cleaned up using solid phase extraction. A C18 column (Varian bond elut) was 
placed in a vacuum box and primed first by the addition of 2 ml of methanol (add 2 x 1 ml) and then 
2ml of H2O (add 2 x 1 ml).  
10. 20µL of the peptide mixture was then injected onto the RP-LC column and analysed using LC-




10.9.2  University of Manchester Trypsin digest protocol 
1. Chemicals were obtained from Sigma-Aldrich (Poole, Dorset, UK) unless indicated otherwise.  
2. Extracted dust samples were sequentially reduced, alkylated and digested using an in solution 
protocol designed to reduce volumes of reagents and therefore maximise protein concentration in the 
final sample as follows.  
3. To 5 µl sample 10 µl of 250 mM ammonium bicarbonate and 4 µl of 50 mM dithiothreitol (DTT) 
were added prior to heating at 80
o
C for 10 min.  
4. Samples were then incubated at room temp for a further 20 min before the addition of 4.5 µl of 150 
mM iodoacetamide.  
5. Alkylation was performed at room temp for 30 min in the dark.  
6. Samples were then digested by the addition of 2.5 µl of 0.1 mg/ml trypsin with incubation at 37oC 







10.10 Appendix 10: Airborne peanut experiments 
The Casella Tuff personal air sampling monitor (Figure 39) to measure airborne peanut was recommended 
by Professor Frank J Kelly PhD, Director of the Analytical & Environmental Sciences Division at King’s 
College London University who has extensive experience in environmental air sampling methods. The 
Casella Tuff personal air sampling monitor has been used in previous studies to measure other airborne 
indoor allergens (HDM allergen in the homes of asthmatic children), 
(401)
 and is easily portable, has 
controllable airflow control and the pump has a long (22 hour) battery life; it could therefore be left running 
for a long periods of time, which was particularly useful when the air sampling monitor was left overnight in 
different homes in the attempt to detect airborne peanut.  
 
Figure 39: Casella Tuff personal air monitor and Whatman glass-fibre filters  
 
 
The pump was run at 2 litres (L) of air per minute as recommended by the manufacturer. This is equivalent 
to an infant’s respiratory minute volume: tidal volume (5 ml/kg) x respiratory rate (40 breaths per minute) 
using an estimated infant weight of 10 kg. Whatman glass-fibre filters with a pore-size of 0.7 µm were 
inserted into the IOM sampling head. These glass fibre filters were extracted using the Veratox peanut 
ELISA kit extraction solution in the same way that surface wipes were extracted (see Publication 1 online 
Glass fibre filters (pore-size 0.7 µm) 
Inhalable occupational medicine 
(IOM) sampling head 




repository).  To convert from the results obtained in the Veratox ELISA read-out to µg/m
3 
the following 
calculations and assumptions were used: 
1. Veratox ELISA results for whole peanut divided by four to obtain peanut protein, thus for 
example 1000ng/ml whole peanut equates to 250ng/ml peanut protein. 
2. Glass-fibre filter is extracted in 2ml extraction solution thus multiply result by 2 to obtain results 
in ng/ml, thus 250ng/ml would become 500ng/ml 
3. To convert from ng/ml to µg/m3 the following information was utilized: 
a. Casella pump runs at 2 litres (L)/min  
b. For the majority of experiments the Casella pump was run over 10 minutes which equates to 
20 L of air suctioned 
c. There are 1000 L of air in 1m3 of air thus 20 L of air = 0.02 m3of air 
d. Therefore results for a 10 minute Casella pump run were divided by 0.02 to give value in 
µg/m
3
, thus 500 ng/ml would equate to 25 µg/m
3
 
e. Thus overall 1000ng/ml whole peanut  equated to 25µg peanut protein per m3 
The Veratox polyclonal peanut ELISA LLQ was 100 ng/ml (equivalent to 2.5 µg/m
3
).  
The following experiments performed to detect airborne peanut are depicted in Figure 40. 
The sampling head was held 1 cm (n=3) and 1 m (n=3) above a peanut butter jar/dry roasted peanut bag for 
22 hours and above a simmering pan of satay sauce (Amoy, UK) (10.8 grams peanut) for 10 minutes.  
 
1. Whilst eating peanut butter or dry roasted peanuts, the sampling head was pinned to the researcher’s 
clothes, on the dining-room table, breathed on for 10 minutes or placed overnight on the bedside 




2. The IOM was run for 22 hours in homes with high peanut protein levels in dust (n=5, median peanut 
protein 163.8 μg/gm, range 51.2-365.2 μg/gm). 
 
3. The sampling head was held 1 cm and 1 meter above peanuts being deshelled. New glass fibre filters 
were run in the IOM for 10 minutes before, during, immediately after, 30 minutes and 1 hour after 
deshelling peanuts (n=6). 
Figure 40: Airborne peanut experiments with IOM: over peanut butter jar (a), simmering satay sauce (b), 
KP peanut bag (c), bed-side table overnight (d) 1cm above shelling peanuts (e) 
(a)                                 (b)                                    (c)                             
    
(d)                          (e) 





10.11 Appendix 11: MAAS PA definition and dust collection methodology  
10.11.1 Details of PA definition in MAAS 
All children with evidence of PS at age 8 years (peanut SPT ≥3mm or sIgE ≥0.2kUA/L) were offered an 
OFC to peanut. Open OFCs were applied amongst children who had a history of tolerating peanut on 
consumption; all other children underwent a DBPCFC.
(468)
 OFCs were considered positive after 
development of at least two objective signs indicating an allergic reaction; these included flushing, pruritus, 
urticaria, angioedema, abdominal tenderness with increased bowel sounds, vomiting, diarrhoea, sneezing, 
rhinorrhoea, cough, hoarse voice, stridor, wheeze, >20% fall in FEV1, >30% drop in blood pressure or loss 
of consciousness. 
(468)
 Children with a convincing history of an immediate hypersensitivity reaction upon 
exposure to peanut, combined with: (1) peanut sIgE ≥ 15kUA/L
(149)
 and/or SPT ≥ 8mm(18) (age 8 years) were 
considered peanut allergic and did not undergo OFC. Previously this cohort showed that using a cut-off of 
peanut sIgE ≥ 15kUA/L had excellent specificity of 96.2% thus correctly classifying peanut allergic children, 
however a relatively poor sensitivity of 55.2% thus falsely classifying children with peanut sIgE < 15kUA/L 
as peanut tolerant. Thus using this 15kUA/L cut-off to not challenge children to peanut would have resulted 
in 3.8% of children being incorrectly classified as peanut allergic when they were tolerant; however, 
children with peanut sIgE <15kU/L did undergo OFC thus this decision was not affected by the low 
specificity of peanut sIgE using a cut-off of 15kUA/L. 
 
Children with a convincing history of an immediate hypersensitivity reaction upon exposure to peanut and 
SPT ≥ 3mm who refused consent for OFC were either excluded from analysis or considered peanut allergic 
based on Ara h 2 ≥ 0.35 ISU at subsequent follow up at age 11 years.(468) Previous work by Nicolaou et al. 
(468)
 showed that Ara h 2 was the most important component allergen to accurately discriminate between PA 
and peanut tolerant subjects (see Figure 41). Using an ImmunoCAP cut-off of Ara h 2 ≥ 0.35kU/L correctly 




diagnosing all children with PA, but specificity was 96.1% thus resulting in 2 children receiving a false 
positive PA diagnosis.   
 
Figure 41: ROC curve for PA versus tolerance using whole peanut versus component allergens.  




10.11.2 MAAS dust samples collection procedure 
Dust samples were collected predominantly at 36 weeks gestation from a 1m
2
 area of the lounge-sofa as 
previously described.
(463)
 If no dust sample was available antenatally from the lounge-sofa then dust samples 
from 6 or 12 months were analysed for peanut protein (where available).  The sampling head was loaded 
with a mesh filter, to remove particles >300 µm diameter (such as carpet fluff and gravel) allowing a sample 
of fine dust to be collected onto a 5 µm pore size vinyl filter (Plastok Associates Ltd, Wirral, UK). 
Immediately after collection, the dust sample was transferred into pre-weighed petri dishes and coded in the 
Manchester Immunity and Inflammation Laboratory. Dust processing and extraction was already performed 




MAAS dust collection procedure: 
The sampling head was loaded with a mesh filter, to remove particles >300mcm diameter (such as carpet 
fluff and gravel) allowing a sample of fine dust to be collected onto a 5 mcm pore size vinyl filter (Plastok 
Associates Ltd, Wirral, UK). Immediately after collection, the dust sample was transferred into pre-weighed 
petri dishes and coded. On return to the laboratory the filled petri dish was weighed to calculate the mass of 
fine dust collected and stored at -4 
o
C until extraction. After each sample collection the sampling head was 
cleaned using an Alcowipe to prevent contamination of subsequent samples. 
 
MAAS dust extraction procedure: 
A 100 mg* aliquot of the dust was then extracted by rotation with 2  ml borate-buffered saline with 0.1% 
Tween 20 pH 8.0**, at room temperature for 2 hours before being centrifuged for 20 minutes at  2500 rpm 
at 4oC. The supernatant was stored at -20 
o
C until analysed for allergen content. 
* For samples weighing <50mg, 1ml of borate-buffered saline (0.1% Tween 20, pH 8.0) was added for 
extraction. For samples weighing 50mg-100mg, a proportional amount of borate-buffered saline was added, 
e.g. for a sample weighing 75mg, 1.5ml of buffer would be added. 
** Borate-buffered saline: A concentrated stock solution was made with 360g NaCl, 12.2g Boric  acid and 
19.5ml NaOH (1N). This stock solution was made up to 2 Litre with distilled water. A working solution was 
made by diluting the above stock solution by   20-fold with distilled water. 1/1000 (0.1%) volume of Tween 





10.12 Appendix 12: FLG loss-of-function mutations and genotyping in MAAS and CoFAR 
10.12.1 FLG loss-of-function mutations 
Six FLG loss-of-function mutations (R501X, 2282del4, S3247X, R2447X, 3673delC and 3702delG) 
associated with eczema in individuals of European Caucasian descent were assessed. The mutations for 
these FLG polymorphisms are described as follows:  
R501X: 
 ARG501TER’ arg501-to-stop (R501X) mutation arises from a G (guanine) to A (adenine) point 
mutation (DNA) (or C (cytosine) to T (thymine) transition on probe) near the start of repeat 1 in exon 3 of 
FLG gene.  
 In wild type FLG this sequence (CGA in RNA) codes for the amino acid arginine however 
individuals with R501X mutations the UGA RNA sequence codes of a premature stop codon.  
 Minor allele frequency (MAF) for this mutation (G (guanine) to A (adenine) point mutation) is 5%.  
2282del4: 
 Not a SNP but a 4 base pair (bp) deletion 
 4-BP deletion of CAGT acts as a stop mutation 
 The 2282del4 mutation leads to a premature termination codon 107 bp downstream and, like R501X,        
stops protein translation within the first filaggrin repeat. 
R2447X: 
 R2447X mutation arising from a C-to-T transition (same mutation as R501X) near the start of repeat 
8 in exon 3 of the FLG gene.  
 WT: CGA (RNA) codes for Arginine amino acid  





 S3247X mutation arising from a transition from G to T (DNA) (C to A on probe) near the start of 
repeat 9 in exon 3 of the FLG gene 
 WT: UCA (RNA) codes for serine amino acid  
 MUT: UAA codes for nonsense (premature stop codon) 
3673delC: 
 Deletion of cytosine base in FLG repeat 3 in exon 3  
 Codes for nonsense (premature stop codon) 
3702delG: 
 Deletion of guanine base in FLG repeat 3 in exon 3 
 Codes for nonsense (premature stop codon) 
 
10.12.2 DNA Extraction 
DNA was extracted from PBMCs using a standard DNA extraction kit. The amount of DNA was normalised 
following extraction to ensure consistency between patients prior to FLG genotyping.  This was achieved by 
diluting DNA with water to achieve a 100ng/µl solution. 
 
10.12.3 Real-time quantitative polymerase chain reaction 
FLG genotyping employs the use of real-time quantitative polymerase chain reactions (RT-qPCR) thus I will 
explain this assay in more detail. PCR is a method whereby a specific region of DNA can be targeted for 
amplification, eliminating the need for large quantities of DNA. The PCR Mastermix contains DNA 
extracted from PBMCs (normalised for each patient), FLG primer sets, deoxynucleoside triphosphates 





1. dNTPs are molecules which contain a nucleoside (A, C, G, and T, which stand for adenine, cytosine, 
guanine, and thymine) bound to three phosphates and are the building blocks of DNA. 
 
2. Primers are short oligonucleotides, which are complementary to specific regions of the DNA 
template to be amplified. These have been designed specifically for each FLG polymorphism of interest and 
are described in Error! Reference source not found..
(268)
 There is a forward primer which allows DNA 
polymerase to add dNTPs to the unzipped DNA strand in a 5’ to 3’ direction.  
 
There is a second reverse primer which allows DNA polymerase to add dNTPs to the unzipped DNA strand 
in a 3’ to 5’ direction. The primers do not bind to the target DNA sequence; this is identified using specific 
probes for the wild-type or mutant allele.  
 
3. Probe sets are short oligonucleotides, designed to hybridize to the DNA sequence of interest, 
synthesised between the forward 5’ and reverse 3’ primers. These probes contain a fluorescent reporter 
molecule (such as 6-carboxyfluorescein (FAM) or VIC®) linked covalently to the terminal base nucleotide 
at the 5’ end of the probe and a quencher molecule (such as MGB-NFQ (non-fluorescent quencher) or 
tetramethylrhodamine (TAMRA)) linked covalently to the terminal nucleotide at the 3’ end of the probe. 
Probes cannot be extended by Taq DNA polymerase as they lack a free hydroxyl group. These have been 




4. DNA polymerases are enzymes, which catalyse the synthesis of DNA strands from dNTPs using an 
existing strand of DNA as the sequence template. Taq DNA polymerase from Thermus aquaticus is a 
thermostable DNA polymerase which means that the enzyme is able to withstand denaturation temperatures 




Additionally Taq DNA polymerase has 5'-3' exonuclease activity; this disassembles the probe bound to the 
DNA sequence of interest that is in its way whilst it is building the second strand of DNA. This exonuclease 
activity is how the fluorescent reporter probe method works (described below).  
5. Magnesium ions (Mg 2+) are an essential cofactor for PCR as Mg2+ forms a soluble complex with 
dNTPs, which is essential for incorporation of the subunits. Mg
2+
 also stimulates the DNA polymerase 
activity.  
6. Buffer is used to ensure a suitable pH for the PCR reaction to take place. 
Table 21: Primers and probes for FLG mutation screening.  
Point mutations highlighted in bold for R501X, R2447X and S3247X.  
Mutation Primer pairs Probes 
R501X 
Forward 5’CAC TGG AGG AAG ACA 
AGG ATC G 3’ 
Reverse 5’ CCC TCT TGG GAC GCT GAA 
3’ 
Wild type 5’ 6-FAM-CAC GAG ACA GCT  C-
MGB-NFQ 3’ 
Mutant 5’ VIC-CAT GAG ACA GCT CC-
MGB-NFQ 3’ 
2282del4 
Forward-1 5’ TCC CGC CAC CAG CTC C 
3’ 
Forward-2 5’ CCA CTG ACA GTG AGG 
GAC ATT CA 3’ 
Reverse 5’ GGT GGC TCT GCT GAT GGT 
GA 3’ 




Forward-1 5’ ACG TGG CCG GTC AGC A 
Forward-2 5’ AGC ACT GGA GGA AGA 
CAA GGA T 3’ 
Reverse 5’ CCT GAC CCT CTT GGG ACG 
T 3’ 
Wild type 5’ 6-FAM-CAC GAG ACA GCT  C-
MGB-NFQ 3’  
Mutant 5’ VIC-CAT GAG ACA GCT CC-
MGB-NFQ 3’  
S3247X 
 
Forward 5’ CCA GAA ACC ATC GTG 
GAT CTG 3’ 
Reverse 5’ TGC CTG ATT GTC TGG AGC 
G 3’ 
Wild type 5’ 6-FAM-CAG TCA AGG CAC 
GG-MGB-NFQ 3’ 







10.12.4 Background of RT-qPCR technique 
The first step of RT-qPCR is where the two DNA chains of the double helix are ‘unzipped’ by disrupting the 
hydrogen bonds at 98 ºC (denaturation step). The temperature in the thermocycler then reduces to between 
50-65 ºC (annealing step). At this stage primers hybridise to DNA sequences at each end of the target DNA 
sequence.  Taq DNA polymerase catalyses the synthesis of DNA strands from these primers adding 
complementary dNTPs to the existing strand of DNA to reform a double stranded DNA chain (extension 
step). The intervening DNA is thus synthesised by DNA polymerase reactions in opposite directions. As a 
result, two double stranded DNA copies are produced of the target DNA.  Thus, for each PCR cycle the 
DNA sequence of interest is amplified 2 fold. 
 
Real-time quantitative PCR uses a fluorescent reporter probe method and allows for quantification of the 
amplified DNA sequences (or amplicons) as they are generated during the PCR cycle. The fluorescent 
reporter probe method detects only DNA sequences contained within the probe, thus allows for specific 
detection of the DNA sequence required, even in the presence of non-specific DNA amplification. There is a 
fluorescent reporter molecule at the 5’end of the probe and a quencher molecule at the 3’ end of the probe. 
While the probe is intact, the proximity of the quencher dye rapidly absorbs any light emitted by the reporter 
dye by a process called fluorescence resonance energy transfer (FRET).  
 
The probe anneals downstream from one of the primer sites and is cleaved by the exonuclease activity of the 
Taq DNA polymerase as the forward or reverse primer is extended. The nucleotide carrying the reporter 
molecule (fluorescent marker) and the nucleotide carrying the quencher molecule are thereby separated from 
one another and the fluorescent marker can now emit detectable light when stimulated by a laser. Thus, as 
the number of amplicons doubles in each PCR cycle so the amount of fluorescent energy also doubles; this 





10.12.5 RT-qPCR system employed for FLG genotyping 
Genotyping for R501X, S3247X and R2447X FLG loss-of-function mutations was performed using a 
Taqman based allelic discrimination assay (Applied Biosystems, Life Technologies, Cheshire, UK). 
(260)
 The 
ABI PRISM® 7700 Sequence Detection System is a fully integrated RT-qPCR system which includes a 
built-in thermal cycler, a laser to induce fluorescence, charge-coupled device detector, real-time sequence 
detection software, and TaqMan® reagents for the fluorogenic 5' nuclease assay. Primer and probe sets were 
ordered from ABI (Warrington, UK). The FLG wild-type probes were labelled with FAM reporter dyes and 
the FLG mutant probes were labelled with VIC® reporter dyes in order to be able to differentiate these 
alleles.  Applied Biosystems Universal PCR Master mix, reaction volumes of 10 ul and 30ng of DNA were 
used. Primers were used at 500 nM and probes at 300 nM and 1.5mM of Magnesium Chloride (MgCl) was 
already added to the PCR Mastermix. The cycling reaction was as follows: 95 ºC for 10 minutes, then 40 
cycles of 92 ºC for 15 seconds and 60 ºC for 1 min. Using the plate type ‘Allelic Discrimination’ the ABI 
PRISM® 7700 Sequence Detection System, the different alleles are identified by their respective fluorescent 
marker (Figure 42). 
 













10.12.6 Sizing of a fluorescent-labelled PCR fragment  
Mutation 2282del4 was genotyped by sizing of a fluorescent-labelled PCR fragment on a 3100 or 3730 
DNA sequencer (Applied Biosystems). The primers were ordered from Metabion, Planegg-Martinsreid, 
Germany. For this technique two primers were used and no probes. The forward primer was labelled with 
the fluorescent dye FAM and the reverse primer was not labelled. PCRs were performed in 10µl reaction 
volumes in 384 well plates and contained 40ng genomic DNA per reaction.  The PCR Mastermix was made 
up of the following; Water (5.75ul), 10 X buffer (1ul), 2282del4 Forward 2 primer (0.1ul), 2282del4 
Reverse 1 primer (0.1ul), dNTPs (1ul), Taq DNA polymerase (0.05ul). PCR reactions were amplified by 
heating to 95 ºC for 15 minutes (initializing step), then 40 cycles of 95 ºC for 20 seconds (denaturation step), 
61 ºC for 30 seconds (annealing step) and 72 ºC for 30 seconds (extension step) then 72 ºC for 10 minutes. 
The product was pooled with 3 other fragments – diluted 1:4, and 1ul of the diluted and pooled products 
were added to 5ul of formamide and 0.2ul ROX size standards. The product was then run on the ABI 3100. 
Data were analysed and the fragments were sized using the Genescan software. Genotypes were assigned 
based on size; the smaller mutant fragment was 192bp and the larger wild-type fragment was 196bp.  
 
10.12.7 GeneScan analysis 
FLG loss-of-function mutations 3673delC and 3702delG were assessed by GeneScan analysis of 
fluorescently labelled polymerase chain reaction (PCR) products. Initially screening was performed by 
sizing of fluorescent labelled PCR products through ‘Genescan fragment analysis’ (GeneMapper 4.1, 
Applied Biosystems), as the 3673delC and 3702delG has one less base than the wild-type genes. The 
heterozygous 3673delC mutation is 223bp versus wild-type which is 224bp (Figure 43). Following 
screening, DNA sequencing was performed to assess where the deletion had occurred. The guanine deletion 
in one allele led to the two alleles becoming out of sync thus overlapping base pairs highlighted where this 




Figure 43: Genescan fragment analysis of FLG 3673delC.  
 
 






10.13 Appendix 13: Statistical analysis for MAAS and CoFAR 
10.13.1 Comparison of demographics and clinical characteristics  
In all cohorts, demographics and clinical characteristics of participants (see Section 6.14) were compared 
between the group of participants that were included in the LR analysis i.e. those with available dust for 
analysis and FLG genotyping (and in the case of the CoFAR study infantile eczema) versus demographics 
and clinical characteristics from excluded participants. This was performed to assess whether the included 
group was biased towards more atopy, PS or PA as this could affect the results obtained.  Demographics and 
clinical characteristics on information were compared using Chi-squared test for proportions (such as peanut 
SPT and sIgE data), Student’s t-test for normally distributed data (such as age at assessment of child) and 
Mann-Whitney U for non-normally distributed data (such as peanut protein levels in dust).  
 
10.13.2 Logistic regression (LR) analysis 
Theory of the LR model 
LR can be used to predict a categorical dependent/ outcome variable on the basis of continuous and /or 
categorical independent or predictor variables to determine the effect size on the outcome variable in terms 
of odds ratios.
(469)
 The LR function f (z) is defined by the equation in f(z) = 1/ (1-e
-z
); where z (logit) equates 
to α0 + the sum of (β*x);  α0 is the constant of the equation (intercept) and β is the regression coefficient of 
the predictor variable x.  In a multivariate LR model there can be several predictor variables (e.g. FLG 
genotype, atopic eczema and parental atopy) which are added together. In the LR equation the risk of the 
outcome variable (z) always falls between 0 and 1 regardless of its estimate which is useful for predicting 








Application of the LR model 
LR analysis was used to determine risk factors for PS and PA. PS/PA was used as the dependent (outcome) 
variable and the independent (predictor) variables included FLG genotype, atopic eczema, egg sensitization 
and other predictors of PS/PA. Log transformation was used for peanut protein levels in dust in order to 
reduce the extent of skewing of this variable; however, as the independent variable in a LR analysis, normal 
distribution is not mandatory. Univariate followed by multivariate LR analysis was performed to adjust for 
variables which showed a trend towards an association with PS or PA (see Section 6.14).  Highly related 
predictor variables such as presence of eczema and severity of eczema were not included in the same LR 
model, as the model would become unstable. Where FLG mutations were entered into the multivariate 
statistical model, participants with non-Caucasian or missing ethnicity data were excluded from the analysis 
as the FLG loss-of-function mutations assessed have only been associated with eczema in Caucasian 
European populations. 
(257;277)
 In LR models where the outcome variable was a very small proportion of the 
total number of participants (such as PA), a penalized LR model was used to adjust for unbalanced data.
(471)
 
The number of covariates in the multiple logistic regression model were reduced following review by the 
JACI so that only those covariates with the highest clinical relevance were included in the final model. 
Additionally goodness of fit analyses for regression models were used to ensure that the addition of each 
covariate improved the fit of the model. 
 
Longitudinal LR analyses 
In MAAS analysis of PS was repeated at different time-points which allowed for longitudinal LR analysis. 
A penalized Generalized Estimating Equations (GEE) via quasi-least squares approach was used with an 
exchangeable working correlation matrix to account for repeated measures within individuals who were 
assessed at different ages.
(472)
 GEE represents an extension of the generalized linear model (GLM) to allow 
for analysis of repeated measurements or other correlated observations such as clustered data. 
(473)




study, PS assessment at two time-points meant that there was clustering of data at these two time points, 
however genetic and lifestyle factors which would stay consistent over time would be a source of within-
person correlation over time. The working correlation matrix represents the within-subject dependencies 
which can have one of the following structures: independent (no correlation between repeated measures), 
autoregressive (where correlation diminishes exponentially with time), exchangeable (assumes a constant 
time dependency), M-dependent (correlation does not change with time until it drops to zero at time M) and 
unstructured (correlations are estimated without constraints). 
(474)
An exchangeable working correlation 
matrix was chosen for the GEE analyses as it was assumed that the within person correlation would not 
change with time. GEE has the advantage that it provides consistent regression parameter estimates 
regardless of the choice of working correlation structure.  GEE was used for PS status only and not PA as 
PA was thought to be a more permanent state (i.e. you are either peanut allergic or not) whereas PS could be 
more variable over time. 
 
10.13.3 Relationship between EPE and skin barrier function  
Wald’s test was used in the LR model to assess the interaction of EPE and FLG genotype or eczema on 
PS/PA. Statistical analysis involved a logistic model to investigate the relationship between the probability 
of PS/PA and EPE and markers of atopy or skin barrier impairment in each study.  The hypothesis was 
assessed by testing the significance of the interaction slope using Wald’s test (two-sided with P<0.05) in the 
LR model: log (Probability sensitization / (1-Prob Sensitization)) = a + bEXPE + bFILM + bINTExM.  
Where EXP = EPE, FIL= FLG genotype and INT = Interaction 
 
The measure of EPE in this model was the log of the peanut concentrations in the dust samples and M was 
an indicator variable with value 1 for FLG loss-of-function mutation or eczema and 0 for wild-type FLG 




and with FLG wild-type was also assessed using the equation: e




In CoFAR, the relationship between EPE and eczema on PS/PA was also assessed in a stratified analysis 
comparing all children, children with a history of eczema and children with a history of severe eczema. The 
predictive probability of PS and PA was calculated from the univariate and multivariate regression model in 
order to create the predictive probability plots in both MAAS and CoFAR studies. 
 
Threshold levels for environmental peanut protein in dust 
In MAAS threshold levels for peanut protein in dust for PS and PA were calculated using the intersection 
between FLG wild-type versus mutation in the multivariate regression model. To evaluate the 
reproducibility of the thresholds obtained and uncertainty around these thresholds bias corrected bootstrap 
cross-validation was performed with 1000 replications to determine 95% CI for threshold peanut protein in 
dust levels. Bootstrapping is the preferred method for internal validation where data for model development 
and evaluation are both random samples from the same underlying population.
(475)
 Bootstrapping is 
performed by the bootstrap sample being drawn from the same number of patients (n) as in the original 
sample, but some are excluded, others included once, twice, etc. (called replacement). The model is 
developed in the bootstrap sample, and then validated in the original sample; thus it is called internal 
validation. To obtain stable results, the procedure is usually repeated 1000 times. The bias corrected 
bootstrap confidence intervals were used rather than percentile confidence intervals because the distribution 





10.14 Appendix 14: Optimisation of techniques for mechanistic assays in Publication 5 
10.14.1 Selection of culture medium 
Initial peanut cultures were performed using RPMI 1640 culture medium (Sigma-Aldrich Company LLC) 
with 5% autologous serum. The serum was created by spinning down plasma at 3000 rpm for 5 minutes at 
room temperature followed by passage through a sterile filter to remove all debris. Two problems were 
encountered after performing cultures with RPMI 1640 with 5% autologous serum: on some occasions 
clotting occurred in the culture well and there was insufficient RNA yield for microarray hybridisation. I 
thought that clotting might be trapping cells in the culture wells that were required for FACS sorting, thus a 
serum free medium was considered which has been shown to be effective in human T cell culture.
(476;477)
 
Advantages of using a serum free medium were the lack of coagulation factors, likely increased yield of 
cells following culture, and a standardized culture method, given the variability of autologous serum from 
each individual. Drawbacks were increasing the artificiality of the experimental system by removing serum 
factors (including IgE which could lead to facilitated antigen presentation) and the possibility of higher 
background Th cell activation due to properties within the serum free medium; however, given that gene 
microarray would differentiate between gene expression from peanut stimulated versus unstimulated 
cultures it was thought that this would counteract any non-specific stimulation related to the culture medium.  
 
 
Thus, the serum free medium AIM-V® (Adoptive Immunotherapy Media) containing 50ug/ml Streptomycin 
sulfate and 10ug/ml Gentamycin sulfate was used in addition to 2-Mercaptoethanol (2-ME) (both from 
Invitrogen Life Technologies, Thermo Scientific Inc, UK), with a stock solution of  0.04mM 2-ME per 1ml 
of AIM-V® medium. AIM-V® is a proprietor medium based on Dulbecco’s modified Eagle medium and 
Ham's F-12 nutrient mix, supplemented with Tween-80, human albumin and transferrin, linoleic and 
palmitic acid.
(478)




biological antioxidant and is therefore used in cell culture. 
(479)
 No further clotting was found in the culture 
wells and the number of cells sorted became sufficient for further analysis. 
 
 
10.14.2 Peanut protein concentration for stimulating cultures 
Cultures were stimulated in 200µg/ml whole defatted peanut protein extract (ALK Abello) or serum-free 
medium for 18 hours to detect early allergen-specific response as previously described.
(79)
 A ratio of 90% 
peanut stimulated versus 10% non-stimulated was used in order to ensure that there were enough peanut 
stimulated cells for RNA extraction. The optimum concentration of peanut extract was previous established 
by titration experiments by culturing PBMCs in different peanut concentrations to determine the levels of 
PBMC proliferation in peanut allergic versus NA individuals; 
(480)
 there were good PBMC proliferative 
responses at day 5 in doses above 100µg/ml peanut antigen (see Figure 45). Rather than choosing the 
maximum concentration of peanut antigen (300-1000 ug/ml) to obtain proliferative PBMC responses, it was 
important to consider the optimum peanut antigen concentration where there was a difference in 
proliferation between memory T helper cells from PA versus NA donors, but not too high so as to get non-
specific responses from naïve T cells or cytotoxic T cells. In addition, at higher peanut antigen 
concentrations B cells could also be stimulated through peanut agglutinins.  Previous studies have also 
evaluated mRNA expression of  IL4, IL13, IL9 and IFN-γ following PBMC culture in 50µg/ml, 100µg/ml 
or 200µg/ml peanut protein; similar results were found for all three concentrations at 3 hours, 1 day, 2, 3, 4, 
5 and 6 days culture. 
(449)
  Therefore 200µg/ml peanut protein was chosen as the concentration for peanut 







Figure 45: Proliferation of PBMCs from children with PA versus using different concentrations of peanut 
antigen in PBMC culture  




10.14.3 Obtaining sufficient RNA for microarray 
I initially had difficulty obtaining sufficient numbers of FACS sorted cells to obtain RNA that was enough 
good quality for microarray analysis. One option, which has previously been performed, would have been to 
pool RNA samples;
(79)
 however, I had concerns that it would not be possible to detect an outlier sample and 
thus decided to review ways to optimise the amount of RNA that could be extracted from the sorted cells. I 
anticipated that the number of peanut specific Th cells following FACS sorting would be low for peanut 
allergic children and even lower for NA children. Previous studies have shown that the frequency of peanut-
specific circulating CD4+ Th cells is 0.61% for peanut allergic individuals and 0.08% in NA individuals;
(480)
 
peanut specific cells were identified by the number of divisions cells underwent in the presence of peanut 




division. The Qiagen RNA extraction kit guidance advises that mammalian cells contain 10-30pg of total 
RNA; 
(481)
 however, our laboratory team advised that FACS sorted T cells typically contain 1 pg of total 
RNA (personal communication Prof David Cousins, Sept 2012); of this 1-5% of total RNA is mRNA.  
 
10.14.3.1 Pilot experiment to determine RNA yield 
A pilot experiment was performed to assess the quality and quantity of RNA that could be extracted per 
PBMC.  Increasing numbers of PBMCs were extracted using the miRNeasy Mini kit (Qiagen, UK) and were 
assessed for integrity using the Agilent RNA 6000 Pico Kit. A second elution was performed for the 
500,000 cell sample by adding another 30 µl of RNAse free-water to the column to determine whether it was 
worth increasing the volume of eluate and thus decreasing its concentration. There was both increased 
quantity and increased RNA quality (RIN) obtained dependant on the number of cells from which the RNA 
was extracted (Table 22). On the basis of this pilot experiment I obtained a median 0.78 pg total RNA per 
PBMC (range 0.28-1.65pg/cell). There was an additional 20% RNA to be gained from repeated elution on 
the miRNeasy Mini spin column; thus it was worthwhile performing this step and then using a vacuum 
concentrator to reduce the total volume of eluate thereby increasing the concentration. 
 
Table 22: Quantity of RNA and RIN dependent on number of PBMCs assessed. 




RNA per cell  RIN 
5,000 275 8.25 1.65 1.0 
10,000 288 8.64 0.86 2.2 
20,000 317 9.51 0.48 4.2 
40,000 605 18.15 0.45 8.1 
80,000 754 22.62 0.28 6.9 
125,000 3243 97.29 0.78 8.5 
500,000 14250 427.5 0.86 9.1 




10.14.4 RNA integrity evaluation  
Following methodological optimisation a higher yield of RNA was obtained. The quality and quantity of 
total RNA was examined on an Agilent 2100 Bioanalyzer (Agilent Technologies, Wokingham, UK) using 
the Agilent RNA 6000 Pico Kit (Agilent Technologies, UK) which has a range of detection from 50-
5000pg/µl total RNA. Analysis was performed according to the manufacturer. Integrity of RNA was 
assessed using the RNA Integrity Number (RIN) and Bioanalyzer plots for marker and ribosomal peaks,  
(482)
 an example of which is displayed in Figure 46. The amount and quality of RNA and cDNA obtained 






Figure 46: Agilent RNA 6000 Pico Kit Bioanalyzer for 2nd peanut allergic child (PA2). 
RIN, marker and ribosomal peaks (18S and 28s) displayed. nt=nucleotides. FU=fluorescence units. 
     PA2 P+ CD69+Β7+                          PA2 P+ CD69-Β7+ 
RIN: 8.6             RIN: 8.5 
 
                         PA2 P+ CD69-CLA+               PA2 P+ CD69+CLA+ 
            RIN: 9.1               RIN: N/A 
 
                       PA2 P+ CD69-Β7+                PA2 P+ CD69-CLA+ 










10.15 Appendix 15: RT-qPCR analysis 
To confirm the microarray findings, RT-qPCR was performed on newly recruited individuals from a tertiary 
paediatric allergy clinic. RNA was extracted from peanut-stimulated PBMC obtained from an independent 
group of 12 PA and 18 peanut tolerant donors (of which 12 were peanut sensitized). Methods of the PBMC 
culture and RT-qPCR are described in the online repository of Publication 5. Target gene expression in a 
given sample was quantified by assessing how many PCR cycles were required before the fluorescent 
marker for a specific gene crossed the cycle threshold (Ct); this was then compared against the endogenous 
control 18S ribosomal RNA (∆Ct) then against the peanut unstimulated control (∆∆Ct) and converted to 




  Genes with no amplification were assigned a Ct 
value of 40 as previously described;
(484)
 this would be the Ct value obtained if there was only one copy of 
the DNA sequence of interest in the starting sample.  
 
Figure 47 displays an RT-qPCR amplification plot of a range of genes expressed in PBMCs from a PA 
child. Genes expressed following PBMCs cultured in peanut antigen are displayed in purple (both CD69+ 
and CD69- Th cells are included) and genes expressed following PBMCs cultured in media alone are 
displayed in green (both CD69+ and CD69- Th cells are included). Figure 48 displays an RT-qPCR 
amplification plot for IL9 in the same PA child whose PBMCs were either cultured in peanut (purple) or 
media alone (green). The Ct is the intersection between the amplification curve and the threshold line. 
Thresholds for different genes are displayed as horizontal coloured lines which cross the amplification plots. 
The amplification plots which start around 8-9 PCR cycles and which cross the threshold between 11-16 
PCR cycles are the 18S gene which is expressed very early on in the PCR cycle. The genes of interest start 
from 20-33 PCR cycles and cross the threshold between 25-43 PCR cycles. Thus, for example, if the sample 
contains 32 more copies of the target gene then the threshold of detection is reached after 5 fewer PCR 
cycles (2
5
=32); if the original sample contains 1024 more copies of the target gene then the threshold of 
detection is reached after 10 fewer PCR cycles (2
10




PBMCs from the PA child both when cultured in peanut protein or media alone; however, IL9 expression is 
only found in those PBMCs cultured in peanut (purple amplification plot) and not in those cultured in media 
alone (green lines are not amplified but show ‘noise’ at later cycles).  
 
Figure 47: RT-qPCR amplification plot for all genes expressed in PA patient. ∆Rn (delta normalised 
reporter) is fluorescence emission intensity of the reporter dye divided by that of the passive reference dye. 
 
Figure 48: RT-qPCR amplification plot for IL9 in peanut allergic patient.  
 
18S 
18S IL9 
